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UNDERSTANDING THE EP IGENOME US ING
SYSTEM GENET ICS
Sander Willem Timmer
Genetics has been successful in associating DNA sequence variants
to both dichotomous and continuous traits in a variety of organisms,
from plant and farm animal studies to human disease. With the advent
of high-throughput genotyping, there has been an almost routine gen-
eration of genome-wide association studies (GWAS) between human
disease traits and genomic regions. Despite this success, a particular
frustration is that the majority of associated loci are in non-coding
regions of the genome and thus interpretation is hard.
To improve characterisation of non-coding regions, molecular as-
says can be used as a phenotype, and subsequently be used to explain
how genetics alter molecular mechanisms. In this thesis, the inter-
play of three molecular assays that are involved in regulating gene
expression is studied. On 60 individuals, several assays are performed:
FAIRE-chip, CTCF- seq, RNA-seq and DNA-seq.
In the first part, the discovery and characteristics of FAIRE-QTLs is
presented. The identified FAIRE-QTLs show strong overlap with other
molecular QTLs, histone modifications, and transcription factors.
The second part consists of the integration of genome-wide molecu-
lar assays in a human population to reconstruct the human epigenome.
Each of the molecular assays is associated with each of the other assays
to discover phenotype-to-phenotype correlations. Furthermore, QTL
data are used to dissect the causality for these phenotype-to-phenotype
correlations in a system genetic manner.
The third part presents a comprehensive view of CTCF binding on
the X chromosome, and its implications for X-chromosome inactivation.
A novel X chromosome-wide CTCF effect is observed. Using the
gender of each of the cell lines, observations are made about which
CTCF sites are dosage-compensated, active on both chromosomes, or
are only bound in females.
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Part I
INTRODUCTION

1
INTRODUCTION
The last two decades have seen a remarkable increase in quantit-
ative genetics, which involves the association of DNA sequence
variants with both dichotomous and continuous traits in a wide
range of species. Decreasing costs of high-throughput genotyp-
ing and sequencing has led to an almost routine generation of
genome-wide association studies (GWAS) between human dis-
ease traits and genomic regions (Hindorff et al., 2009; Johnson
and O’Donnell, 2009). Unfortunately, the majority of associated
loci are in non-coding regions of the genome, and are therefore
difficult to interpret (Schaub et al., 2012).
To improve our understanding of non-coding regions, it is
possible to use molecular assays as a characterisation of phen-
otype, permitting the exploration of how genetic changes alter
molecular mechanisms. By using a system genetics approach,
the complex molecular interplay can be studied (see review
(Sieberts and Schadt, 2007)). This has been successfully investig-
ated in Drosophila melanogaster; for complex traits, (Ayroles et al.,
2009).
In this thesis, I will explore the genetic control and interrela-
tionships of three molecular components: chromatin accessib-
ility measured with Formaldehyde-Assisted Isolation of Regu-
latory Elements (FAIRE), transcription factor (TF) binding for
CCCTC-binding factor (CTCF), and gene expression. Serendip-
itously, I discovered a novel relationship between CTCF and
X-chromosome inactivation. Before describing this work, I will
first introduce genetics generally, and then review previous
work in this area. I will also provide a short introduction into
X-chromosome inactivation.
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1.1 history of genetics
1.1.1 Inheritance
Even before the discovery of the molecular basis of inheritance,
scientists conducted simple experiments on heritability. One of
the earliest examples of this is the research performed by Gregor
Mendel on pea plants. By measuring seed shape, flower colour,
seed coat tint, pod shape, unripe pod colour, flower location,
and plant height in both parents and offspring, he was able to
establish some of the fundamental laws of heritability (Mendel,
1866). For example, Mendel noted that when a white flower
plant is crossed with a purple flower plant, the first generation
offspring (F1) is not a mix of both colours, but consist purely of
purple, which is the dominant colour (dominant allele). When
plants from the F1 are crossed in a second generation (F2), the
dominant colour is present in a 3:1 ratio, and thus it is evident
that the recessive colour was not lost in the F1.
Francis Galton aimed to determine whether similar rules
applied to humans. Galton began studying variation and herit-
ability in human populations using physical appearances, such
as his quantitative study of height (Galton, 1869), to mental char-
acteristics, including genius qualities (Galton, 1907). However,
concerningly, he was also the founder of eugenics as he wanted
to exploit this field of research to improve mankind (Galton,
1904). In his early research, Galton discovered that abilities are
most likely inherited, but that environmental factors could bias
his results; thus, he concluded that such studies are more use-
ful when performed with twins (Galton, 1876). To conduct this
type of research, Galton innovated several statistical methods,
including standard variation and regression towards the mean,
(Galton, 1879) that are still widely used today. It was under
Galtons supervision that Karl Pearson worked on developing
concepts including the p-value (Pearson, 1900), correlation (Pear-
son, 1920), and principal components analysis (Pearson, 1901).
1.1 history of genetics 5
1.1.2 Inheritance is by genetics
Thomas Morgan, a fly geneticist, was a sceptic of Charles Dar-
win’s natural selection theory (Darwin, 1861). Particularly, in his
opinion, it seemed highly unlikely that new species could occur
solely due to the introduction of slight individual differences
(Morgan, 1903). Morgan discovered that some mutant pheno-
types in Drosophila melanogaster were following Mendel’s law.
He showed that when a white-eyed male (a male-only muta-
tion) was crossed with a red-eyed female, all offspring (F1) were
red-eyed. When crossbreeding the F1, the offspring (F2) again
included some white-eyed males. Morgan concluded that some
traits were sex-linked and must be carried on one of the sex
chromosomes, while other traits are probably carried on other
chromosomes (Morgan, 1911). By combining the white-eyed
mutants with another sex-linked trait, miniature wing, Morgan
made important discoveries about the heritability of these traits.
Morgan noted that, although both phenotypes are sex-linked,
they are not inherited in such a way that both mutants are
always together in F2. This is, arguably, the first example of as-
sociation between phenotypes. Morgan called this phenomenon
chromosomal crossover (Morgan, 1916; Sturtevant et al., 1915). In
honour of this discovery, the unit for linkage is called a morgan.
In the process of these discoveries, Alfred Sturtevant, under the
supervision of Morgan, published the first chromosomal map
(Sturtevant, 1913). In the process of describing these discoveries,
Morgan changed his opinion about Darwin’s theory.
When Ronald Fisher published a genetic model showing that
variation among a population is consistent with Mendelian in-
heritance (Fisher, 1919), the new field of population genetics
emerged. In addition to his contribution to population genet-
ics, Fisher published a myriad of essential statistical terms and
methods including variance (Fisher, 1919), analysis of variance
(ANOVA) (Fisher, 1922b), and Fisher’s Exact Test (Fisher, 1922a).
Fisher also published papers addressing proper use of statist-
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ical methods (Fisher, 1925) and recommended practices related
to study design (Fisher, 1935). Moreover, in his book about
evolution, Fisher described how inheritance is not limited by
the extremes of the parents (blending inheritance), but follows
the particulate inheritance model, which was first described
by Mendel (where particles refer to present-day genes) (Fisher,
1930). It is within this period that Karl Sax first observed that
a single gene could control both a qualitative trait (colour) and
quantitative trait (weight) of seeds (Sax, 1923).
1.1.3 The modern genetic heritability era
In the late 1940s and early 1950s,many great scientific break-
throughs were achieved in the field of molecular biology. This
included the discovery that DNA, and not protein, is the carrier
of genetic material in 1944 (Avery et al., 1944), followed by the
proposition of the structure of DNA in 1953 (Watson and Crick,
1953). The first successful RNA sequencing of the Lac operator
in 1973 (Gilbert and Maxam, 1973) and the first synthesis of a
gene in 1979 (Khorana, 1979) are among these accomplishments.
The next significant step involved inventions that made it pos-
sible to read out the actual DNA sequence in a more systematic
and straightforward way.
Sanger sequencing, as it is known today, was the first method
that made it possible to sequence DNA, by the use of templates
and DNA polymerase (Sanger et al., 1977). Another method
for sequencing was published at the same time, using chemical
fragmentation (Maxam and Gilbert, 1977). However, because
Sanger sequencing uses enzymatic synthesis instead of chemical
fragmentation, Sanger sequencing is simpler to perform and
safer to use. For these reasons, Sanger sequencing became the de
facto standard for sequencing. Sanger sequencing is performed
by radioactively labelling different termination base pairs. Be-
cause the termination base pair is attached randomly, reads will
be terminated at different lengths. The terminated reads are
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then transferred to four independent gel lanes (one lane per
base pair), where the order of base pairs can be determined by
reading out the lines on each of the four lanes. At later stages,
Sanger sequencing was optimised to use dye labelling and ca-
pillary electrophoresis, which features made it a highly efficient
method.
All of these breakthroughs in techniques to read out sequences
of DNA on a large scale led to the establishment of several large
sequencing projects. Noteworthy are Haemophilus influenzae as
the first living organism that was fully sequenced (Fleischmann
et al., 1995), Caenorhabditis elegans as the first animal to be fully
sequenced (C. elegans Sequencing Consortium, 1998), and the
first human chromosome (22) that was fully sequenced (Dun-
ham et al., 1999). These efforts led to two major consortia, one
public (Lander et al., 2001) and one industrial (Venter et al.,
2001), to sequence the human genome and deliver the first
complete reference human genome. The promise of attaining
a working human genome sequence resulted in a new wave
in large-scale genetics efforts. A vital point demonstrated by
these projects was that most of the human genome is not con-
tained within genes and is not transcribed (i.e. non-coding),
which is sometimes dubbed junk DNA. Several large-scale inter-
disciplinary projects were founded to understand what, if any,
functionality was present within these non-coding parts of the
genome. The ENCODE project discovered that nearly the entire
genome shows biochemical activity (ENCODE Project Consor-
tium, 2012; ENCODE Project Consortium et al., 2007), indicating
large amounts of regulatory functionality in the non-coding por-
tions of the genome. Other projects focussed on the discovery
of common genetic variations worldwide(1000 Genomes Pro-
ject Consortium et al., 2010, 2012) and the determination of the
normal variation in gene-expression (Lappalainen et al., 2013).
Another consortium focussed on discovering the predisposition
to common diseases (Lohmueller et al., 2003; Wellcome Trust
Case Control Consortium et al., 2007).
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1.2 the human epigenome
The history and definition of epigenetics are interpreted differ-
ently depending on the research field addressing this topic. In
the eyes of Conrad Waddington, the epigenetic state and fate
of a cell is like a ball rolling down a hill, finding the local min-
imum (Waddington, 1957). Once a state is set, it will stay in that
state or change into a future state, but it can never be reversed
back into its original pluripotent state. Waddington stated that
genetics cannot explain the difference between cell types (be-
cause the genetic background will not change); he demonstrated
this using Drosophila embryos, and concluded that the observed
phenomena must be due to epigenetics (Waddington, 1952). In
Waddington’s time, epigenetics was most often used to explain
differences that genetics could not explain. In the 1970s, a dif-
ferent definition for epigenetics emerged. With the discovery of
DNA methylation, made simultaneously by Riggs (Riggs, 1975)
and Holliday (Holliday and Pugh, 1975), epigenetics became
known to additionally include chemical modifications. Bird ad-
ded to the field of epigenetics the knowledge that CpG islands
are regions rich with CpG sites, on which DNA methylation can
occur at the cytosine of the CpG dinucleotides (Bird et al., 1985;
Bird, 1986).
The structural composition of DNA in cells is largely de-
termined by the wrapping of DNA inside nucleosomes around
histones, necessary to fit a genome into the nucleus (Woodcock
and Ghosh, 2010). Each nucleosome is composed of four basic
histones: H3, H4, H2A and H2B. The histones H3 and H4 are
bound in one dimer, and the histones H2A and H2B are bound
in another dimer. The final nucleosome consists of two of each
of the different types of dimers that are bound together in a
histone octamer complex (Luger et al., 1997).
The wrapping of the DNA around this histone octamer com-
plex is coordinated by biochemical events such as methylation,
acetylation, phosphorylation and ubiquitination of different
1.2 the human epigenome 9
residues of the histone. Most of these events occur at the unstruc-
tured tails of the histone and happen post-translation (Allfrey
et al., 1964). The current status of research indicates that there
are more than 100 different posttranslational modifications, each
of them affecting the histones and the nucleosome. Many of
these modifications are still poorly understood in terms of what
causes them, which effects they might have, and whether these
are directed effects or random biochemical events (Jensen et al.,
2002) (see review (Bannister and Kouzarides, 2011; Strahl and
Allis, 2000)).
The chemical modifications of the DNA and histone proteins
exist in a complex interplay with genetics. This interplay of ge-
netics and epigenetics, that determines the chromatin structure,
is known as the epigenome (Bernstein et al., 2007). Changes
to the epigenome, regulated by the genome (Birney, 2011), can
be cell-state specific (Mikkelsen et al., 2007) or may correlate
with diseases like cancer (Jones and Laird, 1999) (see review
(Jones and Baylin, 2007; Portela and Esteller, 2010)), ageing (Hor-
vath, 2013) (see review (Gentilini et al., 2013)), and development
(see review (Feng et al., 2010; Smith and Meissner, 2013)). The
difference between the epigenome and the genome is that the
epigenome is constantly altering, while the genome is not.
The functional annotation of all histone modifications is still
far from complete. However, some of the more common modi-
fications have been well-studied. Acetylation and methylation of
lysine is one of the most well-understood histone modifications.
The acetylation of lysine occurs, in almost all cases, in regions of
chromatin accessibility and in transcribed regions. Methylation
of lysine, in contrast, has a different effect depending on which
residue is methylated. Table 1.1 (ENCODE Project Consortium,
2012) summarises some of the most well-studied histone modi-
fications (see review (Bannister and Kouzarides, 2011; Strahl
and Allis, 2000)).
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Table 1.1: Overview Histone modifications and their putative func-
tional annotation (Bannister and Kouzarides, 2011; ENCODE
Project Consortium, 2012; Strahl and Allis, 2000).
Name Putative function
H2A.Z Histone protein variant (H2A.Z) associated with reg-
ulatory elements with dynamic chromatin
H3K4me1 Mark of regulatory elements associated with enhan-
cers and other distal elements, but also enriched down-
stream of transcription starts
H3K4me2 Mark of regulatory elements associated with pro-
moters and enhancers
H3K4me3 Mark of regulatory elements primarily associated with
promoters/transcription starts
H3K9ac Mark of active regulatory elements with preference
for promoters
H3K9me1 Preference for the 5’ end of genes
H3K9me3 Repressive mark associated with constitutive hetero-
chromatin and repetitive elements
H3K27ac Mark of active regulatory elements may distinguish
active enhancers and promoters from their inactive
counterparts
H3K27me3 Repressive mark established by polycomb complex
activity associated with repressive domains and silent
developmental genes
H3K36me3 Elongation mark associated with transcribed portions
of genes, with preference for 3’ regions after intron 1
H3K79me2 Transcriptionassociated mark, with preference for 5’
end of genes
H4K20me1 Preference for 5’ end of genes
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1.3 ccctc-binding factor (ctcf)
There are currently over 3,200 transcription factors (TFs) known,
and these proteins are involved in all known biological pathways
(Yusuf et al., 2012). One central TF that is known for its extremely
diverse functionality is the Zinc finger CCCTC-binding factor
(CTCF). Since its discovery in chickens, as a C-myc repressor in
1990 (Lobanenkov et al., 1990), it has been successfully associated
as being involved in chromatin organisation, gene regulation,
enhancer-blocking, insulating, DNA-looping, imprinting, and
X-chromosome inactivation. CTCF is considered to be one of
the key chromatin regulatory TFs, and is known to be essential
for establishing and maintaining the 3-dimensional genome
structure (see review (Phillips and Corces, 2009)).
The 11 zinc fingers of CTCF bind the DNA with a 50-60 base
pair (bp) footprint within the middle a DNase I hypersensitive
site (Boyle et al., 2011). From the 11 zinc fingers, only 4 are
essential for CTCF binding, and these bind mainly to the highly
conserved 12bp motif (Ohlsson et al., 2001) that is conserved
in both vertebrates (Kim et al., 2007; Schmidt et al., 2012) and
fruit flies (Holohan et al., 2007). CTCF binding also shows tissue-
specific binding activity (Schmidt et al., 2010). Furthermore,
differences in the CTCF motif between individuals can result in
different CTCF binding (Maurano et al., 2012).
In regions adjacent to CTCF, there is often an increase in
methylation (Stadler et al., 2011). Interestingly, when Stadler
introduced genetic mutations inside the CTCF binding motif,
both CTCF binding and the adjacent methylation were lowered
(Stadler et al., 2011), indicating that CTCF is driving the methyl-
ation.
CTCF is known to be an insulator binding protein (Wallace
and Felsenfeld, 2007). There is also high enrichment of CTCF
around chromatin barriers known for active and repressive his-
tone modifications (Cuddapah et al., 2009). All of this previous
work emphasises CTCF’s role in the regulation of gene expres-
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sion by actively controlling regulatory histone modifications
(Phillips and Corces, 2009).
1.3.1 Cohesin
CTCF is also implicated in chromosome structure. The cohesin
protein complex is a well-known complex of proteins that, to-
gether with CTCF, acts as a structural binding unit for chro-
mosomes. The full cohesin complex consists of five conserved
core proteins: SMC1, SMC3, RAD21, SA1 and SA2. Both SMC1
and SMC3 are part of the highly conserved family of Struc-
tural Maintenance of Chromosomes (SMC) proteins that act
through ATPase (Merkenschlager and Odom, 2013). Cohesin,
when bound with CTCF, is thought to trap DNA molecules
using a so-called "embrace model" (Haering et al., 2008). Addi-
tionally, cohesin can form a complex with a mediator to bind
two cohesin loops, creating DNA loops (Kagey et al., 2010).
1.3.2 CTCF loops
In previous studies using ChiA-PET (Section 1.7.0.2) in humans
(Merkenschlager and Odom, 2013; Sanyal et al., 2012), as well
as model organisms like mouse (Handoko et al., 2011), there is
evidence that CTCF insulating loops can be local (cis), remote
(trans) and interchromosomal. Handoko illustrated that, for the
mouse, depending on the length of the CTCF loop, the CTCF
sites are correlated with different histone patterns. Loops with
length <200kb overlap mainly with active histone modifications,
such as H3K4 methylation. Loops longer than 200kb correlate
with known repressive histone modifications (Handoko et al.,
2011).
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1.4 the sex chromosomes
In humans, there are 22 pairs of autosomes and one pair of
allosomes, or sex chromosomes. Females have two copies of the
X chromosome (XX), and males have one copy of the X chromo-
some and one of the Y chromosome (XY). The actual phenotypic
determination of sex is found in genes located on the Y chromo-
some; the majority of genes on the X chromosome are not related
to sex-specific functionality (Ross et al., 2005). Because of the
different copy numbers of X chromosomes, males and females
show differential disease susceptibility (see reviews (Libert et al.,
2010; Ober et al., 2008)). For females, for example, monosomy
of the X-chromosome can lead to the Turner syndrome.
It is commonly accepted that the current set of sex chromo-
somes is the results of the, still on-going, evolutionary transform-
ation from a normal pair of autosomes (Lahn and Page, 1999).
Lahn showed that 19 ancestral genes, with homologs on both the
X and Y-chromosomes, have similar nucleotide divergence. The
ancestral allele for male determination is now solely located at
the Y chromosome (Graves, 2006). As the Y chromosome evolved
over time, genes beneficial to males crossed over towards the Y
chromosome (Burgoyne, 1982), adjacent to the sex-determination
locus (Skaletsky et al., 2003). Both the X and Y-chromosomes
contain two pseudoautosomal regions (PAR), PAR1 and PAR2,
which recombine during meiosis (Graves et al., 1998; Hinch
et al., 2014). In mammals, to the best of established knowledge,
only humans have 2 PAR regions; other closely-related species,
including chimpanzee and rhesus macaque, have only a single
PAR region (Bachtrog, 2013; Carninci et al., 2006). This obser-
vation provides strong evidence that both PAR regions evolved
independently.
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1.4.1 Discovery of X-chromosome inactivation
If both copies of the X chromosome in females were to be tran-
scribed, there would be an imbalance betweenmales and females
in sex-chromosome gene transcription, which could impair nor-
mal functionality. For this reason, mammals have evolved a
genetically-driven system called dosage compensation, in which
one of the female’s X-chromosome expressions is silenced dur-
ing an early developmental stage. By using this system, there is
one active X chromosome (Xa) and one inactive X (Xi) in females.
The obvious benefit of this system is that that X chromosome
genes have the same transcription levels in males as in females.
The study of the mechanisms driving X-chromosome inactiv-
ation, and thus dosage compensation, has been ongoing since
Susumu Ohno showed in 1959 that each X chromosome of the
X-chromosomes pair in females appears different under the mi-
croscope(Ohno et al., 1959). One of the X chromosomes looks
like a functional autosome, while the other is condensed and het-
erochromatic, also called a Barr body (Barr and Bertram, 1949).
Following these discoveries in 1961, Mary Lyon proposed that
X-chromosome inactivation is a random process (Lyon, 1961).
This system of random inactivation was proposed after the ob-
servation that in female mice, the coat colour has patches of
normal and mutant colour and is not uniform as would be ex-
pected if either the paternal or the maternal X chromosome were
consistently inactivated. Coat colour, including mottled patterns
(Lyon, 1961), had been linked to mutations in several X-linked
genes. As the fur coat is not uniform, this could only be due to
random inactivation of the paternal or maternal X chromosome.
This would result in gene expression that originated sometimes
from the mutated gene and sometimes from the original gene.
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1.4.2 The X-inactivation center
X-chromosome inactivation in mammals stands as one of the
major illustrations of epigenetic gene regulation (see review
(Pollex and Heard, 2012)). A major driving force for achieving
silencing in one of the X chromosomes is the X-inactivation
center (XIC) (Penny et al., 1996), remarkably, XIC is not essential
for maintenance of the inactivation (Brown and Willard, 1994).
At the XIC, there are 4 noncoding RNA genes, Xist, Tsix, Jpg
and Ftx. Xist is the main ncRNA that silences the inactive X
chromosome (Brown et al., 1991; Herzing et al., 1997). Tsix is
the antisense gene of Xist and is involved in the early stages of
X-chromosome inactivation, though not the silencing step itself
(Lee et al., 1999). Interestingly, moving the XIC to an autosome
will lead to the inactivation of one of the chromosome pair,
as shown in a study in which Xist was used to silence one
chromosome in trisomy (Jiang et al., 2013). During inactivation,
the Xist ncRNA binds and then coats the entire X chromosome
(Clemson et al., 1996), except for the regions that host escape
genes (Carrel and Willard, 2005), and alters the 3D structure of
the X chromosome (Engreitz et al., 2013) into a Barr body.
1.4.3 CTCF in X-chromosome inactivation
CTCF has been identified as a factor involved in regulating
X-chromosome inactivation (Chao et al., 2002). Between Tsix and
Xist is a CTCF site that shows strong binding and is most likely
involved with Xist induction (Spencer et al., 2011). In terms
of X-chromosome inactivation, CTCF binds to the XIC (Chao
et al., 2002) and is most likely involved in inducing Xist in early
X-chromosome inactivation (Spencer et al., 2011). CTCF is highly
clustered with the transcription factor YY1, and is a key factor
in controlling Xist expression (Donohoe et al., 2007). During
inactivation, YY1 anchors the Xist RNA to the DNA to silence
the specific X chromosome (Thorvaldsen et al., 2011). Mutations
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in some specific CTCF sites can lead to skewed X-chromosome
inactivation (Pugacheva et al., 2005).
1.5 cell lines for molecular phenotyping
When studying the basic processes of biology, working with
primary tissue is challenging. Many biochemical assays require
at least 106 cells. It is difficult to access one particular cell type
from a living donor at this scale. For this reason, many studies
are performed on immortalised cell lines, which grow well in
the laboratory. This technique was established with the HeLa
cell line, the first immortal cell line obtained from a single cancer
patient in the 1950s. The HeLa cell line (Gey et al., 1952) was
essential for the discovery of the polio vaccine (Scherer et al.,
1953). HeLa cell lines were the beginning of a long tradition of
research performed on cell lines (see review (Masters, 2002)).
The recent publication of the full genome sequence of HeLa
indicates how essential this immortal cell line has been, even for
present-day research (Landry et al., 2013).
Following HeLa, many other cell lines were established that
were are derived from cancer tumours. For example, K562 is
derived from leukaemia (Lozzio and Lozzio, 1975) and MCF-7
from breast cancer (Soule et al., 1973). Although all of these cell
lines are a useful resource for replenishable cells, they provide
a poor platform for comparing differences between healthy
individuals. As each cell line originates from a different tissue
and has its own "broken" cancer genome (Greenman et al., 2007),
these cell lines cannot be used within a population study, as
direct comparison of these cell lines would indicate cancer-
or tissue-specific differences, rather than individual specific
differences.
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1.5.1 Lymphoblastoid cell lines
A breakthrough in creating cell lines from healthy individuals
involved the ability to transform B lymphocytes by Epstein-Barr
virus (EBV) into lymphoblastoid cell lines (LCLs) (see review
(Miller, 1971)). These cell lines are, like HeLa, immortalised
and thus capable of indefinite growth, making them ideal to
study biological effects on a population level, while being able
to compare to previously-performed experiments on cells from
the same line. Because LCLs originate from B lymphocytes,
there are some genomic regions, such as the lG locus, that are
continuously reorganised (Alt et al., 1992). For this reason, in
studies using LCLs, these regions are often excluded.
Because LCLs can provide almost unlimited quantities of
cells, they are used heavily in many large research consortia
as well as in smaller research studies (see review (Sie et al.,
2009)). Beyond this feature, there is the additional benefit that a
large number of LCLs, from different human populations, have
been genotyped and phased within the HapMap consortium
(International HapMap Consortium, 2003, 2005).LCLs are also
being sequenced (most on low-coverage) during Phase 1 of the
1,000 Genomes Project (1000 Genomes Project Consortium et al.,
2010, 2012), providing access to high-quality genotypes. For
most of the LCLs that are part of the 1,000 Genomes Project, the
transcriptome has been quantified, using RNA sequencing, in
the gEUVADIS consortium(Lappalainen et al., 2013).
Several molecular assays have been successfully performed
on a subset of LCLs. In these studies, inter- and intra-individual
differences were discovered for gene expression (Montgomery
et al., 2010; Reddy et al., 2012), chromatin state (Ernst et al., 2011;
McDaniell et al., 2010), proteome (Joubert-Caron et al., 2000), and
the discovery of molecular Quantitative Trait Loci (QTLs) other
than expression-QTLs, like DNase I sensitivity QTLs (dsQTLs)
(Degner et al., 2012). In ENCODE, a large-scale consortium to
map all functional elements of the genome (ENCODE Project
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Consortium, 2012; ENCODE Project Consortium et al., 2007),
one LCL, GM12878, has been used as one of the core cell lines,
meaning that many molecular assays have been applied to it.
Due to the extensive research that has been performed on
these cell lines, there is a huge potential to build a multidi-
mensional view of molecular phenotypes that can be used for
systematic genetic dissection. This will, in the long term, in-
crease our understanding of molecular pathways and contribute
to enhancing our understanding of the molecular role of many
previously identified noncoding GWAS results.
1.6 quantification of molecular phenotypes
Several molecular techniques have been developed over time
to quantify a large number of genomic sites simultaneously. By
using microarrays (Section 1.6.1), and later next generation se-
quencing (NGS) (Section 1.6.2), it has become feasible to record
large scale measurements of molecular phenotypes. Although
there are differences between microarrays and NGS, both meth-
ods have in common that the first step requires isolating the
DNA of interest, and the second step involves quantifying the
isolated DNA.
1.6.1 Microarrays and tiling arrays
With the development of the first microarrays, it became possible
to measure the abundance of a wide range of specific sequences
simultaneously. A classic microarray is a matrix of points with
specific probes. In essence, the first microarrays were analogous
to many northern/southern blots performed in parallel (Augen-
licht and Kobrin, 1982; Maskos and Southern, 1992) that could,
for example, quantify gene expression (Schena et al., 1995) for
an entire transcriptome at once (Lashkari et al., 1997).
1.6 quantification of molecular phenotypes 19
The basis of a microarray involves having a range of probes
that hybridise to complementary sequences that are fluores-
cently labelled. During measurement, complementary sequences
with the probe will bind, and non-hybridised material is washed
away. By measuring the fluorescent signal for each probe, a
probe-specific quantitative measure is obtained.
Tiling arrays use the same biochemical methodology as mi-
croarrays, but differ in their probe design. Whereas microarrays
will target precisely known sequences of interest (such as a
gene or transcript), in tiling arrays, the genomic sequence is
constantly sampled with evenly distributed probes. Because of
this continuous sampling, tiling arrays will provide an almost
continuous readout for the targeted genomic regions.
1.6.1.1 Examples of use of microarrays
Tiling arrays have been used extensively for measuring mo-
lecular signals in non-coding regions. This technique has been
used to measure signals for transcription factor binding, histone
modifications, and splicing variants (Malone and Oliver, 2011).
Also, genome-wide assays such as FAIRE, DNase I (Crawford
et al., 2006), and methylation (ENCODE Project Consortium
et al., 2007) have been studied extensively using tiling arrays.
Another widely-used application of microarrays is to gen-
otype specific single-nucleotide polymorphisms (SNPs) (Fan
et al., 2000), small insertion or deletion (indels), or copy number
variations (Pinkel et al., 1998) (see review (Gresham et al., 2008)).
On these arrays, probes are designed to match the genetic vari-
ations of interest. In this way, it is possible to acquire a read-out
of the allele with and without SNP, and by comparing these two
signals, to determine what the genotype of the SNP is.
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1.6.2 Next generation sequencing for molecular quantification
Microarrays have been proven to be highly successful in a wide
variety of settings, but involve some serious drawbacks. The
first is that microarrays rely on probe design, and thus will
only measure whatever the probes are designed to measure. The
second, and most significant, is that the hybridisation of probes
with complementary sequences is not always equally strong.
This could mean, for example, that although the expression
of two genes is identical, microarray quantifications can show
differences.
For these reasons, microarrays are being replaced by next-
generation sequencing (NGS) quantifications. NGS is being used
for transcriptomics (see review (Wang et al., 2009)), for CHiP
experiments (see review (Furey, 2012)), and for chromatin con-
firmation studies (see review (Schones and Zhao, 2008)). This
swift change has been driven by the rapid drop in price of NGS,
while offering more extensive genome-wide coverage and higher
sensitivity, and the additional benefit of providing a continual
quantitative measurement of the genome rather than only for
predefined regions. Similar to microarrays, the measurements
themselves are independent of the isolation of genetic material,
making NGS suitable for a wide range of research topics.
There are currently numerous NGS platforms available (see
review (Metzker, 2010)). The most notable and widely used ex-
amples include an array-based pyrosequencing approach known
as 454 sequencing (Margulies et al., 2005), a sequencing-by-
synthesis method called Illumina sequencing (Bentley, 2006),
and sequencing-by-ligation method named SOLiD sequencing
(Valouev et al., 2008).
New sequencing technologies are being developed continu-
ously. Third-generation sequencing methods (e.g. Nanophore
sequencing) promise longer reads and resolution of a single
molecule (Oxford Nanopore Technologies, 2012). At the same
time, second-generation sequencing methods are still improving
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by becoming faster, enhancing scalability, and reducing overall
costs.
I will now outline a number of molecular phenotyping meth-
ods that can be used in combination with microarrays or sequen-
cing.
1.7 chromatin conformation and transcription factor
binding affinity
Several techniques, for example FAIRE (Giresi and Lieb, 2009;
Giresi et al., 2007), DNase I (Crawford et al., 2006), and ATAC
(Buenrostro et al., 2013), have been developed in the field of
molecular biology to assay the conformation of chromatin. In
addition, several Chromatin Immunoprecipitation (ChIP) assays
are able to measure the binding of transcription factors or his-
tone modifications (Furey, 2012; Wang et al., 2012). Each of these
methods can be read out with either microarrays or sequencing.
1.7.0.1 Chromatin Immunoprecipitation
ChIP is an immunoprecipitation technique that permits the
study of the interaction between proteins and DNA (Kuo and
Allis, 1999). With ChIP, it is possible to determine whether a
specific protein is bound to a specific genomic region. ChIP
can be used to determine the binding of TF or the presence
of histone modification (HM). Initially, ChIP was used to in-
vestigate specific cases (e.g. TF x binds genomic region y). In
2000, the combination of ChIP with microarrays (ChIP-chip)
made genome-wide quantifications possible (Iyer et al., 2001;
Ren et al., 2000). In 2007, ChIP was quantified using sequencing
(ChIP-seq) for the first time (Barski et al., 2007; Johnson et al.,
2007; Mikkelsen et al., 2007).
A ChIP experiment consists of the following steps:
1. crosslinking of DNA
2. sonication of DNA
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3. pull down of DNA fragments using immunoprecipitation
4. quantification using microarrays or sequencing
1.7.0.2 Chromatin Interaction Analysis by Paired-End Tag Sequen-
cing
The genome is highly complex and its spatial conformation is es-
sential to its function (Dekker et al., 2002; Lieberman-Aiden et al.,
2009). For some events to occur, different parts of the same, or
sometimes even different, chromosomes are required to interact
with each other. Some factors, like CTCF (Handoko et al., 2011),
are known to influence the structure of the genome in long-
range interactions that enable chromatin interactions (Sanyal
et al., 2012). A method of studying these chromosomal interac-
tions is by using chromatin interaction analysis by paired-end
tag (ChIA-PET) sequencing (Fullwood et al., 2009). The ChIA-
PET technique effectively combines paired-end sequencing with
ChIP. Using ChIA-PET, it is possible to measure binding betwe-
en different regions of the genome through transcription factors.
Because both paired-end tags (PET) are sequenced, the distinc-
tion can be made between non-chimeric CTCF loops (both PETs
are identical) and chimeric CTCF loops (both PETs are different)
(Li et al., 2010).
A ChIA-PET ChIP experiment consists of the following steps:
1. crosslinking of DNA
2. sonication of DNA
3. linkers are introduced to bind the free DNA ends and
ligate together
4. ligated linkers are digested at short distance from the
linkers
5. pull DNA fragments down using immunoprecipitation
6. quantification of DNA fragments using paired-end sequen-
cing
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1.7.1 DNase I hypersensitive sites
A key element in epigenetic, or epigenome, studies is the un-
derstanding and identification of regulatory elements. These
regulatory elements can directly and indirectly regulate the
binding of epigenetic marks and gene expression. Areas of the
DNA that are known to be regulatory for transcription show
a loss of nucleosomes. This lack of nucleosomes can be meas-
ured by the ability of nucleases to act on regions of nucleosome
depletion. Early studies in Drosophila have shown that the 5’
regions of active genes are hypersensitive to DNase I, which is
evidence for nucleosome destabilisation.
Regions of the genome that are sensitive to cleavage by DNase
I are known as DNase I hypersensitive sites (DHSs), and were
discovered in the 1980s (Gross and Garrard, 1988). The resulting
fragments of DNA after digestion by DNase I can be measured
using tiling arrays (Crawford et al., 2006; Sabo et al., 2006)
or sequencing (Hesselberth et al., 2009; Song and Crawford,
2010). Quantification of these DNA fragment can provide a
genome-wide view of genome accessibility. The DNase I method
consists of the following steps:
1. low concentration of DNase I agent added to DNA
2. DNase I cleaves DNA at regions that are accessible
3. capturing of the resulting DNA fragments
4. ligate DNA fragments to sequencing adapters
5. quantification of DNA fragments using microarrays or
sequencing
The DHS regions of the genome are known to be in more
accessible regions, which strongly indicates the presence of reg-
ulatory elements, making these regions of high interest to study
(Thurman et al., 2012). Interestingly, DHS regions themselves are
also under the influence of genetic regulation (dsQTLs) (Degner
et al., 2012).
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1.7.2 Formaldehyde-Assisted Isolation of Regulatory Elements
Another method of identifying nucleosome-depleted DNA is
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE),
which is derived from CHiP protocols (Giresi et al., 2007). When
crosslinking DNA with formaldehyde, the formaldehyde will
by cross-linked with the chromatin. After shearing the DNA by
sonication, only DNA fragments that are not bound by formal-
dehyde will be extracted. In contrast, for the non-treated sample,
all DNA regions are extracted. Depending on whether sequen-
cing or microarrays are used, the DNA fragments are quantified
to discover both chromatin-bound and open chromatin regions.
The FAIRE method consists of the following steps:
1. crosslinking of DNA with formaldehyde
2. sonication of DNA
3. phenol-chloroform extraction of non formaldehyde bound
DNA fragments
4. quantification of DNA fragments using microarrays or
sequencing
1.7.3 Assay for Transposase-Accessible Chromatin
The latest technology for determining the chromatin status is
Assay for Transposase-Accessible Chromatin using sequencing
(ATAC-seq) (Buenrostro et al., 2013). The significant advantages
of ATAC-seq in comparison with the FAIRE and DNase I meth-
ods are that the duration of preparation time and quantity of
cells required are massively reduced, from approximately two
days to a couple of hours and less than 50,000 cells.
In this method, Hyperactive Tn5 transposase loaded with
sequencing adapters is added to a sample. Transposase will
insert itself into regions of open chromatin. After this insertion,
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Transposase will integrate the sequencing adapters to these re-
gions and can subsequently be amplified by PCR and sequenced.
Buenrostro showed that ATAC-seq, although using far less input
material, yields highly similar results in GM12878 for DNase
I-seq (reported R of 0.79 and 0.81) (Buenrostro et al., 2013),
making it a likely candidate for future epigenetic studies.
The ATAC method consists of the following steps:
1. hyperactive Tn5 transposase loaded with sequencing ad-
apters is added to a sample
2. transposase inserts into open chromatin regions
3. integration of sequencing adapters
4. PCR multiplication of regions with sequencing adapters
5. quantification using microarrays or sequencing
1.7.4 Comparison of chromatin accessibility assays
Because nucleosome depletion is a broad aspect of active chro-
matin regulation, the FAIRE assay provides an efficient method
to assay regulatory elements. Previous studies have shown that
FAIRE largely overlaps regions from other chromatin assays like
DNase-seq and ChIP-seq, marking transcription factors, histone
marks, and chromatin accessibility (Giresi and Lieb, 2009; Song
et al., 2011). Another benefit of the FAIRE assay in comparison
with, for example, DNase I, is that it is technically easy to use
this method and it does not require a large quantity of input
material. Because of this latter feature, the FAIRE assay scales
up easily if there is a need to measure many samples. Also, as
FAIRE is sensitive to many of the biochemical activities occur-
ring at the level of DNA, it can be used as a proxy measurement
to discover regions of interest. However, due to this behaviour,
it is difficult to attribute chromatin accessibility solely by using
a FAIRE measurement. For this reason, if the aim of a study is
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the reliable measurement of chromatin accessibility, DNase is
the preferred assay. Additionally, the initial ATAC-seq results
indicate that both FAIRE and DNase as assays for chromatin
accessibility are becoming obsolete, in favour of the former.
1.8 discovery of quantitative heritable traits
Since the early days of population genetics and by methods
developed by pioneers like Fisher (Section 1.1.2), scientists have
been conducting association studies between quantitative traits
and genetic marks by using quantitative trait loci (QTL) studies
and genome-wide association studies (GWAS). Arguably, even
common diseases are most likely not a binary trait (sick versus
healthy) (Wellcome Trust Case Control Consortium et al., 2007),
as in many typical GWAS studies, but can be categorized within
a conditional range and thus actually represent a quantitative
trait that can be studied in a liability model as has been success-
fully shown. For example, for type 2 diabetes (Rung et al., 2009),
glucose fasting (Bouatia-Naji et al., 2008) and C-reactive protein
(Elliott et al., 2009) a quantitative approach has yielded striking
results.
Much effort has been invested in finding molecular traits that
associate with specific genetic variants, where the genetic com-
ponent can be a polymorphism (SNP or SNV), a small insertion
or deletion (indel), a structural variance (SV), or larger haplo-
type blocks. In quantitative traits loci (QTL) studies, genetic
differences between individuals are associated with quantifiable
molecular or whole-body phenotypes that are characterized by
a continuous range of values.
1.8.1 History of QTL mapping
Particularly in the field of plant breeding, QTL studies have
been performed for many decades (see review (Kearsey and
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Farquhar, 1998; Paran and Zamir, 2003; Young, 1996)). In the
early days, in humans these QTL studies used so-called linkage
maps (Lander and Botstein, 1989). The power of identification
of these early linkage studies in humans was due to using
pedigree information and phenotypes that were known to be
heritable (e.g. cystic fibrosis) (Groman et al., 2002; Tsui et al.,
1985). More recent successful QTL studies on humans have used
whole-body phenotypes such as height (Gudbjartsson et al.,
2008; Visscher, 2008) or body mass index (Wang et al., 2011).
On the molecular level, many successful studies have identified
QTLs for gene expression (Montgomery et al., 2010; Veyrieras
et al., 2008), DNase I hypersensitivity (Degner et al., 2012), and
protein levels (Melzer et al., 2008). For many more examples
of complex human traits in genome-wide studies, refer to the
review by Stranger (Stranger et al., 2011).
1.8.2 Molecular QTLs
The easiest to understand, and thus best-studied, molecular
effect under the influence of the genetic variation is gene ex-
pression. These so-called expression-QTLs (eQTL) have been
successful, even when applied to low numbers of LCLs (e.g.
(Göring et al., 2007; Monks et al., 2004; Schadt et al., 2003)), and
in particular when restricted to cis-based variants (Montgomery
et al., 2010; Veyrieras et al., 2008). Other eQTL discovery studies
have shown eQTLs to be specific for splicing events (Lalonde
et al., 2011), that some are highly tissue-specific (Zhang et al.,
2009) and are involved in mechanisms regulating allele-specific
expression (Pickrell et al., 2010).
The effect of an eQTL is sometimes easy to understand, espe-
cially, when the eQTL is nearby the gene it alters. In these cases,
the eQTL can be located inside a promoter region or can alter
the binding of a transcription factor. However, for most eQTLs
there is no easy explanation regarding why this genetic change
leads to transcriptional changes. Large eQTL meta-analysis iden-
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tifies trans-eQTLs that are known to be associated with diseases
(Schadt et al., 2005; Westra et al., 2013), and some studies sug-
gest that these trans-eQTLs are regulating intermediate genes
involved with these diseases (Fehrmann et al., 2011). However,
only by fully understanding what the causal effect of a genetic
alteration in a non-coding region or in trans is, can we achieve
a more systematic understanding of these eQTLs. Most likely,
these eQTLs are not directly affecting transcription, but are al-
tering chromatin status, histone modifications, or the binding
of transcription factors that in turn regulate transcription. Map-
ping these eQTLs to other molecular effects will be essential
to understand and fully utilise the potential of many GWAS
studies.
1.8.3 QTL mapping
The discovery, or mapping, of QTLs is based on the assumption
that a phenotype (P) is determined by the sum of the combin-
ation of genetics (Gi) and the environment (E), see equation 1.
P = Gi + E (1)
However, parents pass on genes and not phenotypes and thus
heritability is the ratio of phenotypic variance (Vp) that can be
attributed to genetic variance (Vg). This type of heritability is
know as broad-sense heritability, see equation 2.
H2 =
Vg
Vp
(2)
The genetic variance can be divided further into additive genetic
effects (Va), dominance genetic effects (Vd) (i.e. interactions bet-
ween alleles at the same locus), and epistatic genetic effects (Ve)
(i.e. interactions between alleles at different loci), see equation 3.
Vg = Vd+ Va+ Ve (3)
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Because each parent transfers only a single copy of each gene to
their offspring (e.g. in offspring, for each locus there is a paternal
and maternal allele), even relatives will most often only share a
single gene copy. For this reason, genetic effects like dominance
and epistatic genetic effects that rely on transfer of both copies
of a single allele from a single parent cannot influence the phen-
otypic resemblance. Narrow-sense heritability is determined
by considering additive genetic (Va) effects solely, and thus is
commonly used to determine heritability, see equation 4 (Houle,
1992).
h2 =
Va
Vp
(4)
When a phenotype is additive, there will be a linear correlation
between the three genotype possibilities (AA, Aa and aa) and
the phenotype. Therefore, for an additive trait, the assumption
is that for each allelic difference, a similar change in phenotype
will be observed. To model a dominant versus recessive effect
in a full model, an additional parameter is needed. For the
discovery, or mapping, of QTLs, classically the choice is between
an additive model and a full model, or in other words, between
a one-parameter test and a two-parameter test.
When using an additive model, the genotypes are converted
into numeric values (AA = 0, Aa = 1, aa = 2) so that they can
be used in a statistical method such as Pearson’s Correlation
or Spearman’s Rank. As Pearson’s Correlation assumes linear
relationships and Spearman’s Rank assumes a monotonic rela-
tionship, the better method to use will depend on the data nor-
malisation steps performed before these further analyses. After
data normalisation, results obtained with Pearson’s Correlation
and Spearman’s Rank are highly similar. However, the ranking
step within Spearman’s Rank negatively affects the power to
discover correlations. In the literature, both Spearman’s Rank
(e.g. (Montgomery et al., 2010)) and Pearson’s Correlation (e.g.
(Degner et al., 2012)) are used for QTL mapping.
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1.8.4 Multiple testing problem
Sample size is an important consideration when performing a
QTL (or any normal GWAS) study (Spencer et al., 2009). As
there are a large number of tests for association performed, a
simple p-value threshold of 0.05 for each test is not sufficient
to conclude significance. Because of multiple testing consider-
ations, finding significance requires a more stringent standard.
For example, when performing a single statistical test, it might
be sufficient to use a simple p-value threshold like < 0.05. This
p-value tells you that there is a 5% chance that this result would
occur by random chance. However, if, for example, you were to
perform 20 tests, in parallel, with the same p-value threshold,
one of these tests could show a positive result purely by chance.
In QTL studies, there are hundreds of thousands of tests per-
formed, and the p-value for judging significant findings has to
be corrected. A potential solution is the Bonferroni correction, in
which the desired p-value threshold is divided by the number
of tests performed (Bonferroni, 1935). However, the downside
of the Bonferroni correction is that it is extremely conservative,
which results in many false negatives. By the introduction of
false discovery rates (FDR), an estimation can be made about
the expected percentage of false positives among the claimed
positives (Benjamini and Hochberg, 1995; Hochberg and Ben-
jamini, 1990). FDRs have subsequently been successfully applied
in many fields (e.g. microarrays (Reiner et al., 2003)).
Another way of dealing with many statistical tests is permuta-
tions. Using permutation, it is possible to determine empirical
p-values. By performing permutations, it is possible to draw a
null distribution. By ranking the real p-value in this null distri-
bution, the confidence of the found association is determined.
Another method that addresses multiple testing, without ex-
pensive computational permutations, involves determining the
adjusted p-values (q-values) (Storey and Tibshirani, 2003), in
which the characteristics of the p-value distribution (specifically,
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the region of flattening of the p-value distribution) are used
to set the expected false positive rate. When applying a robust
mapping approach, even small populations tend to be effect-
ive in discovering QTLs by optimising the study design (see
reviews (Flint and Mackay, 2009; Mackay et al., 2009)). However,
small population studies will suffer from a high false negative
rate, making population size one of the most significant limiting
factors of the QTL mapping rate (Evans and Purcell, 2012).
The constant reduction of costs for tiling arrays and next-
generation sequencing (Wetterstrand, 2013) make it feasible to
study many additional molecular assays in QTL-like studies.
Combining this fact with the already-available cell line resources,
such as LCLs, there is enormous future potential for large-scale
systematic QTL mapping.
1.9 scope of this thesis
The present thesis is divided into three parts. In the first part,
the discovery and characteristics of FAIRE-QTLs is presented. A
tiling array is designed to measure 10,507 regulatory elements
for FAIRE activity. Using the HapMap v3 genotypes, FAIRE-
QTLs are discovered. By overlapping these with other QTL and
ENCODE datasets, some of the informative characteristics of
these QTLs are discussed.
In the second part, the molecular assays and QTLs, performed
in a human population, are integrated. The human population
used for these experiments is composed of 60 individuals having
northern and western European ancestry (CEU). On these 60
individuals, several assays are performed: FAIRE-chip, CTCF-
seq, RNA-seq and DNA-seq. Each of the molecular assays is
associated with each of the other assays to discover phenotype-
to-phenotype correlations. Furthermore, QTL data are used to
dissect the causality for these phenotype-to-phenotype correla-
tions.
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The third part presents a comprehensive view of CTCF bind-
ing on the X chromosome, and its implications for X-chromosome
inactivation. The transcription factor CTCF is known for its mul-
tifunctionality. There is not a single main function for CTCF
that is observed, as its function depends on cell state, cell type,
co-factors, or location. In the population of LCLs discussed, a
novel X chromosome-wide CTCF effect is observed. Using the
gender of each of the cell lines, observations are made about
which CTCF sites are dosage compensated, active on both chro-
mosomes, or are only bound in females.
Part II
D I SCOVERY OF QUANTITAT IVE
TRAITS

2
F INDING QTLS FOR CHROMATIN
ACCESS IB IL ITY
This chapter describes the results of discovery and the char-
acterisation of Formaldehyde-Assisted Isolation of Regulatory
Elements (FAIRE) regions as Quantitative Trait Loci (QTL). Data
from this chapter will later be re-used in Chapter 3 and Chapter
4.
2.1 introduction
By measuring FAIRE (Giresi et al., 2007) for a small population
of 60 lymphoblastoid cell lines (LCLs) that are part of HapMap,
it is possible to identify FAIRE-specific QTLs (FAIRE-QTLs).
Having a list of FAIRE-QTLs is useful for the interpretation of
genome-wide association studies (GWAS). If a FAIRE-QTL is
also known as an expression-QTL (eQTL), this might provide
a causal reason for the change in expression driven by this
genotype. However, because of the small sample size, there will
be many unidentified FAIRE-QTLs. In addition, when this study
was designed in 2009, the most cost-effective way to measure this
quantity of cell lines using a molecular assay was by using tiling
arrays. The tiling array was designed in such a way that probes
are targeted for known regulatory features. By design, the tiling
array is most likely enriched for regions with FAIRE activity.
However, as this process only assays known regulatory features,
it provides a limited view of how FAIRE acts genome-wide. In
essence, this should be interpreted as a pilot study, indicating
the potential for further discovery of FAIRE-QTLs, and thus
should be repeated using sequencing and a larger sample size
to achieve a more definitive result.
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2.2 results
To understand the genetic regulation of epigenetic marks, I
conducted a study using FAIRE as a quantitative phenotype
of chromatin accessibility. This was performed in LCLs rep-
resenting 60 unrelated individuals from northern and western
European ancestry (CEU) from the International HapMap Pro-
ject (International HapMap Consortium, 2003, 2005, 2007) and
the 1,000 Genomes (1000 Genomes Project Consortium et al.,
2010, 2012). I further address variance in this type of study
design and explore the relationships of FAIRE-QTLs with other
molecular and disease QTLs.
For this study, I performed all of the analysis. The growing
of cells and performing the tiling arrays was performed by the
group of Jason Lieb at University of North Carolina.
2.2.1 FAIRE intensity data for 60 CEU individuals
Sites of accessible chromatin were identified by FAIRE-chip us-
ing a custom Nimblegen probe design. The FAIRE-chip targets
10,507 regulatory regions that were previously identified as reg-
ulatory regions using DNase I, and that showed inter-individual
variance for CTCF binding in two trios (McDaniell et al., 2010).
Each identified regulatory region was ranked on inter-individual
variance, which enhances the likelihood of discovery of FAIRE-
QTLs.
The FAIRE-chip does not have genome-wide coverage. To
determine whether the measured FAIRE signal is only active
for the targeted regulatory element, two probes tiling the target
region were added. Using the readout of these two probes, I
was able to ensure that the measured FAIRE signal is specific to
the target region rather than a much larger region. The control
probes are approximately 100bp up- and downstream of the
target region. For example, for a regulatory region of interest,
our FAIRE-chip targets the signal over two control probes and
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several target probes (Figure 2.1). The target probes are sum-
marised into a probeset (FAIRE-peak). The FAIRE-peak signal,
for each target region, is the ratio of FAIRE-treated sample and
control sample. I used the statistical method Robust Multichip
Average (RMA) (Irizarry et al., 2003) to average all probes into
probesets, resulting in a final summary statistic (Section 2.5.1).
SNPs are only considered FAIRE-QTLs when the genotype as-
sociation is significant for the probeset but not for the control
probes.
To discover probe-specific variation in the FAIRE-chip, two
individuals are assayed five times as replicates. In this way,
both inter- and intra-individual variance can be determined for
each probe, and probes that exhibit too much inter-individual
variance can be removed.
In summary: There are 60 individuals assayed using our
FAIRE-chip, and two of these individuals are assayed five times
as replicates. All 60 individuals are genotyped, 56 in HapMap
v3, and 46 in Phase1 of the 1,000 Genomes Project.
2.2.2 Filtering out intra-individual variance
One of the most significant challenges when working with mi-
croarrays is hybridisation variation of the probes. The DNA
molecule in the sample may not hybridise equally well to each
probe for each individual sample.
For cell lines GM12891 and GM12892, replicates were grown
and harvested for FAIRE-chip. The comparison of replicates
indicated that the probe intensities of the last replicate were
negatively correlated. This could indicate a swap in CYS3 and
CYS5 for these samples (e.g. the background was labelled with
the wrong dye). To ensure data integrity, I decided to remove
these samples from the analyses.
To examine the role of the microarray design in introducing
signal variance, I filtered the most variable FAIRE-probes. The
variability for each probe was determined by taking the aver-
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tiling probes
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control left
control right
regulatory element
Figure 2.1: FAIRE tiling array design. For each regulatory element
of interest, a set of probes is designed to measure the
FAIRE signal (blue probes). To ensure that measured effects
are due to this specific regulatory element, a background
control probe is added on the left (red) and right (green)
side.
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age between the estimated standard deviation for both intra-
individual replicates sets. Using this method, individual spe-
cific probe variance will bias the filtering less significantly, as
only probes that are highly variable in both individuals will be
filtered. The top 1%, 5% and 10% ranking variable FAIRE-probes
were filtered out and used to determine the optimal filtering.
For the remaining four replicates, the intra-individual vari-
ance of replicates for both individuals was lower than the inter-
individual variance, as indicated by reduced correlation in the
inter-individual samples (Pearson R2 = 0.49 - 0.57 for within
GM12891 (Table 2.1) or GM12892 (Table 2.2), compared with R2
= 0.41 - 0.47 for between GM12891 and GM12892 (Table 2.3)).
Examining the effect on the Pearson correlation coefficients
(R2) for both the inter-individual (Table 2.3) and intra-individual
cases (Table 2.1, GM12891; Table 2.2, GM12892) comparisons
indicated that I could reduce the overall noise and improve
correlation by filtering the top 10% most variable probes across
all data sets.
The comparison of probe intensities between GM12891 rep-
licate 1 against GM12891 replicate 2 is shown (Figure 2.3). The
colouring indicates which probes remain after filtering the top 1,
5 and 10% of intra-individual variance. The Pearson correlation
coefficient between the two replicates increases from R2 = 0.49
to R2 = 0.57. It is clear that obvious outliers between the two
replicates have been removed, and that the probe intensities of
the probes after filtering are far more consistent between the
replicates.
To study the inter-individual variance, I compare the probe
intensities of GM12891 replicate 1 against GM12892 replicate 1
(Figure 2.2). The Pearson correlation coefficient between the two
replicates increases from R2 = 0.41 to R2 = 0.47, indicating that
the results are more comparable. Importantly, filtering improves
intra-individual variance more than it removes inter-individual
variance. This is significant because the inter-individual variance
is the signal of interest.
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Figure 2.2: Effect of filtering FAIRE probes on GM12891 replicate
1 against GM12892 replicate 1 as an example of inter-
individual variance. Probes are ranked by variance and
filtered accordingly. Effect for filtering none, top 1%, top
5% and top 10% is shown in colour coding.
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Figure 2.3: Effect of filtering FAIRE probes on GM12891 replicate 1
against replicate 2 as an example of intra-individual vari-
ance. Probes are ranked by variance and filtered accord-
ingly. Effect for filtering none, top 1%, top 5% and top 10%
is shown in colour coding.
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Table 2.1: Pearson correlation coefficient for the intra-individual vari-
ance and the effect of filtering for replicate GM12891. The
average estimated standard deviation for the probes is given
after each filtering step. Probes are filtered in order of their
respective variance.
Replicate
GM12891 SD 1 vs 2 1 vs 3 1 vs 4
No filter 0.78 0.49 0.52 0.47
1% 0.74 0.51 0.53 0.48
5% 0.66 0.54 0.56 0.51
10% 0.62 0.57 0.58 0.55
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Table 2.2: Pearson correlation coefficient for the intra-individual vari-
ance and the effect of filtering for replicate GM12892. The
average estimated standard deviation for the probes is given
after each filtering step. Probes are filtered in order of their
respective variance.
Replicate
GM12892 SD 1 vs 2 1 vs 3 1 vs 4
No filter 0.63 0.51 0.53 0.57
1% 0.61 0.53 0.56 0.59
5% 0.57 0.57 0.59 0.63
10% 0.54 0.60 0.62 0.65
Table 2.3: The results of the Pearson correlation coefficient for the inter-
individual variance. The resulting correlation coefficient for
different levels of filtering is given.
Replicate
GM12891 vs GM12892 1 vs 1 2 vs 2 3 vs 3 4 vs 4
No filter 0.41 0.55 0.54 0.66
1% 0.42 0.56 0.55 0.68
5% 0.45 0.58 0.57 0.69
10% 0.47 0.59 0.59 0.70
2.2.3 Filtering polymorphic probes
Since the design of the FAIRE-chip, new genotype datasets have
been published with novel SNPs and indels. SNPs and indels are
a known source for probe measurement variability in microarray
experiments when they are within the microarray probes. To
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remove this potential bias, I excluded 14,728 FAIRE-probes that
overlap with SNPs from the high-coverage trios from the CEU
1,000 Genomes pilot (1000 Genomes Project Consortium et al.,
2010). At the time of this study, this dataset best resembles the
population of this study.
2.2.4 Properties of the filtered FAIRE probes
Variance in hybridisation can be caused by differences in GC
content (Kuo et al., 2002). In a comparison of GC content bet-
ween filtered and non-filtered probes, there is no evidence that
explains the variance observed in the filtered probes (Figure
2.4 and 2.5), and the probe filtering did not exclude any of
the regions from the analysis (i.e. at least one probe for each
regulatory region remained).
Furthermore, comparison of the QTL analysis after removal
of these highly variable probes indicated that the removal of
these probes resulted in more QTLs (Section 2.2.5 and Figure
2.6a).
Therefore, for the discovery of FAIRE-QTLs, I applied a probe-
filtering step prior to calculating the FAIRE-peak signals. The
top 10% of FAIRE-probes sorted by variability (measured by
standard deviation) in the 4-day replicates dataset were filtered.
From these highly variable FAIRE-probes, 1,497 overlap the
probes that are filtered due to being polymorphic. Filtering both
the highly variable and the polymorphic FAIRE-probes removes
26,992 FAIRE-probes (19.6% of the FAIRE-probes (Table 2.7)).
After filtering, the probes are summarised into probesets using
RMA, which I refer to as FAIRE-peaks.
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GC content FAIRE-probes
Figure 2.4: GC content for the FAIRE probes that are non-polymorphic
and have low FAIRE variance.
GC content FAIRE-probes
Figure 2.5: GC content for FAIRE probes that are polymorphic or are
have high FAIRE variance.
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2.2.5 Finding proximal QTLs
In this section, I will use the 10,506 FAIRE-peaks and HapMap
genotypes to discover FAIRE-QTLs. Analogous to eQTL studies
(Stranger et al., 2007b), I identified associations by calculating
the Spearman’s Rank correlation. I correlate the signal betwe-
en each FAIRE-peak and proximal SNPs. I associate all SNPs
within 500kb up and downstream of the FAIRE-peak (1Mb win-
dow with FAIRE-peak in the middle), because with the current
sample size, only QTLs showing large effects can be discovered,
and these are mostly proximal. Empirical p-values under the
null distribution were determined by permuting the FAIRE an-
notation of the samples (N=1000, Section 2.5.4 for this method).
I consider SNPs within this window as being cis-acting. Associ-
ations were calculated for SNPs genotyped in 56 of the individu-
als in HapMap v3. Both of the replicate cell lines (GM12891 and
GM12892) used for filtering the FAIRE-probes were excluded
from the QTL analysis to avoid potential bias due to the applied
filtering method.
To study the impact on the QTL analysis of filtering the highly
variable probes identified from the replicate analysis, I com-
pared associations calculated with and without variable probe
filtration (Figure 2.6a). Comparisons of the Spearman’s Rank
p-values by using a Quantile-Quantile-plot (QQ-plot) indicate
that the unfiltered dataset revealed few, if any, significant associ-
ations. Upon filtering, the association results deviated from the
normal distribution at observed p-values smaller than 1.95x10−6,
providing a strong indication of significance above this level.
The top ranking association showed genome-wide significance
at a p-value of 3.7x10−11.
The associations based on the filtered data have lower p-values
and pass a more stringent empirical p-value threshold (Figure
2.6b, Figure 2.6c). This leads to more significant association
results after permutations when filtering is applied. In total,
significant QTLs can be found for 42 FAIRE-peaks (empirical
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Figure 2.6: FAIRE-QTLs QQ plot. For filtered and unfiltered FAIRE-
peaks, QTLs are mapped and empirical p-values are cal-
culated. In the QQ-plot, the filtered FAIRE-peaks result
in more significant results (a). The permutation empirical
p-value approach demonstrates that there are fewer signi-
ficant FAIRE-QTLs before filtering (b) than after filtering
(c).
p-value =< 0.5). Several QTLs are significantly associated with
multiple FAIRE-peaks, resulting in a total of 173 FAIRE-QTLs
(Table 2.4 brief overview FAIRE-QTLs, Supplementary Table
B.1 all FAIRE-QTLs). Given the empirical p-value threshold for
significance that was used, there is a considerably high level
of potential false discoveries. In the discussion section of this
chapter, I will address this concern in more detail.
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Table 2.4: Brief overview FAIRE-QTLs. The number of FAIRE-QTLs,
FAIRE-peaks and overlap with eQTLs is given for different
empirical p-values.
Empirical p-value FAIRE-peaks FAIRE-QTLs Overlap with eQTLs
<0.1 20 48 1
<0.2 24 94 19
<0.3 28 107 21
<0.4 31 121 24
=<0.5 42 173 45
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2.2.6 Functional analysis of FAIRE-QTLs
To understand the functionality of the discovered FAIRE-QTLs,
a more detailed analysis of these associations is performed. First,
I examine a FAIRE-QTL example. Second, I overlap FAIRE-QTLs
with other regulatory elements. Third, I overlay FAIRE-QTLs
with whole-body phenotype GWAS results. Finally, I overlay
FAIRE-QTLs with other molecular QTLs.
2.2.6.1 Example FAIRE-QTL
To illustrate how a FAIRE-QTL might look, I picked the fol-
lowing example. For FAIRE-peak 6090, located on chromo-
some 9 (138,444,546 to 138,446,041), the best association is with
rs2590504 (Spearman’s Rank p-value of 6.3x10−8) (Figure 2.7a).
Our probe design permitted me to confirm that the association
is specific to the targeted region and not part of a larger genomic
feature. I also tested the significant SNP for correlation with the
left and the right control probe (Figure 2.7b and Figure 2.7d). In
both cases, the correlations were not sufficiently significant to
pass the permutation threshold (empirical p-value > 0.5) (Figure
2.7c, p-values are 0.065 and 0.007, respectively). This contrasts
with the target region, in which the FAIRE-peak is significantly
correlated with the SNP (Figure 2.7d).
The location of the most significant SNP for each FAIRE-peak
is studied to determine if there is any location preference with
respect to the FAIRE-peak. Half of the FAIRE-QTLs are within
157,158bp distance of the targeted FAIRE-peak; this quantity
is significantly larger than expected (Figure 2.8, Fisher Exact
Test p-value = 0.001). This result is similar to eQTLs studies in
which SNPs proximal to the gene or transcript are most often
the eQTLs that are discovered.
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Figure 2.7: Example FAIRE-QTL for FAIRE-peak 6090, on chromosome
9 from 138,444,546 to 138,446,041. a) The genes surround-
ing the FAIRE-peak. b) All proximal FAIRE-peak SNPs
that have been tested for association with rs2590504 are
coloured red; our FAIRE-QTL and all other SNPs are col-
oured by their LD with respect to rs2590504. c) Schem-
atic overview of FAIRE-peak probes and flanking left and
right probe. d). Boxplots with associations of left flanking
probe, the FAIRE-peak and the right flanking probe with
rs2590504.
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Figure 2.8: Distance of the strongest FAIRE-QTL to its FAIRE-target.
The p-value of the FAIRE-QTL is given on the Y-axis and
the distance on the X-axis. Colour coding indicates the
empirical p-value under the null distribution. Half of the
significant associations are within 157,158bp of the FAIRE-
peak.
2.2.6.2 Regulatory enrichment of FAIRE-QTLs
To understand what other regulatory information is known
about the FAIRE-QTLs, I evaluated the data published by EN-
CODE (ENCODE Project Consortium, 2012). I selected all 173
significant FAIRE-QTLs (empirical p-value =< 0.5) and over-
lapped them with the regions identified by ENCODE as being
functional, using the Regulome DB tool (Boyle et al., 2012). The
Regulome DB tool will return a score indicating the level of
regulatory data that overlaps each SNP. A Regulome DB score
is a combination of a number and a letter. The number is the
52 finding qtls for chromatin accessibility
main score, where a score of 1 indicates that the SNP is an eQTL
and is overlapping transcription factor (TF) binding, while a 2
indicates there is an overlap with a TF but not with an eQTL.
Furthermore, the scoring varies depending on whether the SNP
overlaps with a DNase footprint, DNase peak and TF motif.
The letter portion of the score provides information about how
important the overlapping dataset is; for example, a TF motif is
more important than being located within a DNase peak. For a
complete description of the Regulome DB scoring scheme, refer
to Section 2.5.7
For five SNPs, Regulome DB reported that the SNPs might
be tri-allelic in some other population than CEU, and thus
excludes them. For 36 of the SNPs, Regulome DB reported
the lowest score, indicating no overlap with ENCODE data.
More interestingly, 28 SNPs were assigned the highest score,
indicating an overlap with at least one eQTL, and 9 had a
score of 2, indicating an overlap with a transcription factor
binding region and at least 2 other features (Table 2.5). The
highest-scoring SNP, rs10814581, was identified with a score of
1b. This score indicates that this SNP is an eQTL, inside a TF
binding, a DNase Footprint, and a DNase peak. Refer to Section
2.5.7 for RegulomeDB scoring.
I identified 54 FAIRE-QTLs that map within ENCODE FAIRE
peaks. There are 71 FAIRE-QTLs overlapping DNase-seq peaks
and that are identified as regions involved in chromatin struc-
ture. This gives a strong indication of the validity of these FAIRE-
QTLs as being directly involved in rearranging chromatin ac-
cessibility. For nine of our FAIRE-QTLs, there is an overlap with
CTCF binding sites. For 50 FAIRE-QTLs, there is an overlap
with one or multiple motifs. These results permit me to have
high confidence that the identified FAIRE-QTLs are SNPs that
have a regulatory function.
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Table 2.5: Enrichment of FAIRE-QTLs in ENCODE using Regulome
DB. The score indicates with how many regulatory datasets
the FAIRE-QTL overlaps and whether a given SNP is an
eQTL. A Regulome DB score of 1 indicates that the SNP
is an eQTL and overlaps transcription factor (TF) binding,
while a 2 indicates that there is an overlap with a TF but
not with an eQTL. Furthermore, the scoring varies depend-
ing on whether the SNP overlaps with a DNase footprint,
DNase peak and TF motif. For a complete description of the
Regulome DB scoring scheme, refer to Section 2.5.7.
Regulome DB score Number of FAIRE-QTLs
1b 1
1d 3
1f 24
2a 1
2b 8
3a 2
4 11
5 32
6 50
7 36
Excluded 5
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2.2.7 Comparison of FAIRE associations to other association studies
I selected known associations for autoimmune-related diseases
including Crohn’s disease, ulcerative colitis and Type 1 dia-
betes. I used the most recent list of known associations from the
Wellcome Trust Case-Control Consortium (WTCCC) (Wellcome
Trust Case Control Consortium et al., 2007) and the meta-analysis
results for Crohn’s disease and ulcerative colitis (Jostins et al.,
2012).
Because both our study and many GWAS were designed to
genotype functional regions of the genome, this will lead to a
bias. It is to be expected that a random selection of genotypes
with a phenotype associated to them (e.g. a GWAS hit) will be
more likely in non-coding but regulatory regions of the genome,
and thus are potentially biased for the FAIRE signal. By adding
height as an additional non-disease phenotype as a control that
is, most likely, non-immune related, the normal enrichment for
FAIRE within GWAS hits can be assessed.
For each SNP associated with a GWAS phenotype, I identified
SNPs that were also tested in this FAIRE association study. As
any SNP can be associated with several FAIRE-peaks, there can
be several FAIRE-QTL p-values for each SNP associated with
a disease. I plotted the FAIRE-peak p-values as a QQ-plot for
each disease association study and non-disease phenotype to
gain insight into potential enrichment of FAIRE-QTLs for other
phenotypes.
Coincidental overlap is a major point of concern when assess-
ing the direct overlap of QTLs with different GWAS studies. In
the case of a coincidental overlap, the lead QTL or GWAS-hit
for both associations is not in Linkage Disequilibrium (LD) with
each other, and thus the association is not driven by the same
genetic effect. To address this issue for each of the overlapping
SNPs, I determined what the LD between the overlapping SNP
and the lead FAIRE-QTL for that FAIRE-peak is. To accomplish
this, I used PLINK and the 1,000 Genomes CEU population.
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Figure 2.9: FAIRE-QTLs results when genotypes are selected that are
identified in GWAS studies. Shown are overlapping FAIRE
p-values for Height, Crohn’s disease, Type 1 diabetes and
Ulcerative colitis. The genomic inflation factor (λ) is given
for each QQ-plot; the red lines indicate the 95% confid-
ence interval. All disease phenotypes show FAIRE-QTL
enrichment, while height shows no abbreviation from the
expected distribution.
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When the LD is high (measured in r2), there is a high confidence
that both SNPs are a non-coincidental overlap. I classified each
of the overlapping SNPs as low LD (r2 < 0.3), medium LD (r2
between 0.3 and 0.7) and high LD (r2 > 0.7).
For several of the autoimmune-related diseases, the LCL
FAIRE-QTL p-values deviated from the expected uniform distri-
bution, indicating that the disease-associated SNPs at the tail of
the uniform distribution are likely to also influence chromatin
accessibility. In the other non-immune-related GWAS pheno-
types, including height, the QQ-plot does not deviate from the
expected uniform distribution, suggesting that the FAIRE-QTLs
p-values are uniformly distributed, and that none of the LCL
FAIRE-QTL SNPs show evidence of being enriched (Figure 2.9).
However, for none of the disease-associated SNPs I was able
to identify significant FAIRE-QTLs (empirical p-value > 0.5). As
our sample numbers are small, this is most likely due to the
effect size of the chromatin signatures nearby the selected SNPs
being too small to be detected as significant.
2.2.7.1 Expression QTLs
Several studies have examined the effect of noncoding variants
on a variety of molecular traits, including RNA expression,
chromatin accessibility, and transcription factor binding. To
better understand the interplay of these molecular traits and
to identify the extent of FAIRE-QTL involvement in expression
variation, I examined the overlap of the FAIRE-QTLs identified
here with other molecular trait datasets.
RNA-sequencing has been performed on the same 60 individu-
als. In these data, expression-QTLs (eQTLs) have been identified
for whole-transcript and exon expression levels using the same
HapMap genotypes (Montgomery et al., 2010). In Chapter 3 and
Chapter 4, I will discuss the direct correlation of FAIRE to gene
expression. Presently, I overlap the FAIRE-QTLs with the eQTLs
from Montgomery et al. The eQTLs have been published with
three different levels of permutation FDRs (< 0.001: 103 eQTLs,
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Figure 2.10: FAIRE-QTLs show enrichment for expression-QTLs
(Montgomery et al., 2010). The genomic inflation factor
(λ) is given and the red lines indicate the 95% confid-
ence interval. The colour coding indicates the Linkage
Disequilibrium (LD) between the lead QTL SNPs for both
phenotypes when there is an overlap. The LD shows that
SNPs with better p-values are nearly all non-coincidental
overlaps.
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< 0.01: 836 eQTLs and < 0.05: 3,258 eQTLs). From the set of
eQTLs at FDR < 0.05, there are 45 that are also FAIRE-QTLs.
I selected all SNPs that are eQTLs (FDR < 0.05) and tested
them for being a FAIRE-QTL. If an eQTL has been associated
with several FAIRE-peaks, only the best FAIRE-QTL is used.
Similarly to the overlap with GWAS phenotype, I determined
whether the overlapping SNPs are coincidentally overlapping
or not. Most of the SNPs overlapping are in low LD (3,096), and
only a minority is in medium (60) or in high LD (102). In the
QQ-plot, if I actively selected for known eQTLs in our study,
I observed a strong signal for significant FAIRE-QTLs (Figure
2.10). This indicates that many of the genotypes involved in
regulating expression are also likely to be involved in regulat-
ing chromatin signatures. The plot also indicates that a group
of overlapping QTLs are in tight LD with each other. This is
revealed by the sudden horizontal trend in the QQ-plot. The
FAIRE-QTLs with the highest p-values tend to be in high LD
with lead eQTL, indicating that they are driven by the same, or
similar, genetic effects.
2.2.7.2 DNase I QTLs
Chromatin accessibility can also be measured using DNase
I hypersensitivity. In a recent study, Degner et al. have ap-
plied DNase-seq on 70 individuals from YRI descent (Yoruba
in Ibadan, Nigeria) (Degner et al., 2012). By using DNase-seq
as a quantitative molecular trait, 8,902 DNase I-sensitive QTLs
(dsQTLs) were identified using HapMapv3 genotypes imputed
with the 1,000 Genomes Project genotypes. Because the sample
size of the dsQTL study is larger and the YRI population has
more genetic variation than the CEU population (1000 Genomes
Project Consortium et al., 2012), the dsQTL study has greater
statistical power to detect QTLs.
As I only use HapMap genotypes, I remove all non-HapMap
genotypes, leaving 6,464 dsQTLs. For each of the 6,464 dsQTLs,
I select the p-value from the FAIRE association. If a dsQTL has
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been associated with several FAIRE-peaks, only the FAIRE-QTL
with the lowest empirical p-value is used. For many of the
dsQTLs, there is no significance to any of the tested nearby
FAIRE-peaks.
For each FAIRE-QTL that is with a dsQTL, I determine if the
overlap is coincidental or not by determining the LD. Most of
the SNPs overlapping are in low LD (6,227) and only a minority
is in medium (176) or in high LD (61). Despite the two studies
being performed in different populations, the QQ-plot of the
FAIRE-QTLs that overlap indicates that there is an overlap of
chromatin accessibility QTLs (Figure 2.11). More importantly,
the overlapping QTLs with a low p-value (high in -log10) tend
to be the FAIRE-QTL or in high LD (green dots) with the FAIRE-
QTL and thus are non-coincidental overlaps.
I also noticed that there is a stronger deviation for the eQTLs
for FAIRE-QTLs identified in the matched European population
(Figure 2.10) than for the dsQTLs identified in the Yoruban
population, suggesting that there are haplotypes specific to each
population that are drivers for both expression and chromatin
accessibility.
2.2.8 Low coverage sequencing data to improve QTL discovery
The availability of tag-SNP genotypes from the HapMap Pro-
ject and the low coverage sequence genotypes from the 1,000
Genomes Project provided the opportunity to model the results
achievable using genome sequence-level data. I had originally
selected the entire set of the samples to be part of the expec-
ted Phase1 release of the 1,000 Genomes Project set. However,
currently only 46 of the samples have been sequenced and pub-
lished. Here, I refer to the genotypes derived from the 1,000
Genomes Phase1 release as the "denser" genotypes. Using these
denser genotypes requires an increased number of statistical
tests for the same window than when using HapMap geno-
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Figure 2.11: FAIRE-QTLs show enrichment for dsQTLs. There are
6,464 dsQTLs overlap with SNPs that are tested for being
a FAIRE-QTL. There is enrichment evident, indicating
that some of the dsQTLs are also FAIRE-QTLs. The light
red lines represent the 95% confidence interval for the ex-
pected distribution of p-values. The colours of the points
indicate the Linkage Disequilibrium (LD) between the
overlapping SNP and the lead FAIRE-QTL for that FAIRE-
peak. Overlapping SNPs with a high p-value are nearly all
in high LD with the lead FAIRE-QTL for their respective
FAIRE-peak.
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types. Because of this, lower p-values are required to pass the
equivalent empirical p-value threshold.
Nevertheless, comparison of the associations identified using
both genotypes showed that in many cases it is beneficial to
have denser genotypes available. This is because the causal
genetic variation, or a SNP in stronger LD with the causal
genetic variation, was present in the denser genotypes and thus
easier to detect even with lower sample size. To illustrate this, I
selected two FAIRE-QTL examples.
The first example involves FAIRE-peak 6090. I was able to
reconfirm the FAIRE-QTL to the same locus with the denser gen-
otypes. However, when the same SNP was tested for association,
the observed p-value was worse due to the lower sample size
(Figure 2.12). In addition, due to the greater genotype density,
the permutation-derived empirical p-value will be lower because
of the larger null distribution.
The second example involves FAIRE-peak 12062. To identify
the FAIRE-QTL using the original HapMap genotypes, the SNP
is not in enough LD with the causal locus to obtain a significant
p-value (Figure 2.13). When I re-analysed the same FAIRE-peak
with the 1,000 Genomes SNPs, I was able to obtain a significant
FAIRE-QTL. Consequently, while the statistical power was lower
due to the more limited sample size, new FAIRE-QTLs could be
identified.
A similar number of FAIRE-QTLs are discovered by using
HapMap as with the 1,000 Genomes genotypes. However, when
considering our empirical p-value cut-off, I identified more
FAIRE-QTLs with the HapMap genotype set than the 1000 Gen-
omes genotype set. For this reason, I focused the main analysis
on FAIRE-QTLs using the HapMap genotypes.
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Figure 2.12: Denser genotypes reconfirm the previously-identified
QTL. Due to lower sample numbers, when the same SNP
is tested for association, the p-value is worse for 1,000Gen-
omes genotypes. Inset is the zoomed-out FAIRE-target
region. The red lines outline the FAIRE-peak target.
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Figure 2.13: Denser genotypes are beneficial in identifying greater
number of QTLs. When denser genotypes are available,
these can help to identify new significant QTLs that would
not have been discovered with less dense genotypes. In
this example, the dense genotypes from 1,000 Genomes
enable identification of additional QTLs. The red lines
outline the FAIRE-peak target.
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2.3 conclusion
In this study, I utilised the FAIRE signal to identify chromatin
accessibility QTLs in a small population. Targeting 10,506 gen-
ome locations with known regulatory properties using tiling
arrays, I was able to identify 173 FAIRE-QTLs (empirical p-
value < 0.5) for 41 unique FAIRE sites. Furthermore, I will show
that denser genotypes from the 1,000 Genomes Project can be
beneficial. Using a denser genotype set, I identify additional
FAIRE-QTLs. However, because of the increased multiple testing
penalties and lower sample size, I used the HapMap genotypes
for the identification of FAIRE-QTLs. One in four of the identi-
fied FAIRE-QTLs were previously also identified as an eQTL.
Despite targeting only a small portion of the genome, using a
relatively small sample size, I identified strong associations of
SNPs with chromatin accessibility assayed by the FAIRE method.
This leads to new insights for several SNPs around the genome
in non-coding regions and suggests the function of regulating
chromatin directly or indirectly. Specific genotypes can lead
to the increase and decrease of accessibility, and thus are a
major force in regulating expression on a molecular level. As I
have shown, many of our identified FAIRE-QTLs are involved
with or related to biochemical events in the genome identified
by the ENCODE project. This strengthens evidence that these
FAIRE-QTLs are directly involved in adjusting and regulating
gene expression. However, without measuring additional assays
in the same individuals, it is impossible to ascertain the real
molecular function associated with these SNPs.
An important lesson for study design from this work is the ad-
dition of replicates when working with cell lines. I determined
that a small number of probes tend to have intra-individual vari-
ation that can give misleading inter-individual signals for the
targeted region. By removing the top 10% most variable probes
showing intra-individual variation, I was able to boost the sens-
itivity of our study, enabling application of more stringent em-
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pirical p-value thresholds without losing any associations. This
knowledge strengthens the case for ensuring that population
studies include multiple replicates for a few individuals.
In comparison with early tiling array eQTL studies, I found
fewer associations. The Pritchard group, using Illumina whole-
genome expression arrays (Stranger et al., 2007a), were able to
identify associations for 6.5% of targeted genes (Veyrieras et al.,
2008), compared with our results identifying a significant asso-
ciation for 1.6% of the targeted functional ENCODE elements at
the least stringent empirical p-value threshold. This difference
in yield between studies can be explained by our study design
focusing only on targeted regions of the genome, in which I
might not cover FAIRE regions of interest. However, the most
important reason is that in our study there is a much smaller
number of samples. Potentially, this also shows the limitation of
using tiling arrays for the readout. With the vast amount of data
published by the ENCODE consortium, a more optimal tiling
array could likely be designed that includes additional regions
showing inter-individual variance. Furthermore, with the de-
creasing costs of next-generation sequencing, FAIRE-sequencing
of all samples could be considered to increase the coverage of
FAIRE-QTLs on the human genome.
Many GWAS studies result in large numbers of associations
with non-coding genotypes, leaving the molecular explanation
unaddressed. The expectation is that many of these non-coding
genotypes are in regulatory regions where they, directly or indir-
ectly, influence gene expression. I found that many SNPs identi-
fied in GWAS show non-significant enrichment for FAIRE-QTL,
and that larger sample sizes could identify the significant SNPs
as FAIRE-QTLs. It is likely that these SNPs contribute to the
control of gene expression or transcription factor binding either
by directly altering protein-binding sites or perhaps through
regulating the accessibility of chromatin. Identification of these
SNPs as FAIRE-QTLs suggests plausible molecular mechanisms
to explain the association with disease. These results strengthen
66 finding qtls for chromatin accessibility
the idea of medical epigenetics, in which disease samples are
not sequenced and genotyped only to find genetic variations,
but also include the study of several epigenetic marks and chro-
matin accessibility. Our data suggest that FAIRE, or any other
chromatin accessibility assay, would be a good assay to include
in such a setting.
One in four of the FAIRE-QTLs is also an eQTL for transcript
or exon expression levels. As these eQTLs are identified using
the same individuals, this indicates a close biochemical connec-
tion between open chromatin and gene expression. For many of
the cases in which an SNP is both an eQTL and a FAIRE-QTL,
I found a strong correlation between the transcript levels and
the FAIRE-peak intensities, which will be discussed further in
Chapter 3 and Chapter 4.
Having established the benefits of a chromatin accessibility
assay in an association study, the choice of FAIRE in this study
is likely not optimal. Earlier publications have shown that there
is a high amount of overlap between DNase I hypersensitive
regions and FAIRE regions, which would make their results
complimentary (Song et al., 2011). In addition, it is known that
FAIRE has lower sensitivity at a similar sequence coverage than
DNase I (Kumar et al., 2013), making it the less favourable
assay in current practice. These readouts will create bias in
the analysis and lead to false positives in the association study.
At the moment, no DNase I sequencing data exists for the
same cell lines as in this study. Only a couple of cell lines
(mainly GM12878) are part of the central ENCODE cell lines,
and thus have DNase-seq available. However, these are not
nearly sufficient to perform a similar study as ours, because
the sample number is too low to reach any level of significance.
Instead, these DNase I data could be used to assess whether the
signal is consistent with the FAIRE-chip signal.
In later chapters (Chapter 3 and 4.) it is established that a
better signal for the FAIRE-chip is obtained when using each
FAIRE-probe independently as a measurement of chromatin
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accessibility. Using the 1,000 Genomes imputed genotypes, also
used for mapping CTCF-QTLs (Chapter 3), I am able to identify
16,972 FAIRE-probe QTLs with a significant empirical p-value
of < 0.01. This indicates that for inter-individual differences
that can be measured by FAIRE, they are most often located in
more narrowly-defined regions. Hence, using the independent
FAIRE probes will increase the amount of FAIRE-QTLs tremend-
ously and would make subsequent analysis potentially different
than their current presentation. It is noteworthy that when a
FAIRE-peak QTL has been discovered, the same genotype is
also associated with at least one of the individual FAIRE-probes.
Consequently, the FAIRE-probe QTL set is a superset of the
FAIRE-peak QTL set. For publication of the present chapter, it
will be best to use only the imputed genotypes associated with
the FAIRE probes as our main finding. It is still of interest to re-
port that some larger regions of the FAIRE signal are associated
with a QTL, in contrast with the FAIRE-probe QTLs.
2.4 data
2.4.1 Genotype data
I used HapMap Phase III version 2 genotype data for 57 of
the individuals in our main analysis (International HapMap
Consortium, 2003, 2005, 2007). For 46 of these individuals, I
used the June 2011 release genotypes of the 1,000 Genomes
Project as our denser genotypes data (1000 Genomes Project
Consortium et al., 2010, 2012). All individuals are from the CEU
population. Genotypes with a minor allele frequency (MAF) <
0.05 were filtered.
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2.4.2 FAIRE-chip data
I used FAIRE intensity levels that were measured in lympho-
blastoid cell lines (LCLs) from 60 unrelated individuals of the
CEU HapMap (HapMap individuals of European descent) pop-
ulation. The FAIRE intensities used were measured with our
custom-designed Nimblegen chip array (FAIRE-chip). Regions
of interest were selected by using the ENCODE pilot data. The
targeted regulatory regions have shown a high level of vari-
ation for DNaseI or CTCF signals between four individuals
(McDaniell et al., 2010). The targets are evenly distributed across
the genome and were prioritized by the presence of an allele-
specific signal from the four individuals, indicative of a possible
functional genetic polymorphism. For each target, a dense set
of between 10 and 21 probes of variable length (40-60bp, aver-
age 46bp) with, on average, 110bp intervals were designed to
measure the FAIRE signal.
2.4.3 Expression-QTLs
For exons and whole transcripts, eQTLs were obtained using
the mRNA fraction of the transcriptome (Montgomery et al.,
2010). These eQTLs are mapped within same 60 LCLs as my
study using 37-base pairs paired-end Illumina sequencing. In
total, 4,781 eQTLs are reported.
2.4.4 GWAS and molecular QTL datasets
I selected different sets of molecular QTLs, whole-body QTLs,
and immune-disease GWAS results from various sources (Table
2.6).
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2.5 methods
2.5.1 Robust Multi-array Average
I used the NimbleScan software version 2.6 www.nimblegen.com/
products/software/nimblescan/index.html to obtain Robust
Multi-array Average (RMA) (Irizarry et al., 2003) processed
expression values for our FAIRE-chip microarrays. RMA of
microarrays consists of the following steps:
1. The raw intensity probe values are background-corrected
2. The corrected probe values are Log2-transformed
3. The Log2 probe values are quantile-normalized
4. A linear model is fit to the normalized data to obtain an
intensity measure for each probe set on each array.
2.5.2 Filtering FAIRE-probes
For filtering and quality control purposes, five replicates have
been generated for GM12891 and GM12892. This yields five
measurements for each replicate (10 samples in total). Due to
potential sample swap, one replicate is dropped. Accordingly,
there are four usable replicates (8 samples in total).
For each probe, the average standard deviation in both in-
dividuals is determined. The probes are ranked descending
according the standard deviation of the replicates. The 10%
most variable probes are then removed from our dataset, prior
to RMA processing. Next, probes with known SNPs in the 1,000
Genomes Project are filtered (1000 Genomes Project Consortium
et al., 2010, 2012). Sufficient probes remain after filtering to be
able to determine a signal for each FAIRE target (Table 2.7).
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Table 2.6: SNPs that have been considered in the overlap with FAIRE-
QTLs and their corresponding reference
Phenotype Source Number
of SNPs
Crohn’s disease WTCCC and Jostins et.al.
(Jostins et al., 2012; Wellcome
Trust Case Control Consortium
et al., 2007)
73
Ulcerative colitis WTCCC and Jostins et.al.
(Jostins et al., 2012; Wellcome
Trust Case Control Consortium
et al., 2007)
47
Height Open GWAS (Johnson and
O’Donnell, 2009)
277
Type 1 diabetes NHGRI GWAS (Hindorff et al.,
2009)
387
Expression-QTLs Montgomery et al. (Montgomery
et al., 2010)
4,781
DNaseI-QTLs Degner et al. (Degner et al., 2012) 8,902
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Table 2.7: Effect of filtering FAIRE probes per chromosome and background. Polymorphic probes are probes that overlap SNPs in the low
coverage samples of the 1,000 Genomes and are subsequently filtered. The top 10% variable probes (the most intra-individual
variable probes) in our replicates are filtered. In both, all of the polymorphic and intra-individual variable probes are filtered.
Chromosome FAIRE-targets Original
probes
Polymorphic
probes
Variable
probes
Polymorphic +
variable probes
1 1006 12689 11424 11405 10277
2 766 9128 8181 8141 7296
3 641 7564 6808 6735 6049
4 422 4716 4213 4154 3717
5 504 11442 10296 10034 9025
6 596 7043 6325 6181 5552
7 515 6062 5428 5367 4805
8 416 4781 4270 4241 3793
9 468 5812 5233 5148 4635
Continued on next page
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Table 2.7: FAIRE probes
Chromosome FAIRE-targets Original
probes
Polymorphic
probes
Variable
probes
Polymorphic +
variable probes
10 476 7033 6334 6089 5502
11 608 7696 6957 6904 6233
12 518 6183 5573 5527 4989
13 211 2288 2057 2040 1834
14 381 4516 4080 4027 3633
15 324 4106 3716 3663 3310
16 396 5328 4800 4799 4333
17 534 7075 6393 6332 5720
18 188 2118 1883 1860 1652
19 590 7684 7029 6865 6286
20 313 3860 3462 3436 3075
Continued on next page
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Table 2.7: FAIRE probes
Chromosome FAIRE-targets Original
probes
Polymorphic
probes
Variable
probes
Polymorphic +
variable probes
21 115 1411 1257 1241 1116
22 250 3356 2998 2974 2654
X 269 3100 2804 3100 2804
BACKGROUND 0 2613 2322 2613 2322
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2.5.3 Testing for associations
I used Spearman’s Rank correlation to perform the pairwise
associations between the FAIRE-probesets or FAIRE-probes and
the genotypes. For each association, the Spearman’s Rank Rho
and p-value are stored. Within R, the function spearman.test
from the package pspearman was used for this purpose. Similar
to eQTL experiments with comparable sample sizes, I restricted
the discovery window to a 1Mb window, 500kb upstream and
500kb downstream, for each FAIRE-peak/FAIRE-probe. The
associations are performed using all of the HapMap and all of
the 1,000 Genomes genotypes. All locations are converted to
hg18 to compare the result of both associations.
2.5.4 Determining significance of associations
To address the multiple testing problem, I applied permutations
to determine the empirical p-value under the null distribution.
The empirical p-value is determined per FAIRE-peak, independ-
ently giving a different empirical p-value for each FAIRE-peak.
Our empirical p-value approach consists of the following 5 steps:
1. For each FAIRE-peak, I randomly swap the sample identit-
ies 1,000 times
2. Each random set of annotations is used to calculate a new
Spearman’s Rank correlation p-value
3. For each permutation, the lowest p-value is stored in the
FAIRE-peak specific null distribution
4. Each association is ranked within the FAIRE-peak specific
null distribution
5. Each rank is divided by the number of p-values in the null
distribution
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The rank in the null distribution divided by the number of
p-values in the null distribution is defined as our empirical
p-value (5).
Empirical p-value =
rank p-value in null distribution
number of permutations + 1
(5)
2.5.5 Identifying of FAIRE-QTLs previously identified in other phen-
otypes
After identifying FAIRE-QTLs in the current dataset using the
HapMap genotypes, I address their potential functionality by
overlapping with SNPs implicated in known GWAS pheno-
types from previously-published studies obtained from the
NHGRI GWAS or Open GWAS catalogs. Also, for Crohn’s
disease and ulcerative colitis, I used the most recent list of
known GWAS results from the Wellcome Trust Case-Control
Consortium (WTCCC) (Wellcome Trust Case Control Consor-
tium et al., 2007) and a large meta-analysis study (Jostins et al.,
2012). Because the FAIRE-QTLs were identified in lymphoid
cells, I assumed that the most likely overlap enrichment would
be with SNPs implicated in immune-related diseases, as op-
posed to other phenotypes. I selected known associations for
immune-related diseases including Crohn’s disease, ulcerative
colitis and Type 1 diabetes, as well as for height (Table 2.6).
2.5.6 Identifying known biochemical ENCODE regions using Reg-
ulomeDB
I selected all of the identified FAIRE-QTLs with an empirical
p-value of 0.5 and lower. I loaded this set of SNPs into the
RegulomeDB (Boyle et al., 2012). Two SNPs were discarded
because of possible tri-allelic annotation, and 1 SNP could not
be found for unknown reasons. After removal of those SNPs,
there were 163 SNPs that could be overlapped with known
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ENCODE regions. For each SNP, a Regulome DB score was
assigned (Table 2.8).
2.5.7 Regulome DB score
For Regulome DB the given score (Table 2.8) for each SNP
indicates the overlap with regulatory data (Boyle et al., 2012).
Table 2.8: Regulome DB score
Score Supporting data
1a eQTL and TF binding and matched TF motif and
matched DNase Footprint and DNase peak
1b eQTL and TF binding and any motif and DNase
Footprint and DNase peak
1c eQTL and TF binding and matched TF motif and
DNase peak
1d eQTL and TF binding and any motif and DNase
peak
1e eQTL and TF binding and matched TF motif
1f eQTL and TF binding or DNase peak
2a TF binding and matched TF motif and matched
DNase Footprint and DNase peak
2b TF binding and any motif and DNase Footprint
and DNase peak
2c TF binding and matched TF motif and DNase
peak
3a TF binding and any motif and DNase peak
3b TF binding and matched TF motif
4 TF binding and DNase peak
5 TF binding or DNase peak
6 other
7 none
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2.5.8 Data visualisation
Within R (Team, R Development Core, 2005), the package Gg-
plot2 (Wickham, 2009) was used to visualise all data.
For visualisation of an example FAIRE-QTL plot, I used Lo-
cusZoom (Pruim et al., 2010). In a LocusZoom plot the genomic
surrounding of the FAIRE-peak and the genotypes tested for
FAIRE-QTL are shown. In addition, for all genotypes the LD
towards the best scoring FAIRE-QTL is given.

Part III
D I SSECT ING EP IGENET IC
CORRELAT IONS US ING GENET ICS
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In this part of my thesis, I dissect how molecular regulatory
mechanisms are intertwined. This is accomplished by combin-
ing molecular and genetic population datasets. The datasets
combined in this part are from the Formaldehyde-Assisted Isol-
ation of Regulatory Elements (FAIRE) chapter (Chapter 2), a
collaborative project involving CTCF ChIP-seq (described be-
low), gene expression data from gEUVADIS (Lappalainen et al.,
2013), and transcription factor and histone modification data
from the ENCODE project (ENCODE Project Consortium, 2012).
For this section of my thesis research, I worked together in a
larger collaboration that resulted in a single publication about
CTCF biology, on which I am the joint first author (submitted).
To avoid confusion, I will first describe the general purpose of
the CTCF project and subsequently describe my portion of the
project.
In a population overlapping the individuals from the FAIRE
study, CTCF ChIP-seq experiments have been performed on
51 LCLs from CEU descent to discover Quantitative Trait Loci
(QTLs or CTCF-QTLs) and to study CTCF biology.
Zhihao Ding from theWellcome Trust Sanger Institute, Hinxton,
United Kingdom, performed peak calling, finding CTCF-QTLs
and characterising these. In addition, from the 51 individuals,
only 41 are part of the phase 1 release of the 1,000 Genomes
Project. To be able to use denser genotypes, Zhihao imputed
SNPs and indels for the missing 10 cell lines.
YunYun Ni from the University of Texas at Austin, Austin,
United States, performed the ChIP-seq experiments and defined
the allele-specific behaviour of CTCF in these lines.
I performed the discovery of insulating CTCF-loops by util-
ising the population data (Chapter 3), defining causality of
QTLs on insulating loops (Chapter 4), and investigating CTCF
behaviour on the X-chromosome (Chapter 5).

3
CORRELAT ING MOLECULAR PHENOTYPES
This chapter describes the results obtained from studying the
integration of FAIRE, CTCF and gene expression on the auto-
somes of 60 individual LCLs. Section 3.2.6, which addresses
CTCF-to-CTCF correlations, is part of a submitted paper on
which I am the joint first author. The other sections have been
written for this thesis.
3.1 introduction
For even the simplest biological process, there is a complex
myriad of interactions between many molecules. For example,
let us consider the change of gene expression due to a gen-
omic variant. Though the observation of the change of genotype
seems to infer a change in expression, this effect is almost never
a binary effect (i.e. active versus inactive). On the DNA level,
there is a complex system at play that combines dozens of
transcription factors (TF), histone modifications (HM), and chro-
matin accessibility changes. Each of these has to be ordered
in a specific way to accomplish the eQTL regulatory function.
Although the eQTL is correlated with the gene expression, to
fully comprehend the reason for this, an improved view of the
epigenome and its regulation is essential. This becomes even
more vital in understanding disease GWAS results, which are
commonly found in non-coding regions overlapping or nearby
regulatory elements (Schaub et al., 2012).
There is a great interest in the research community in increas-
ing the understanding of how different molecular phenotypes
interact. By acquiring a view of the epigenome in a group of indi-
viduals, it will be possible to improve our understanding of the
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interplay between components of the epigenome. In this chapter,
I integrate three datasets for a population of CEU LCLs. First,
I have the FAIRE dataset, as described in Chapter 2. Second, I
have a CTCF ChIP-seq dataset. Finally, I have a RNA-seq dataset
containing transcript abundances (Lappalainen et al., 2013).
There are several potential reasons that correlations exist bet-
ween different molecular phenotypes. I am interested in the
correlations caused by the biochemical link between molecules.
However, I must first address other sources of variance that
could introduce correlations. For example, the gender of the
individual or technical variances could create a systematic bias
leading to correlation. Another type of systematic variation can
be due to the cell lines themselves. Because each of the LCLs is a
mixture of B-cells, there can be differences in measured signals
due to a different ratio of B-cell subtypes (e.g. different ratio of
immature and mature B-cells).
To remove these sources of variation, different strategies may
be applied. First, by removing several components from a Prin-
cipal Components Analysis (PCA), the larger systematic effects
can be removed. Second, the molecular assays are performed
in different laboratories, using different cell growths, and thus
correlations cannot be driven by experimental factors specific to
a lab. Third, by performing permutations, I determine an empir-
ical p-value with which it is possible to determine significance
at a higher threshold than when using the Bonferoni correction,
while addressing the multiple testing problem. After these steps
are completed, the correlations that remain are most likely to be
due to biochemical interactions.
3.1.1 Molecular interactions
The different measured molecular phenotypes are known to
have the ability to regulate each other. CTCF is known to be
bound slightly upstream of open chromatin regions and often
changes the chromatin status (Boyle et al., 2008). In turn, open
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chromatin is known for its transcription activity (Gilbert et al.,
2004). Another molecular function of CTCF is to act as an in-
sulator protein. By forming a loop between two independent
CTCF sites, it can block accessibility to enhancers, promoters
and genes by changing the chromosomal 3D structure. By insu-
lating these regions, CTCF can regulate gene expression (Kim
et al., 2007).
By utilising individual differences for each of the molecular
phenotypes, I can discover the correlation between them (Fig-
ure 3.1). For example, if different CTCF sites have a correlating
profile of intensities across our individuals, these might be in-
volved in forming a CTCF-to-CTCF loop, or any other larger
biochemical mechanism. By doing this pair-wise, for all sites,
with all molecular phenotypes available for my population, I
can identify correlations between the assays and thus, poten-
tially, biochemical interactions. The combined discovery of all
correlations will help to create a limited epigenome view. In
Chapter 4, I will further study the epigenome by determining
the direct and indirect causal effects of QTLs.
FAIRE CTCF
RNA
Figure 3.1: Schematic overview of the integration of the different mo-
lecular assays analysed in CEU LCLs. Pairwise correlations
are performed between each assay.
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3.2 results
In this chapter, I will identify correlations between CTCF-RNA
pairs, CTCF-FAIRE pairs, FAIRE-RNA pairs, and CTCF-CTCF
pairs. To exclude any potential sex-chromosomal effects, only
the autosomes are used in this chapter.
3.2.1 Correlating assays
To identify whether molecular assays are correlated, pairwise
correlations are performed. To test for correlation, I use Spear-
man’s Rank correlation. Furthermore, when applicable, permuta-
tions are performed to calculate empirical p-values.
3.2.1.1 Discovery of significant associations
In order to address the multiple testing concern, permutations
(1,000) are performed on the pairwise correlations to determine
empirical p-values. With empirical p-values, it will be possible
to determine which correlations are significant and are not
occurring due to chance. The empirical p-values approach is
similar to the one used for FAIRE-QTL discovery in Chapter 3.
I will briefly explain the reason for using empirical p-values
and how this is implemented. For each pair tested for associ-
ation, I seek to determine whether they are significantly cor-
related with each other. However, problems might arise, as
some sites will be correlated, at some level, by pure chance.
The simplest solution would be the application of the Bonfer-
oni correction. However, the Bonferoni correction is, with the
number of correlations performed, too strict and will lead to an
unhelpful number of false negatives. The applied permutations
technique that will help to determine the empirical p-value is
more sensitive and, although computationally intensive, is used
in this thesis.
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Empirical p-values are determined on a site-by-site basis. For
each site, all of the other sites that are tested for association are
permuted 1,000 times. In each permutation, the annotation of
the individuals is randomly swapped for one site and correlated
against the other, original site. From each random permutation
round, the lowest p-value is stored. The collection of lowest
p-values is used to form a null distribution. By determining the
position of the original associated p-value in the null distribu-
tion, the chance of being able to find the same result by chance is
obtained. This is our empirical p-value. To illustrate an example,
consider correlating 500 A sites with 500 B sites. Site A1 is cor-
related with 500 B sites. Each of these correlations is permuted
1,000 times. For each permutation round, the best p-value is
stored in our null distribution (in this case, our null distribution
will contain 1,000 p-values). To obtain the site-specific empirical
p-value, the p-value of this correlation is ranked in the null
distribution (Equation 6).
Empirical p-value =
rank p-value in null distribution
number of permutations + 1
(6)
3.2.2 CTCF to RNA
As the first component of dissecting the epigenome, I evalu-
ate CTCF-RNA pairs. There are 37,245 RNA transcripts and
55,166 CTCF sites with CTCF ChiP-seq binding affinity on the
autosomes. To limit the search space, only intra-chromosomal
pairs are tested for correlation. In total, there are 107,989,952
intra-chromosomal CTCF-RNA pairs that are associated with
each other.
3.2.2.1 Results CTCF-RNA pairs
For each chromosome, a QQ-plot shows the results of these tests
(Figure 3.2). The colours of the points indicate the empirical
p-value threshold for that specific correlation. For CTCF-RNA
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pairs, it was possible to permute the CTCF sites or RNA expres-
sion. I decided to permute the RNA expression 1,000 times. In
the QQ-plot, I noted several points of interest, especially those
having p-values < 1x10−6 (green line) that deviated from the
expected uniform p-value distribution. For example, for chromo-
some 7 there is a clear group of points with empirical p-value
< 0.01 that derives from the line. Depending on the empirical
p-value threshold, there are between 7,297 (empirical p-value <
0.1) and 711 (empirical p-value < 0.01) significant CTCF-RNA
pairs (Table 3.1). In the remainder of this section, I consider
CTCF-RNA pairs significant at empirical p-value < 0.1.
Table 3.1: Overview statistics results for CTCF to RNA correlations.
Number of CTCF-RNA pairs per chromosome is reported.
Number of significant results per chromosome is given for
empirical p-values 0.1, 0.05 and 0.01.
Chr Combinations <0.1 <0.05 <0.01
1 18744880 712 347 74
2 10780536 531 276 55
3 7649994 468 232 48
4 4756536 411 190 30
5 5797274 421 209 44
6 6421618 408 195 45
7 5928228 417 212 45
8 3903540 297 142 36
9 3872790 291 153 27
10 4162995 366 185 34
11 7113106 369 169 29
12 5892201 382 199 32
13 1088898 156 79 20
14 3115534 330 161 22
15 2641272 263 117 22
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16 3129300 250 120 27
17 5498295 321 158 35
18 840180 178 89 14
19 3985185 314 168 31
20 1381408 176 76 16
21 282862 69 30 9
22 1003320 167 83 16
Total 107989952 7297 3590 711
3.2.2.2 Close-by correlations have positive Rho
Because CTCF is a known transcription factor (TF), the expect-
ation is that a change in binding of CTCF corresponds to a
potential change in transcription levels. To test this assumption,
I used all 7,297 significant CTCF-RNA pairs and binned them
according to the distance between the CTCF site and the gene.
There is a strong bias for significant CTCF-RNA pairs to be in
close proximity (< 10kb) to each other (Chi-square test p-value
< 1.8x10−9, Figure 3.3). The most significant CTCF-RNA pairs
are observed when the CTCF site is overlapping with a gene.
One of the interesting questions that can be answered with
this correlation approach is whether there is a generally positive
or negative effect (and thus correlation) between CTCF and
RNA. The Spearman’s Rank correlation Rho value indicates
the direction of the correlation. For example, if the Rho value
is positive, this is due to the phenomenon that when CTCF
binding is higher, there is higher gene expression. I took all of the
Spearman’s Rank correlation Rho values of both significant and
insignificant pairs. I separated them over several distance bins
(Figure 3.4). The reported distance is the distance between the
CTCF site and the gene. There is a strong trend for overlapping
CTCF-RNA pairs and CTCF-RNA pairs within 10kb distance
between each other to have a positive correlation (Chi-square
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Figure 3.2: QQ-plots for CTCF-RNA pairs on all human autosomes.
Each sub-plot represents a different chromosome. Empir-
ical p-value colour coding is based on 1,000 permutations
of the RNA sites.
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Figure 3.3: Distance plot for 7,297 CTCF-RNA pairs on all human
autosomes where empirical p-value < 0.1. The main plot
shows all pairs within 1Mb distance between each other.
The smaller plot is an overview of all pairs within 50Mb
distance between each other.
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test p-value = 0.004). However, given the nature of correlations,
no direction of causality can be determined by the Rho value.
Hence, correlations alone are not sufficient to determine whether
CTCF binding is changing gene expression or vice versa.
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Figure 3.4: Kernel smoothed density of Rho values CTCF to RNA
(violin plot). For a given distance, the Spearman’s Rank
correlation Rho value distribution is given. For each dis-
tance bin, the Rho distribution for the significant pairs
(empirical p-value < 0.1) and the non-significant pairs are
given. Overlapping and proximal (< 10kb) significantly
correlated pairs have mainly positive Rho values.
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3.2.3 CTCF to FAIRE
In this portion of dissecting the epigenome, I investigate the re-
lation between CTCF binding and chromatin accessibility meas-
ured by FAIRE. There are 55,166 CTCF sites with ChiP-seq
binding affinity and 10,509 FAIRE sites with FAIRE-chip ex-
pression on the autosomes. In total, there are 29,782,408 intra-
chromosomal CTCF-FAIRE pairs that are tested for association
using Spearman’s Rank correlation.
3.2.3.1 Results CTCF-FAIRE pairs
As shown for CTCF-RNA pairs, I create a QQ-plot for each
chromosome (Figure 3.5). For CTCF-FAIRE pairs permutations, I
permute the FAIRE sites 1,000 times to obtain empirical p-values.
In the QQ-plot, I noted several points of interest, especially with
Spearman’s Rank p-value < 1x10−6 (green line) that deviate
from the expected uniform p-value distribution. For example,
for chromosome 3 there is a clear group of points with empirical
p-value < 0.01 that are deviated from the expected p-value
trend. Depending on the empirical p-value threshold, there
are between 1,593 (empirical p-value < 0.1) and 147 (empirical
p-value < 0.01) significant results (Table 3.2). In the remainder
of this section, I consider significance at empirical p-value < 0.1.
Table 3.2: Overview statistics results for CTCF-to-FAIRE correlations.
Number of CTCF-FAIRE pairs per chromosome is reported.
Number of significant results per chromosome is given for
empirical p-values 0.1, 0.05 and 0.01.
Chr Combinations <0.1 <0.05 <0.01
1 5042072 151 69 12
2 3156686 114 46 11
3 2396699 112 53 9
4 1218736 40 17 3
5 1596305 65 29 11
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6 1910776 101 50 10
7 1501740 83 37 10
8 1073280 41 20 4
9 1088568 73 36 9
10 1290285 84 43 11
11 1779008 96 40 6
12 1562806 83 40 5
13 301519 43 20 4
14 779907 54 25 5
15 640548 46 24 2
16 752400 64 27 3
17 1380390 105 48 8
18 239324 29 16 3
19 1240770 101 48 11
20 490784 49 21 3
21 69805 17 7 1
22 270000 42 24 6
Total 29782408 1593 740 147
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Figure 3.5: QQ-plots for CTCF-FAIRE pairs on all human autosomes.
Each sub-plot represents a different chromosome. Empir-
ical p-value colour coding is based on permuting the CTCF
sites 1,000 times.
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3.2.3.2 Direct overlap of CTCF and FAIRE does not drive correla-
tion
For molecular phenotypes such as CTCF and FAIRE, a strong
correlation would normally be expected based on the proximity
of each of the sites. For example, when chromatin is open, it
would be more likely that CTCF could be bound. In our data
set, there is no indication that such an effect is present. However,
when looking at FAIRE sites that overlap CTCF sites (sometimes
multiple ones), there is no evidence in our association results to
support such a theory (Figure 3.6). A reason for this could be
that the actual accessible chromatin effect is only visible on the
probe level and not on the probeset level.
Number of CTCF sites in FAIRE probeset
Figure 3.6: CTCF sites that are overlapping FAIRE-targeted regions.
There is no difference in observed Spearman’s Rank correl-
ation p-values between CTCF sites that overlap the FAIRE
probeset and are not overlapping.
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3.2.4 CTCF to FAIRE probes
Regions targeted by FAIRE probesets are much larger than
the CTCF peaks. Because of this, direct changes derived from
CTCF binding might be missed in the averaging of all FAIRE
probes into a probeset. This might be the reason for the lack
of difference in results for sites that directly overlap (Section
3.2.3.2). To avoid this problem, I run the same analysis again, but
this time using each individual FAIRE probe as an independent
measurement of the FAIRE signal.
In total, there are 131,891 FAIRE probes. There are 384,023,280
intra-chromosomal CTCF-FAIRE probe pairs on the autosomes
that are tested for correlation using Spearman’s Rank correla-
tion. Using probes in comparison with the probesets yields an
additional 14,815 significant correlations (empirical p-value <
0.1), and much better p-values are observed (Figure 3.7, Table
3.3).
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Figure 3.7: QQ-plot CTCF-FAIRE: difference for using FAIRE probes
versus FAIRE probesets. he light red lines represent the
95% confidence interval for the expected distribution of
p-values. The genomic inflation factor (λ) is given for each
dataset. The FAIRE probes yield more correlations that
deviate from the expected trend than the FAIRE probesets
do.
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3.2.4.1 Results CTCF-FAIRE probe pairs
For each chromosome, a QQ-plot shows the results of the cor-
relations (Figure 3.8). The colours of the points indicate the
empirical p-value threshold for that specific correlation. In this
QQ-plot, I noted several points of interest, especially Spearman’s
Rank correlation p-values < 1x10−6 (green line) that deviate from
the expected line. For example, for chromosome 9 there is a clear
group of points with empirical p-value < 0.01 that deviate from
the expected p-value distribution. Depending on the empirical
p-value threshold, there are between 16,408 (empirical p-value <
0.1) and 1,563 (empirical p-value < 0.01) significant results (Table
3.3). In the remainder of this section, I consider significance at
empirical p-value < 0.1.
Table 3.3: Overview statistics results for CTCF to FAIRE probe correla-
tions. Number of CTCF-FAIRE probe pairs per chromosome
is reported. Number of significant results per chromosome
is given for empirical p-value thresholds of 0.1, 0.05 and
0.01.
Chr Combinations <0.1 <0.05 <0.01
1 63597268 1543 725 113
2 37516096 1119 551 109
3 28281796 1075 518 113
4 13619808 513 257 52
5 36168162 1252 623 105
6 22579858 958 486 107
7 17676792 819 407 82
8 12334980 575 283 48
9 13496146 803 418 81
10 19024265 819 394 71
11 22518496 1116 526 109
12 18654111 727 370 66
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13 3269552 285 124 27
14 9244252 515 245 46
15 8117562 457 227 45
16 10123200 624 295 55
17 18288875 920 411 94
18 2696214 269 129 28
19 16159452 1017 497 125
20 6052480 427 218 39
21 856477 150 68 14
22 3624480 425 197 34
Total 383900322 16408 7969 1563
3.2 results 101
Figure 3.8: QQ-plots for CTCF-FAIRE probe pairs on all human auto-
somes. Each sub-plot represents a different chromosome.
Empirical p-value colour coding is based on permuting the
CTCF sites 1,000 times.
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The expectation is that CTCF and FAIRE probes are more
likely to correlate than FAIRE probesets (Section 3.2.3). To study
this, I took all CTCF-to-FAIRE probe pairs that had an empirical
p-value < 0.1. Of these significant pairs, there were 12 pairs
that overlapped. From these 12 pairs, only 1 had a negative
Rho value (-0.6), while all other pairs had a Rho larger than
0.5 (rounding these Rho values, 9 had Rho 0.5 and 2 had Rho
0.6). This suggests that in the cases in which both CTCF and
FAIRE are measured for a particular location, there is a positive
correlation, suggesting a potential biochemical link.
Although the number of significant pairs that overlap is lower
than in CTCF-RNA pairs (Figure 3.3), there is a strong tendency
to be in close proximity with each other (Figure 3.9). CTCF-
FAIRE probe pairs within 100kb distance of each other are signi-
ficantly more often correlated to each other than more distant
pairs (Chi-square test p-value < 1.4x10−7).
I took all of the Spearman’s Rank correlation Rho values
of both significant and insignificant pairs and separated them
over several distances between the CTCF site and the FAIRE
probe bins (Figure 3.10). There is a strong trend for pairs within
10kb distance of each other to have a positive correlation. This
suggests that when CTCF sites are correlated and overlapping
or proximal (< 10kb) to a FAIRE probe, they have a positive
correlation (Chi-square test p-value = 0.04).
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Figure 3.9: Histogram CTCF-FAIRE probe distance for all significant
(empirical p-value < 0.1) pairs for all within 50Mb between
each other (A), and all pairs within 1Mb distance between
each other (B).
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Figure 3.10: Kernel-smoothed density of Rho values for CTCF to
FAIRE probes (violin plot). For a given distance, the Spear-
man’s Rank correlation Rho value distribution is given.
For each distance bin, the Rho distributions for the signific-
ant (empirical p-value < 0.1) pairs and the non-significant
pairs are given. Overlapping significant pairs have only
positive Rho values. Proximal pairs (< 10kb) are signific-
antly positively correlated to each other (Chi-square test
p-value = 0.04).
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3.2.5 FAIRE probes to RNA
In this portion of my exploration of the epigenome, I investigate
FAIRE to RNA expression. When testing the correlation between
CTCF and FAIRE, it was determined that for examining molecu-
lar phenotype correlations, it is preferable to analyse the probes
instead of the probesets (Section 3.2.4). In this section, I will,
for this reason, use FAIRE probes. In total, there are 261,574,637
intra-chromosomal FAIRE-RNA pairs that are tested.
3.2.5.1 Results FAIRE-RNA pairs
For each chromosome, a QQ-plot shows the results of the cor-
relations (Figure 3.11). The colours of the points indicate the
empirical p-value threshold, obtained by permuting the RNA. In
the QQ-plot, I noted several points of interest, especially below
the Spearman’s Rank correlation p-value < 1x10−6 (green line)
from the expected distribution. For example, refer to chromo-
some 19, where there is a group of FAIRE-RNA pairs with em-
pirical p-value < 0.01 that deviate. Depending on the threshold,
there are between 17,058 (empirical p-value < 0.1) and 1,880
(empirical p-value < 0.01) significant FAIRE-RNA pairs (Table
3.4). In the remainder of this section, I consider FAIRE-RNA
pairs significant at empirical p-value < 0.1.
Table 3.4: Overview statistics results for FAIRE probes to RNA ex-
pression correlations. Number of FAIRE-RNA pairs per
chromosome is reported. Number of significant results per
chromosome is given for empirical p-values 0.1, 0.05 and
0.01.
Chr Combinations <0.1 <0.05 <0.01
1 47456860 1867 917 205
2 23878848 1093 548 102
3 15475944 1049 553 144
4 7767252 568 294 65
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5 20984628 1479 746 149
6 14107129 1013 544 122
7 12324046 727 336 69
8 7233653 590 294 58
9 9676980 762 387 98
10 10823787 974 496 94
11 18708976 1062 528 116
12 12075399 902 469 110
13 1743456 313 146 37
14 6873352 552 263 47
15 5485616 537 289 66
16 8775216 670 334 82
17 15048525 757 371 85
18 1397880 252 131 31
19 14561180 836 434 93
20 3400660 554 274 51
21 657526 124 66 13
22 3117724 377 202 43
Total 261574637 17058 8622 1880
I used the distance between the FAIRE and RNA for each
FAIRE-RNA pair to study whether proximal or overlapping
sites are more likely to correlate. Of the significant FAIRE-RNA
pairs, there are 91 pairs that overlap. From these 91 pairs, only 1
has a negative Rho value (-0.6), while all other pairs have a Rho
larger than 0.5 (rounding these Rho values, 50 have Rho 0.5, 35
have Rho 0.6, and 5 have Rho 0.7). This result suggests that in
cases where there is an overlap, FAIRE is positively correlated
with RNA abundance (Chi-square p-value < 1.0x10−24). For the
non-overlapping significant pairs, there is a strong tendency to
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Figure 3.11: QQ-plots for FAIRE-RNA pairs on all human autosomes.
Each sub-plot represents a different chromosome. Empir-
ical p-value colour coding is based on permuting the RNA
sites 1,000 times.
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be in close proximity (< 10kb) between each other (Chi-square
p-value < 1.0x10−14, Figure 3.12).
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Figure 3.12: Histogram of FAIRE-RNA distance for all significant (em-
pirical p-value < 0.1) pairs. The main plot shows all pairs
within 1Mb distance between each other. The smaller plot
is an overview of all pairs within 50Mb distance between
each other.
FAIRE probes show mainly positive correlation with RNA.
Nearly all significant FAIRE-RNA pairs that are overlapping or
proximal have a positive Spearman’s Rank Rho (Figure 3.13). In
comparison with CTCF-FAIRE pairs and CTCF-RNA pairs, the
FAIRE-RNA pairs have a positive Spearman’s Rank correlation
Rho value for all distances. For FAIRE-RNA pairs, I observed
that most significant correlations within 100kb have a positive
Spearman’s Rank correlation Rho value (Chi-square p-value <
1.0x10−16).
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Figure 3.13: Kernel smoothed density of Rho values FAIRE-RNA (vi-
olin plot). For a given distance, the Spearman’s Rank
correlation Rho value distribution is provided. For each
distance bin, the Rho distribution for the significant pairs
and the non-significant pairs are given. Proximal (< 100kb)
and overlapping significant pairs have mainly positive
Rho values (Chi-square p-value < 1.0x10−16).
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3.2.6 CTCF to CTCF
There are several biochemical models in which CTCF sites form
a loop. To study the correlating properties of CTCF, I performed
Spearman’s Rank correlation for each pair of CTCF sites on
autosomes. I call these correlations CTCF-CTCF pairs. As for
CTCF-CTCF pairs both sides of the pair are from the same
dataset, permutation-based empirical p-values are not feasible.
Therefore, a single Spearman Rank correlation p-value threshold
was used to establish significant pairs. There are 57,167 CTCF
sites, and in total there are 80,329,389 CTCF-CTCF pairs tested
for association using Spearman’s Rank correlation.
3.2.6.1 CTCF insulating loops are common
For the 80,329,389 combinations of intra-chromosomal CTCF-
CTCF pairs, I found that 8,060 are nominally significantly cor-
related (Spearman’s Rank correlation p-value < 1.0x10−6). The
fraction of CTCF sites that are significantly correlated are similar
for each chromosome (Table 3.5), and the p-value distribution
for each chromosome is similar (Figure 3.14). Some CTCF sites
are involved in multiple CTCF loops, but the vast majority of
CTCF sites is only associated with a single other CTCF site
(Figure 3.15). The observation that, for most CTCF-CTCF pairs,
the CTCF sites involved are only involved in one nominally sig-
nificant pair, supports the idea that there is no larger systematic
bias driving the correlations.
The distance between significant CTCF-CTCF pairs is highly
variable (Figure 3.16). The distance ranges from proximal sites
(410bp distance) to distal sites (237Mb distance). In general,
most significant CTCF-CTCF pairs are proximal to each other.
The Spearman’s Rank correlation Rho values range for negative
Rho values between -0.78 and -0.62, and for positives betwe-
en 0.62 and 0.97. The number of significant CTCF-CTCF pairs
with positive or negative Rho values is skewed towards posit-
ive correlation, with 559 negatively-correlated pairs and 7,501
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Chromosome
Figure 3.14: QQ-plot for all CTCF-to-CTCF correlations for all auto-
somal chromosomes. Each autosome is coloured differ-
ently.
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positively-correlated pairs. This is as expected, because for a
CTCF insulating loop to be present, both CTCF sites should
have an increased CTCF signal.
To gain a better understanding about how the CTCF-CTCF
pairs are correlated, I compared the Spearman’s Rank correlation
Rho values for the significant pairs versus the insignificant pairs
(Figure 3.17). Irrespective of the distance between the CTCF
sites in a CTCF-CTCF pair, the significantly correlated pairs
have a positive Rho. This indicates that both sites realise similar
additional CTCF binding. This could be an indication of a CTCF
loop being formed between the two CTCF sites directly, or
indirectly through another biochemical complex.
Table 3.5: Overview results CTCF to CTCF correlations. For each chro-
mosome, the total number of tested and significant (Spear-
man’s Rank p-value < 1.0x10−6) CTCF-pairs is given.
Chromosome All combinations Significant pairs
1 12557566 578
2 8489260 463
3 6988191 417
4 4168828 273
5 4994380 159
6 5137615 367
7 4250070 271
8 3326910 235
9 2703975 129
10 3657160 239
11 4279275 370
12 4549636 254
13 1020306 115
14 2094081 736
15 1953276 1675
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16 1804050 258
17 3339820 225
18 809628 67
19 2210253 802
20 1228528 171
21 183921 51
22 582660 205
Total 80329389 8060
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Figure 3.15: Histogram showing the number of significant associations
that are observed for each CTCF site. Most CTCF sites
with a significant correlation (Spearman’s Rank p-value <
1.0x10−6) are only associated with a few sites.
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Figure 3.16: Histogram distance for all 8,060 significant CTCF-CTCF
pairs on all autosomes. Main plot shows CTCF-CTCF
pairs that are within 100kb distance of each other. The
smaller plot is an overview of all pairs within 50Mb dis-
tance of each other. Most significant CTCF-CTCF pairs
are proximal to each other.
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Figure 3.17: Kernel-smoothed density of Spearman’s Rank Rho values
for associated CTCF-CTCF pairs. For a given distance, the
Spearman’s Rank correlation Rho value distribution is
given. For each distance bin, the Rho distributions for the
significant pairs and the non-significant pairs are given.
For any given distance, the significant pairs are mainly
positively correlated.
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3.2.7 Validating CTCF-CTCF pairs using ChIA-PET
To gain additional insight into the significance of the observed
CTCF-CTCF pairs, I explored the overlap with CTCF ChIA-PET
data. I used three CTCF ChIA-PET datasets from ENCODE
(ENCODE Project Consortium, 2012) measured in MCF-7 (in
replicate) and in K562.
As the ENCODE datasets are not performed in LCLs and
use a slightly different chemistry, they explore different CTCF
sites than those investigated in my study. To overcome this
disparity between the datasets, I focus only on the CTCF-CTCF
pairs and ChIA-PET CTCF-CTCF pairs that could have been
identified in both studies. To do this, I overlap all of the CTCF
sites from my study with the CTCF sites in the ChIA-PET data.
Only if both CTCF sites in my study are found as a pair or
independently in the ChIA-PET data do I consider them. In this
way, both studies can identify the same CTCF-CTCF pairs. For
this reason, only the CTCF-CTCF pairs on chromosomes 18 and
20 are considered.
The distribution of Spearman’s Rank Rho values for each set
of overlapping CTCF-CTCF pairs is given for ChIA-PET data-
set MCF-7 replicate 1 (Figure 3.18a), MCF-7 replicate 2 (Figure
3.18b) and K562 (Figure 3.18c) in violin plots. The left violin
plot is for CTCF-CTCF pairs from which both CTCF sites are
found in a ChIA-PET pair, but they are not paired by ChIA-PET.
The right violin plot shows the CTCF-CTCF pairs that are also
identified using ChIA-PET. There are more significant CTCF-
CTCF pairs that overlap ChIA-PET, as is visualised in the higher
density of the right violin plot for significant Spearman’s Rank
Rho values. This tests whether the distribution of the CTCF-
CTCF pairs that overlap ChIA-PET are significantly different
from the non-overlapping ones. I use the KolmogorovSmirnov
(KS) test for this analysis. With the KS test, it is possible to
compare two different distributions and test how equal they
are (goodness-of-fit test). The KS test can be used to determ-
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ine whether the Spearman’s Rank p-values distributions for
ChIA-PET and non ChIA-PET pairs are equal, because as shown
earlier, both distributions are different and the KS test can assess
if these difference are significant. I use the KS test to determine
whether the overlap is greater than the non-overlap. Both MCF-7
replicates (KS p-value = 1.5x10−19 and KS p-value = 1.7x10−10)
and the K562 (KS p-value = 2.8x10−6) are significantly greater.
These results indicate that for all ChIA-PET datasets, the sig-
nificant CTCF-CTCF pairs are significantly more often also a
ChIA-PET CTCF pair. Given the size of the data set, the KS test
is most likely not strict enough. This becomes evident, as the
subtle differences in the distributions do not significantly affect
the KS test results.
In this thesis, I use Spearman’s Rank p-value < 1.0x10−6 as a
threshold for nominal significance for CTCF-CTCF pairs. At this
p-value threshold, the Spearman’s Rank correlation Rho value is
at least 0.62 for positive correlations. However, at this threshold,
there are only a few CTCF-CTCF pairs that overlap with ChIA-
PET CTCF pairs. For this reason, for the FDR calculations, I use
a lower threshold, which is based on the Rho value rather than
the p-value. The FDR discovery rate is determined for CTCF-
CTCF pairs with a Rho > 0.5 (Figure 3.18, red line). The FDR is
determined after transforming the non-overlapping CTCF-CTCF
pairs to match the size of the overlapping CTCF-CTCF pairs.
Both MCF-7 replicates give a FDR of 0.05 at Spearman’s Rank
Rho > 0.5. For K562 at Spearman’s Rank Rho > 0.5, the FDR is
0.11. As these FDRs are determined for a higher Spearman’s
Rank correlation p-value than used previously, it is reasonable
to say that our significant results are all at least significant with
a FDR < 0.05.
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Figure 3.18: CTCF-CTCF pairs overlapping ChIA-PET. A) Overlap
with K562, B) overlap with MCF-7 replicate 1, and C)
overlap with MCF-7 replicate 2. Only MCF replicate 1 has
overlap with inter-chromosomal CTCF-CTCF pairs. For
all ChIA-PET datasets, the overlapping pairs have signi-
ficantly higher Rho values. False Discovery Rates (FDR)
are determined for pairs that are positively correlated
(Spearman’s Rank Rho values > 0.5).
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Both the KS test results and the FDR data indicate that the
CTCF-CTCF pairs identified by correlations are found signific-
antly more often in ChIA-PET data. However, my method of
detection of CTCF-CTCF pairs only discovers pairs that have
individual differences. Therefore, many CTCF-CTCF pairs that
are biochemically linked without these abundant differences can
only be found in the ChIA-PET data.
3.2.7.1 CTCF-loops show specific TFs and HMs profile
CTCF loops are known to have many different molecular func-
tions and roles depending on cell type and environment (Chapter
1.3). Many of these functional differences require that CTCF
must interact with different transcription factors, histone marks,
and different chromosome statuses to perform its function. To
study this with respect to the length of the CTCF loops, all signi-
ficant CTCF-CTCF pairs (Spearman’s Rank p-value < 1.0x10−6)
on chromosomes 18 and 20 are binned based on the distance
between the two CTCF sites of a pair. Each CTCF site that is part
of the CTCF-CTCF pair, thus both the "left" and the "right" CTCF
site, is overlapped with available ENCODE data measured on
GM12878. When replicates are available, multiple overlaps for
the same factor or histone mark are present. For each overlap,
the signal intensity is averaged for the CTCF-pair and scaled
per column to enable direct intensity comparison between the
ENCODE datasets (Figure 3.19).
There is a strong difference in overlapping intensity "pro-
files" for CTCF-CTCF pairs when the distance is shorter than
1Mb. For example, the transcription factors YY1, ZNF143 and
ELF1 overlap strongly with longer loops (> 1Mb), while there is
hardly any overlap with proximal loops (Students t-test p-value
< 0.05). There is no obvious known biological reason for having
this distinctive difference in overlap pattern for these specific
transcription factors. It is interesting to note that Handoko et
al. suggest that in mice, a distinct difference in overlap of TFs
and HMs is observed for loops longer than 200kb (Handoko
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et al., 2011). One of the most commonly known involvements
of CTCF is the cohesin complex. There is no difference in over-
lap profile with members of the cohesin complex, RAD21 and
Smc3, depending on the distance between the CTCF sites. For
the long-distance linkages, a possible reason for the overlap
with many other TFs and HMs can be found in the fact that
these are mainly in hotspot regions or that these are all part of
transcriptional factories (Ling et al., 2006).
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Figure 3.19: CTCF-loops show distinctively different profiles for
lengths. The Y-axis divides CTCF-CTCF pairs based on
distance, from proximal (top) to being located on differ-
ent chromosomes (bottom). The average ENCODE signal
overlapping both CTCF sites is given. The ENCODE sig-
nal intensity is scaled to enable direct comparisons. A
distinctive difference in overlap patterns can be observed
for CTCF loops smaller than 1Mb (Students t-test p-value
< 0.05 for YY1, ZNF143 and ELF1).
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3.2.8 Molecular assays are highly correlating
Combining all of the previously-discovered significant asso-
ciations into a single system could identify larger molecular
systems at play. To discover these systems, I overlap all signi-
ficant FAIRE-CTCF pairs, FAIRE-RNA pairs, and CTCF-RNA
pairs. There are 345 instances where each molecular assay is
significantly associated with another.
I have selected an example to illustrate such a system. Located
on chromosome 1, there is a system involving a FAIRE probe
(chr1:226591906-226591950), CTCF site (chr1:227015770-227016147)
and gene (ENSG00000203685, chr1:226736501-226796915) that
are correlated (Figure 3.20). The regulatory features are proximal
to the gene (144kb and 279kb). The measured RNA originates
from a gene located in middle of the CTCF site and FAIRE
probe (Figure 3.20A). The FAIRE probe and gene expression
are positively correlated (Spearman’s Rank p-value 3.8x10−7,
Rho 0.62). The CTCF site and the FAIRE probe (Spearman’s
Rank p-value 2.2x10−7, Rho -0.66) and the CTCF site and the
gene expression (Spearman’s Rank p-value 1.7x10−4, Rho -0.32)
are negatively correlated (Figure 3.20B). This system provides a
strong example of how the final gene expression is correlated
with the status of FAIRE and CTCF. Although both FAIRE and
CTCF can independently indicate something about the expec-
ted gene expression (or vice versa), it is only when both are
considered that the gene expression can most accurately be pre-
dicted. A potential explanation for this would be that, in this
case, the binding of CTCF is regulating the accessibility of the
proximal chromatin, enabling potential gene expression. This
could be accomplished, for example, by CTCF insulating the
promoter region. However, given the current data, this hypo-
thesis is not statistically testable. To further study this observed
system of correlations, I overlapped the location of the FAIRE
probe, CTCF site, and gene with FAIRE, DNase I, CTCF, SMC3,
RAD21 and ATF3 data from ENCODE measured in GM12878
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(ENCODE Project Consortium, 2012) (Figure 3.20C). I also in-
cluded the average FAIRE probe intensity; this highlights the
regions that are measured with the FAIRE tiling array. The CTCF
site overlaps with both SMC and RAD21; this indicates a poten-
tial involvement of CTCF in cohesin. CTCF in a cohesin complex
is known for its regulatory function, and thus this could indic-
ate the reason for the observed correlations. The FAIRE probe
overlaps a region with higher DNase I activity. However, not
visible on this plot, the actual probe does not overlap with a
DNase I peak. The FAIRE-probe is, however, overlapping with
an Activating transcription factor (ATF3) peak. This could be
the reason why this FAIRE probe is showing correlation with
both the CTCF and the gene expression, as it might be a proxy
measurement for the actual ATF3 activity. Noteworthy is that
the FAIRE-seq in GM12898 for this entire region does not show
any FAIRE signal. This lack of signal strengthens the idea that
the FAIRE-probe is actually based on ATF3 activity.
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Figure 3.20: Example FAIRE-CTCF-RNA correlation. A) The FAIRE
probe, CTCF site and gene are all proximal. All three
assays are associated with each other using Spearman’s
Rank correlation. The Rho value indicates the direction
of the correlation. B) The FAIRE probe and the CTCF
site have a negative correlation that affects the gene ex-
pression that is indicated by the colour. C) The region
overlapped with several ENCODE datasets measured in
GM12878 (ENCODE Project Consortium, 2012). The entire
region shows no evidence of FAIRE-seq enrichment. The
FAIRE probe is adjacent to a DNase I-enriched region and
overlaps a ATF3 peak. The CTCF site overlaps a RAD21
and SMC3 peak; this potentially indicates that the CTCF
site is part of the cohesin complex.
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3.3 conclusions
The correlation results in this chapter suggest that, even when
considering only a small population of cell lines, there is a
great abundance of significant correlations. Though some assays
are more often associated with one another, there is no great
imbalance between the results achieved, even when only con-
sidering intra-chromosomal autosome pairs. There are, in total,
8,060 significant CTCF-CTCF pairs, 16,408 CTCF-FAIRE pairs,
7,297 CTCF-RNA pairs, and 17,058 FAIRE-RNA pairs (empirical
p-value < 0.1).
Independent of which assays are associated with each other,
most significant pairs are proximal to each other. This is strong
evidence that these correlations are being driven by local bio-
chemical interactions rather than global cellular features. The
different pairs show for overlapping and proximal pairs that
Spearman’s Rank correlation Rho is nearly always positive. This
is expected, and could indicate that chromatin accessibility is
responsible for gene expression or vice versa (Boyle et al., 2011;
Hoffman et al., 2012; Thurman et al., 2012). There is scientific
evidence for both cases, and my data and analysis can only
identify these correlations, but not determine causality. The
CTCF-CTCF pairs in this result most likely indicate that these
different CTCF sites are biochemically linked (directly in loops
or within larger complexes). When ChIA-PET CTCF data for a
single or multiple LCLs becomes available, this could be used
to validate my results.
3.3.1 The molecular pathway regulating transcription
Combining all of the significant phenotype-to-phenotype correl-
ations can provide a useful indication of how intertwined these
assays are on a functional level. There are 345 examples of sys-
tematic correlations between FAIRE, CTCF and gene expression
(i.e. all assays are correlated with each other). These systems
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show how the different assays interact with each other and that
there is, potentially, a strong link of causality between them.
However, given that I only use molecular assays at a single time
point, no direction of causality can be determined. As such, it
is not possible, for example, to conclude whether chromatin
accessibility enables transcription factor binding, or vice versa.
However, the associations suggest that most assays are posit-
ively correlated when in close proximity. While causality from
DNA towards transcription is a complex combination of bio-
chemical events, our assays, and their correlations, suggest that
this is far from a random process. I have population data for
chromatin accessibility (FAIRE), transcription factor binding
(CTCF), and gene expression. The correlations between all of
these data suggest that gene expression is mostly positively cor-
related with chromatin accessibility (i.e. when chromatin is more
accessible, there is more gene expression). Also, gene expres-
sion is positively correlated with CTCF binding. Furthermore,
chromatin accessibility is, for proximal sites, positively correl-
ated with CTCF binding. This combined knowledge suggests a
far-from-random association between each of the phenotypes.
Unfortunately, using the current combination of only molecular
assays, it is not possible to determine causality. However, as
QTLs are observed for each molecular assay, I will discuss in
the next chapter how I can use QTLs to determine direct and
indirect causality.
3.3.2 Lengths of CTCF-CTCF pairs suggest different roles
For all of the CTCF-CTCF pairs found, a more detailed examin-
ation was performed for those on chromosomes 18 and 20. To
gain insight into the role of CTCF loops, the significant CTCF-
CTCF pairs are overlapped with a wide variety of TFs, HMs and
whole-genome assays measured on GM12878 by the ENCODE
consortium. By clustering the CTCF-CTCF pairs on the length
of the potential loops (the distance between both sites), a clear
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distinctive profile is found. CTCF-CTCF pairs that are within
1Mb distance of each other show less overlap with HMs or TFs.
Rad21 and SMC3, the only members of the cohesin complex that
were measured, show no bias for short or long loops. The longer
CTCF-CTCF pairs show a much stronger overlap profile, with
many of the measured histone modifications as well as several
transcription factors. Most interesting is the difference between
the overlap of factors like YY1, ZNF143 and ELF1, although no
obvious biological functional reason for this is known. However,
mediator is a known transcriptional cofactor involved in bind-
ing two cohesin units to form DNA loops (Kagey et al., 2010),
and I could not study these mediator-enabled DNA loops as
there is no mediator ChIP data available that was measured on
GM12878.
When partially reconstructing the epigenome of a small pop-
ulation using only FAIRE, CTCF, and transcript information, a
high amount of correlation between the different measurements
can be observed. There are thousands of significant correlations,
and when these data sets are combined, there is a strong sugges-
tion that there is a particular way the system works to regulate
transcription. The FAIRE data suggest that the chromatin has
to be in accessible status for CTCF to bind and for transcrip-
tion to be increased. By correlating CTCF sites to each other, I
discovered many potential CTCF loops. There appears to be a
significant difference in biochemical activity depending on the
length of the loops, which indicates a divergence in functionality.
3.4 data
3.4.1 CTCF
I obtained ChIP-sequencing data for 51 unrelated individuals
from the CEU HapMap population. On each of the sequencing
files, peaks were called. To address biological and technical
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variance that had not been accounted for, the data were quantile-
normalised, centred, and the first PCA component was removed.
Out of 63,753 CTCF sites identified, Zhihao found 2,898 CTCF
sites falling in repeat sequences or regions with complex struc-
tures in the genome. We reasoned that a much larger sample
size is required to resolve the complex structures in these re-
gions, and that they should be removed from our analysis. In
detail, 2,578 CTCF sites lie completely within repeat sequences
marked by a merged set consisting of Repeat Masker, Segmental
Duplication, or Simple Repeats data sets from the table browser
of the UCSC Genome Browser. 35 CTCF sites lie within the
Immunoglobulin heavy chain locus (chr14:106053226-106330470)
and 285 fall in the Major histocompatibility complex (MHC)
region (chr6:28477797-33448354). We also removed 3,427 CTCF
sites showing very little signal.
The number of CTCF sites before and after filtering is con-
sistent with the length of each chromosome and ranges, after
blacklisting filtering, from 33 for chromosome Y, to 5012 for
chromosome 1 (Table 3.6).
Table 3.6: Number of CTCF sites per chromosome
Chromosome All After blacklisting
1 5935 5012
2 4970 4121
3 3981 3739
4 3113 2888
5 3429 3161
6 3664 3206
7 3210 2916
8 2839 2580
9 2600 2326
10 2925 2705
11 3070 2926
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12 3156 3017
13 1503 1429
14 2247 2047
15 2242 1977
16 2066 1900
17 2728 2585
18 1369 1273
19 2237 2103
20 1616 1568
21 646 607
22 1196 1080
X 2782 1968
Y 229 33
3.4.2 FAIRE
I obtained FAIRE-chip data for 60 individuals from the CEU
HapMap population. For details, refer to Chapter 2.4.2. When
using the FAIRE peaks, the first PCA vector was removed. The
first three PCA components are removed when using FAIRE
probes to reduce systematic variance.
3.4.3 RNA-seq
I obtained RNA-sequencing data for all individuals of the CEU
HapMap population for whom we have FAIRE or CTCF data
from the Geuvadis consortium (Lappalainen et al., 2013). Paolo
Casale determined a per-gene abundance using BitSeq 0.4.3
(Glaus et al., 2012) for all protein-coding genes. The Ensembl
Homo sapiens GRCh37.69 gene build is used as the reference
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genome (Flicek et al., 2012). The first PCA component is removed
to reduce systematic variance.
3.4.4 ENCODE datasets on GM12878
GM12878 is a lymphoblastoid cell line produced from the blood
of a female donor with northern and western European ancestry
(CEU) by EBV transformation. This cell line has been part of
the original HapMap consortium and has since been featured
as a central cell line for ENCODE (ENCODE Project Consor-
tium, 2012; ENCODE Project Consortium et al., 2007) as well as
for deep sequencing in HapMap (International HapMap Con-
sortium, 2003, 2005, 2007) and 1,000 Genomes (1000 Genomes
Project Consortium et al., 2010, 2012). Due to the study design
of ENCODE, there is a large amount of molecular data available
for this cell line, and due to its nature, it is a good reference cell
line for our CTCF and FAIRE panel. For GM12878, I obtained
data for transcription factors (Table 3.7), histone modifications
(Table 3.8), and genome-wide sequencing assays (Table 3.9).
As within the ENCODE consortium, the following abbrevi-
ations are used to indicate the source lab/university for each
dataset:
• Broad is Broad Institute of MIT and Harvard
• Duke is Duke University
• Haib is HudsonAlpha Institute for Biotechnology
• OpenChrom is Duke University, The University of North
Carolina at Chapel Hill, and The University of Texas at
Austin
• Sydh is Stanford University, Yale University, University of
Southern California, and Harvard University
• Uw is University of Washington
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Table 3.7: Transcription Factors in ENCODE
Lab Transcription
Factor
Number
of peaks
Haib ATF3 1884
Haib BATF 24600
Haib BCL11A 13256
Haib BCL3 6147
Haib BCLAF1 3422
Sydh BRCA1 339
Sydh CHD2 4036
Broad CTCF 40006
OpenChrom CTCF 42492
Sydh CTCF 42808
Uw CTCF 35011
Broad CTCF 61525
Stanford CTCF 79957
Haib EBF1 27622
Haib EBF1 27655
Sydh EBF1 25043
Haib EGR1 1236
Haib EGR1 13662
Haib ELF1 20528
Haib EP300 3687
Sydh EP300 716
Haib ETS1 2879
Sydh FAM48A 11
Sydh FOS 1744
Haib GABPA 5095
Sydh IRF3 711
Continued on next
page
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Table 3.7: Transcription Factors in ENCODE
Lab Transcription
Factor
Number
of peaks
Haib IRF4 14229
Haib IRF4 14229
Sydh JUND 1715
Sydh KAT2A 26
Sydh MAX 2087
Haib MEF2A 16694
Haib MEF2C 6777
OpenChrom MYC 2415
Sydh NFE2 713
Sydh NFKB1 10073
Sydh NFKB1 10390
Sydh NR2C2 1054
Sydh NRF1 5042
Haib PAX5 19618
Haib PAX5 14340
Haib PBX3 7431
Haib POLR2A 20091
Haib POLR2A 34699
OpenChrom POLR2A 12781
Sydh POLR2A 21446
Sydh POLR2A 9040
Sydh POLR3A 150
Haib POU2F2 14441
Haib RAD21 36015
Sydh RAD21 27295
Stanford RAD21 23947
Continued on next
page
3.4 data 133
Table 3.7: Transcription Factors in ENCODE
Lab Transcription
Factor
Number
of peaks
Haib REST 2541
Sydh RFX5 3069
Haib RXRA 2965
Haib SIN3A 10504
Haib SIX5 4442
Haib SLC22A2 14592
Sydh SMC3 25470
Haib SP1 13139
Haib SPI1 35821
Haib SRF 2412
Haib SRF 9118
Sydh STAT1 9
Sydh STAT3 124
Haib TAF1 5169
Sydh TBP 9766
Haib TCF12 15028
Haib USF1 7074
Sydh USF2 6794
Sydh WRNIP1 1138
Haib YY1 22261
Sydh YY1 1821
Haib ZBTB33 1934
Haib ZEB1 8304
Sydh ZNF143 18310
Sydh ZZZ3 740
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Table 3.8: Histone modifications in ENCODE
Lab Histone modi-
fication
Number
of peaks
Broad H2AFZ 40693
Broad H3K27ac 30501
Broad H3K27me3 10100
Broad H3K36me3 37061
Broad H3K4me1 41605
Broad H3K4me2 45162
Broad H3K4me3 24575
Broad H3K79me2 34750
Broad H3K9ac 20320
Broad H3K9me3 26162
Broad H4K20me1 6024
Uw H3K27me3 18085
Uw H3K36me3 44425
Uw H3K4me3 24112
Table 3.9: Genome-wide sequencing assays in ENCODE
Lab Assay Number
of peaks
OpenChrom FAIRE 235562
Duke Dnase 183953
3.4.4.1 CTCF ChIA-PET ENCODE datasets
In the ENCODE datasets, there are no CTCF ChIA-PET assayed
in LCLs available. However, for 2 other cell lines, CTCF ChIA-
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PET has been performed (ENCODE Project Consortium, 2012).
K562 is a female cell line of a patient with myelogenous leuk-
emia (Lozzio and Lozzio, 1975). MCF-7 is a female cell line of
a patient with breast cancer (Soule et al., 1973). For MCF-7, a
replicate CTCF ChIA-PET is also available. In Table 3.10, the
number of ChIA-PET CTCF pairs is provided for chromosomes
18, 20 and between 18 and 20.
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Table 3.10: ENCODE CTCF ChIA-PET dataset
Cell line Chr18 - Chr18 Chr18 - Chr20 Chr20 - Chr20
K562 226 487
MCF-7 439 8 1175
MCF-7 133 561
3.5 methods
3.5.1 Testing for associations
I used Spearman’s Rank correlation to perform the pairwise
associations between each of the datasets. Within R, the function
spearman.test from the package pspearman was used for this
purpose. For CTCF-to-CTCF, CTCF-to-FAIRE, CTCF-to-RNA,
and FAIRE-to-RNA, I limited the associations to all pairs on the
same autosomes. For each pairwise association, the p-value, Rho,
and distance between the sites are stored for further analysis.
3.5.2 Testing associations for significance
To address the multiple testing issue, empirical p-values are
determined for all associations, excepting the CTCF-to-CTCF
associations. To accomplish this, permutations are performed.
The empirical p-value is determined by ranking the original
p-value within a site-specific null distribution. The empirical
p-value is obtained using the following steps:
1. For each region, I randomly swap the annotations 1,000
times
2. Each random set of annotations is used to calculate a new
p-value
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3. For each permutation, the lowest p-value is stored as our-
region specific null distribution
4. Each association is ranked within this null distribution
5. Each rank is divided by the number of p-values in the null
distribution
The rank in the null distribution divided by the number of
p-values in the null distribution is considered our empirical
p-value (7).
Empirical p-value =
rank p-value in null distribution
number of permutations + 1
(7)
For CTCF-FAIRE and CTCF-RNA interactions, I considered
each CTCF site as a tested location. For FAIRE-RNA, I con-
sidered each FAIRE peak, or FAIRE probe, as a tested location.
3.5.3 Comparing CTCF-CTCF pairs with ChIA-PET data
To compare the distribution of identified CTCF-CTCF pairs that
are also CTCF ChIA-PET pairs, I used the KolmogorovSmirnov
(KS) test. CTCF-CTCF pairs are considered to be overlapping
if both CTCF sites overlap a ChIA-PET CTCF pair with at least
1bp.
The KS test is a nonparametric method to compare two
samples for differences in the shape and location of both dis-
tributions. By testing for differences between the two groups
of CTCF-CTCF pairs using the KS test, I am able to determ-
ine whether ChIA-PET pairs are more likely to be significantly
correlated with the population data.
3.5.4 Overlapping assays
To determine which other molecular phenotypes overlap with
the significant pairs, I perform an overlap based on the peaks
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called in ENCODE. I consider an overlap to exist if at least 1bp
is overlapping.
3.5.5 Data visualisation
Within R (Team, R Development Core, 2005), the package Gg-
plot2 (Wickham, 2009) was used to visualise all data.
4
THE DRIVER OF EP IGENET IC CORRELAT IONS
This chapter expands on the results obtained in Chapter 3 by
integrating Quantitative Trait Loci (QTLs).
4.1 introduction
The nature of the epigenomic landscape was assessed with the
combination of the Formaldehyde-Assisted Isolation of Regu-
latory Elements (FAIRE), CTCF binding and gene expression
techniques (Chapter 3). The high correlation of data between
these molecular traits, driven by their functional and biochem-
ical dependency, does not allow determination of the chain
of causality. Genotypes, especially the germ-line variations, are
unique in that they offer a mostly fixed reference point to analyse
the correlations. Assuming that there are no somatic mutations
in the cell lines, each experiment is performed on a fixed set
of genotypes that are tagged in HapMap and 1,000 Genomes.
Given this assumption, the genetic backgrounds for the cells
used for the FAIRE, CTCF and gene expression experiments are
identical. Therefore, any individual differences in the epigenome
are, when the environment is identical, at some level, most likely
due to a causal regulatory genotypic effect. Obviously, some of
the observed epigenome differences can be attributed to pop-
ulation substructures rather than a single genotype. However,
this study has been performed on unrelated individuals, which
have been selected within HapMap to avoid population struc-
tures. Another potential pitfall is that for some of the epigenome
correlations, with genotypic regulation, the regulation could be
attributed to coincidentally-overlapping loci rather than coincid-
ental loci. In these cases, the given genotypic regulation is not in
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linkage disequilibrium (LD) with the real genotypic regulation,
and is thus not causal.
4.1.1 Inference of causality
When assessing association studies and their causality, there
is a chance that the association is confounded and thus false.
Within the field of epidemiology, a method has been established
to avoid such confounding issues. Mendelian randomisation
is the idea, first described by Katan (Katan, 1986), that within
meiosis each allele has an equal chance being parental and
maternal (Katan, 1986), and thus the germline genetic variations
can be used as a proxy for environmental changes (Wheatley
and Gray, 2004) (Lawlor et al., 2008). This random assortment
of alleles, and thus genotypes, gives raise to a situation similar
to a randomised trial (Davey Smith and Ebrahim, 2005). As
such, the knowledge of known effects of genetic variation can be
used to understand what variance can be expected from other
environmentally-influencable phenotypes, such as diseases. The
incorporation of this knowledge of variation in combination
with confounder effects provides a much more reliable method
to affirm genetic association studies that claim causality. When
Mendelian randomisation is applied within population studies,
it has demonstrated its effectiveness. For example, in coronary
disease, it has been shown that not C-reactive protein (C Reactive
Protein Coronary Heart Disease Genetics Collaboration (CCGC)
et al., 2011) but rather lipoprotein(a) is causal (Kamstrup et al.,
2009).
Another method to understand causality is structural equation
modelling (SEM) (Haavelmo, 1943; Wright, 1921). Using SEM, it
is possible to model and study how phenotypes relate to each
other through direct and indirect genetic influence (Gianola and
Sorensen, 2004). When incorporating all genotype-to-phenotype
and phenotype-to-phenotype interactions in a SEM, it would be
possible to predict the effect of a genotype change or the effect
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of an environmental change. However, given the significant
number of unknown phenotypic relations and the effect that
genotypes have on them, constructing an SEM is challenging.
4.1.2 Direct versus indirect causality
In this chapter, I introduce genotypes and analyse the effect on
the phenotype-to-phenotype correlations using assay-specific
QTLs. The interactions between FAIRE, CTCF and gene expres-
sion from the previous chapter are used; however, now the
analysis incorporates the corresponding QTL effects (Figure
4.1). To explore the order of these interactions, I will start from
the genetic effects and infer their direct and indirect molecular
functions. The results of this chapter can be used as an indicator
of these kinds of interactions and their molecular functional-
ity. However, as previously stated, usage of SEM or Mendelian
randomisation would be beneficial to establish true causality.
FAIRE CTCF
RNA
QTL
Figure 4.1: Causality of a QTL inside a complex integration of FAIRE,
CTCF and RNA. A QTL can have an effect on each of these
molecular events independently, but most likely, there is a
single direct causal effect and the rest are indirect causal
effects.
When two sites correlate and one of them has a QTL, this QTL
will also, at some level, correlate with the other site. For example,
if FAIRE correlates with CTCF and there is a known CTCF-QTL,
this QTL will likely show similar significance when tested as
FAIRE-QTL (Figure 4.2). Although both of the genotypes can
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be significantly associated with two different phenotypes, there
is a risk that both QTLs are coincidentally overlapping and
thus are not actually driven by the same genetic effect (e.g. the
best QTLs for both phenotypes are in high LD, but are actually
associated with both phenotypes). When this is not the case,
and both phenotypes are driven by the same genetic effect, it
is interesting to study which processes the QTL is driving the
most.
Obviously, the causality can be similarly dissected for the
same situations holding for CTCF-to-CTCF, CTCF-to-FAIRE,
FAIRE-to-RNA, and CTCF-to-RNA.
FAIRE CTCF
QTL
Figure 4.2: Causality of a QTL. When a QTL is both associated with,
for example, FAIRE and CTCF, the question remains: what
is the real causal effect and what is the indirect effect?
In this chapter, I will use the terms direct and indirect causality.
For each QTL, there is, possibly, a single direct causal effect,
while all other observed changes are indirect (Figure 4.3). For
the population of interest, I have measured chromatin status,
CTCF binding and transcription. These molecular assays were
shown in the previous chapter to be highly correlated. However,
given the limited dataset, there will be other active biochemical
pathways that are unmeasured in these correlations. For this
reason, for not all discovered correlated phenotypes, the direct
causal effect was measured and thus effects are indirect.
Molecular assays are an indirect measurement of the actual
phenotype. Because of this, there might be crosstalk between
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the actual phenotype that is influencing the measurement. Fur-
thermore, the assay could, for various reasons, achieve more
precise quantifications at different genomic locations. For ex-
ample, there will be some crosstalk between FAIRE and CTCF,
as these two biochemical events overlap. For example, in order
for CTCF to bind, the chromatin has to be accessible, and thus
FAIRE can be proxy for CTCF binding.
To dissect whether a QTL is affecting phenotype A or phen-
otype B, several correlation were performed. A naive view of
discovery of the most likely causal pathway would be to assess
the strength of the correlations (given by effect size). In addition,
it is also possible to assess conditional correlation. For each
QTL, I calculate its effect using Spearman’s Rank correlation
and store the p-value for significance and Rho value for the
effect size. For the first correlation, the original phenotype is
used. For the second correlation, I regress out the other molecu-
lar phenotype first. After this, I compare the Spearman’s Rank
correlation p-values (in -log10 scale) to determine the effect of
the regression for both molecular phenotypes (I call this delta).
The delta p-value can be used to determine which phenotype is
most affected by the QTL.
To illustrate this, I provide the following example (Figure
4.4). QTLx is correlated with phenotype A and phenotype B,
both have a similar Spearman’s Rank p-value (8) and Rho value
(0.5). When phenotype B is regressed out of phenotype A, the
Spearman’s Rank correlation between QTLx and the residuals
gives p-value 6 and Rho 0.4. When phenotype A is regressed
out of phenotype B, the Spearman’s Rank correlation between
QTLx and the residuals gives p-value 1 and Rho 0.1. The delta in
p-value indicates that regressing out phenotype A has the largest
effect. Hence, for this particular example, the direct causal effect
of QTLx is most likely phenotype A, making phenotype B the
indirect effect. This method will provide a good indication about
the causality of the QTL in the given epigenetic correlation. The
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delta will be used to rank all pairs; in this way, common patterns
in causality can be discovered.
A potential pitfall of this method is that the compared p-
values are influenced by the quality of the assay that is used. For
example, if an assay has more internal variation, this will, by
nature, lead to worse p-values and thus a potential bias towards
this assay being less-often causal. I also split the result in each
of the plots based on the QTL of discovery; in this way, it is
possible to determine that not all directions of causality are in
the direction of the assay in which the QTL was discovered
originally. To avoid major differences in p-values between the
assays caused by different sample sizes, only individuals are
used that have been evaluated by all three assays. Throughout
this chapter, I will use the delta of Spearman’s Rank p-value to
discriminate between direct and indirect causality.
An issue when overlapping different molecular QTLs is that
sometimes overlapping QTLs are in the same region, but not
being driven by the same underlying locus (i.e. coincidental
overlap of QTLs). In these cases, although a QTL is overlap-
ping, this is not the real or true QTL. One way to address
this problem is to determine the LD between the best QTL
for each of the overlapping molecular phenotype. In this way,
only QTLs that are in high LD should be considered for caus-
ality determination, because only for these cases is the same
locus (and thus genetic regulation) used. Unfortunately, there
is no genome-wide QTL data (each study focussed only on
nearby variants for QTL mapping) for the different molecular
assays, and thus we cannot assess whether the overlapping QTL
is also the best QTL genome-wide. Especially, because many
phenotype-to-phenotype correlations are distal, the QTL data
does not overlap. For this reason, some of the conditional regres-
sions performed in this chapter can be attributed to phenotypes
being driven by two distinct QTLs. This will most likely be true
for many of the pairs that are located far away from each other.
For this reason, I have only showed examples, if possible, when
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the distance between the molecular phenotypes is small and
the LD between the best QTLs is high (r2 > 0.8). However, for
many of the cases that I do not show (but which are part of
the distributions), I cannot determine the LD between the best
QTLs, because the distance between both molecular phenotypes
is too great, and there is no way of knowing if a distal QTL is
actually the best QTL.
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FAIRE
CTCF
RNA
QTL
RNA
Direct causality Indirect causality
FAIRE
CTCF
Other
RNA
CTCF
FAIRE
RNA
FAIRE
CTCF
Figure 4.3: Direct versus indirect causality. Although a genotype might
have been observed to be associated with a specific phen-
otype such as a QTL, this does not necessarily imply a
direct causal effect. Most likely, for many QTLs, the only
observation made will be indirect.
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Figure 4.4: Direct versus indirect causality example. A given genotype
is associated with two different molecular phenotypes as
being a QTL with similar Spearman’s Rank p-value and
Rho. The difference in p-value (delta p-value) is 0, and
thus there is no indication of this QTL being specific for
phenotype A or B. After regressing out phenotype A out
of B and B out of A, the same correlations are performed,
and the difference in p-values is calculated. In this case,
the delta p-value is 5. This indicates that, for this example,
phenotype A is the direct causal effect and phenotype B
the indirect causal effect.
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4.2 results
The high number of associations between FAIRE, CTCF and
gene expression requires a limitation of the potential overlap
between their results. In this chapter, only the significant pairs
are taken into consideration. For the CTCF-CTCF pairs, signi-
ficance is defined as a Spearman’s Rank p-value <1.0x10−6. For
the CTCF-RNA pairs, CTCF-FAIRE probes pairs, and FAIRE
probes-RNA pairs, empirical p-values have been determined
using permutations (1,000 times). Only pairs with an empirical
p-value < 0.1 are considered significant.
There are 8,060 significant CTCF-CTCF pairs, 16,408 CTCF-
FAIRE probes pairs, 7,297 CTCF-RNA pairs, and 17,058 FAIRE
probes-RNA pairs (Chapter 3). In total, there are 26,554 CTCF-
QTLs, 164 FAIRE-QTLs (Chapter 2), and 4,781 RNA-QTLs (Mont-
gomery et al., 2010). Combined, there are 31,406 unique mo-
lecular QTLs. As discussed in Chapter 2, subsequently to this
analysis I have performed QTL analysis using the FAIRE probes
instead of the FAIRE probesets. However, the analyses in this
chapter are based only on using QTLs for the FAIRE probesets.
4.2.1 Random direction of causality
As stated in the introduction of this chapter, a potential pitfall
of my method for determining causality involves differences in
the variance of the assays. I have performed a simple test to test
the effect of the variance on the causality method. I randomly
selected 1,000 significant pairs of CTCF-RNA, CTCF-FAIRE and
FAIRE-RNA. I then constructed 500 random genotype assign-
ments. These random genotypes can only be associated to these
phenotype-to-phenotype pairs by chance. Given this fact, when
using my method for causality determination, if assays have
similar levels of variance, the resulting distribution of the delta p-
values should be uniformly distributed and not skewed towards
any of the assays used.
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The random assessment of causality using the generated gen-
otypes indicates no skew towards any of the used molecular
assays (Figure 4.5). In each case, there are similar numbers of
pairs driven by phenotype A as by phenotype B. Because of this
result, I can assume that when using QTLs instead of generated
genotypes, any given skew in the resulting delta p-values can
be attributed to the QTL and not to a difference in variance of
the molecular assays.
CTCF ~ FAIRE CTCF ~ RNA FAIRE ~ RNA
0
10000
20000
30000
−3 0 3 −3 0 3 −3 0 3
co
un
t
-log10(A removed P - B removed P) 
Figure 4.5: For 1,000 randomly-selected significant CTCF-FAIRE,
CTCF-RNA and FAIRE-RNA pairs (empirical p-value <
0.01), the causality has been determined for 500 randomly-
generated genotypes. For each pair of phenotypes, two
Spearman’s Rank tests were performed to determine the
association between the genotype and the first phenotype
(A) after removing the second phenotype (B), and vice
versa. The distribution of difference in p-values between
the two Spearman’s Rank tests is shown (in -log10). None
of the assays shows evidence for having more variance,
and thus potentially influencing further results.
150 the driver of epigenetic correlations
4.2.2 CTCF to FAIRE
There are 16,408 significant CTCF-FAIRE probes pairs on the
autosomes. When overlapping both the CTCF and the FAIRE
probes with the molecular QTLs, 538 pairs have a QTL. All
538 molecular QTLs are in origin CTCF-QTLs. The reason for
this observation is the low number of original FAIRE-QTLs
identified.
Similar to the strategy explained in the introduction of this
chapter, I used regression to determine causality by comparing
the Spearman’s Rank correlation p-values (Figure 4.6). For the
pairs with a QTL, the comparison of p-values of the regression
tests indicates that 79% of the pairs are driven by CTCF. Hence,
this analysis suggests that, most often, the CTCF is the driver for
the FAIRE probe. Below, I provide an example of when CTCF is
driving (Section 4.2.2.1) and when the FAIRE probe is driving
(Section 4.2.2.2)) the causality.
4.2.2.1 CTCF driving FAIRE
To illustrate how a CTCF site drives the triangle of correlations, I
selected the following example (Figure 4.7A, p-value <1.8x10−5).
The CTCF site (chr22:42928810-42929321) is correlated with a
FAIRE probe (chr22:42612893-42612941) 315.9kb away (Figure
4.7B). The QTL rs299322 (chr22:42941390) is significantly asso-
ciated with the CTCF site (Figure 4.7E, p-value = 0.0019) and
the FAIRE probe (Figure 4.7C, p-value = 0.008). To understand
whether the CTCF or the FAIRE probe is driven by the molecular
QTL, the same correlations were performed after regressing out
the other molecular assay.
For example, for the CTCF-QTL, the FAIRE probe effect is first
regressed out (Figure 4.7F, p-value = 0.009), and for the FAIRE-
QTL, the CTCF effect is regressed out (Figure 4.7D, p-value =
0.97). By eliminating the effect of each assay independently, the
QTL effect can be compared. The removal of the FAIRE effect
from the CTCF signal has almost no consequence (delta Rho
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CTCF−QTL
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Figure 4.6: CTCF-FAIRE probe pairs QTL effect. The division on the X-
axis ranks the effect (delta p-value) between regressing out
CTCF and FAIRE. The majority of pairs are CTCF-driven.
The blue tick is an example showing FAIRE driving CTCF
4.2.2.2. The green tick is an example showing CTCF driving
FAIRE 4.2.2.1
0.06), indicating that, for this QTL, the actual FAIRE levels are
not important. When removing the CTCF effect from the FAIRE
signal, the QTL effect disappears (delta Rho 0.24). This indicates
that the most likely driver for this correlation is CTCF.
Although FAIRE probes as a measure has a higher variability
and can be influenced by several components, the regression
results indicate that, for this QTL, the CTCF has a major impact
and thus is most likely the causal effect. Given that no FAIRE
probe QTLs have been established, I cannot determine whether
this overlap is coincidental. Because of this, the observed dis-
parity in causality could be due to the FAIRE probe not being
driven by the same genetic effect as CTCF, but by another that
is coincidentally overlapping with the CTCF signal.
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Figure 4.7: CTCF-FAIRE probe pair with QTL that is driven by the
CTCF. In this example, the proximal (b) CTCF-FAIRE probe
pair are tightly correlated and are under the influence of a
QTL; individuals are coloured based on their genotype (a).
The QTL is both a cis CTCF-QTL (e) and a cis FAIRE-QTL
(c). By regressing out the CTCF, the FAIRE-QTL is removed
(d). By regressing out the FAIRE probe, the CTCF-QTL is
only slightly impacted (f).
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4.2.2.2 FAIRE driving CTCF
For most CTCF-FAIRE pairs with a molecular QTL, the CTCF
is driven by the QTL, and the FAIRE is indirectly driven by the
CTCF. However, there are examples where the opposite is true
(Figure 4.8A, p-value <5.4x10−8). The CTCF site (chr10:31040756-31041163)
and FAIRE probe (chr5:31041026-31041076) are correlating and
overlapping (Figure 4.8B). The QTL rs10826861 is significantly
associated with the CTCF site (Figure 4.8E, p-value <7.6x10−9)
and the FAIRE probe (Figure 4.8C, p-value <1.6x10−13). The
reason why this QTL was not discovered as a FAIRE-QTL, is
because for mapping FAIRE-QTLs, I only examined the probe-
sets and not each individual probe. To understand if the CTCF
or the FAIRE probe is more important for the molecular QTL,
the same correlations are calculated, but now after regressing
out the other molecular assay. So, for the CTCF-QTL, the FAIRE
probe effect is first regressed out (Figure 4.8F, p-value = 0.13)
and for the FAIRE-QTL, the CTCF effect is regressed out (Figure
4.8D, p-value <4.5x10−4). The removal of the CTCF effect from
the FAIRE has a small effect (delta Rho = 0.34), indicating that
for this QTL, the actual CTCF levels are less important. When
removing the FAIRE effect from the CTCF signal, the QTL effect
disappears (delta Rho = 0.50). This indicates that the FAIRE
signal is more important in driving this correlation. Given that
the QTL overlaps the peak called for the CTCF binding and
only 48bp away from the FAIRE probe, the location would have
suggested causality in the other direction. In addition, because
of the proximity of the molecular signals, the results are less
likely to be influenced by coincidental overlapping and are both
caused by the same locus.
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Figure 4.8: CTCF-FAIRE probe pair with QTL that is driven by the
FAIRE. In this example, the overlapping (b) CTCF-RNA
pair is tightly correlated and is under the influence of an
overlapping QTL; individuals are coloured based on their
genotype (a). The QTL is both a cis CTCF-QTL (e) and a
trans eQTL (c). By regressing out the CTCF, the FAIRE-QTL
is only slightly impacted (d). By regressing out the FAIRE
signal, the CTCF-QTL is removed (f).
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4.2.3 CTCF to RNA
There are 7,297 significant CTCF-RNA pairs on the autosomes.
There are 467 CTCF-RNA pairs that have a molecular QTL.
For 199 CTCF-RNA pairs, the molecular QTL is originally a
CTCF-QTL, and for 287 CTCF-RNA pairs, the molecular QTL is
originally a RNA-QTL. There are 10 CTCF-RNA pairs for which
there is a QTL for both the RNA and the CTCF; however, the
QTL for the RNA and CTCF are different genotypes but in LD
(r2 > 0.8). Regarding both the CTCF-QTLs and RNA-QTLs, only
proximal genotypes were tested; these were not discovered, as
they were outside of the discovery window.
As before, I compare the change in Spearman’s Rank correl-
ation p-value after regression to determine causality (Figure
4.9). The molecular QTLs are divided by the molecular trait
of discovery. There is a distinctive difference in effect between
the CTCF-QTLs and eQTLs. For the CTCF-QTLs, 80% of QTLs
are influenced by removing the CTCF effect, as might be expec-
ted. However, regressing out the CTCF or the RNA similarly
influences the eQTLs (42% CTCF and 58% RNA). Hence, this
analysis suggests that most often the CTCF is the driver for the
RNA, even when the QTL was discovered as an eQTL. I show
an example for when CTCF is the causal effect (Section 4.2.3.1)
and when RNA is the causal effect (Section 4.2.3.2)).
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Figure 4.9: CTCF-RNA pairs QTL effect. The division on the X-axis
compares the effect (measured in p-value) between regress-
ing out CTCF and RNA. The majority of pairs are CTCF-
driven. The blue tick is an example showing CTCF driving
RNA 4.2.3.1. The green tick is an example showing RNA
driving CTCF 4.2.3.2).
4.2.3.1 CTCF driving RNA
In the following example, I show a CTCF-RNA pair that is
driven by a CTCF site (Figure 4.10A, p-value <7.0x10−5). The
CTCF site (chr22:42928810-42929321) is correlated to RNA ex-
pression (chr22:24655897-24659732) 329 kb away (Figure 4.10B).
The QTL rs12483950 (chr22:24296175) is significantly associated
with the CTCF site (Figure 4.10E, p-value <7.2x10−4) and the
RNA expression (Figure 4.10C, p-value <5.2x10−3). The regress-
ing out of the CTCF (Figure 4.10D, p-value = 0.75, delta Rho =
0.45) and the RNA (Figure 4.10F, p-value = 0.007, delta Rho =
0.09) suggests that CTCF is the most likely direct causal effect of
the QTL, and that the changes in gene expression are indirect.
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Figure 4.10: CTCF-RNA pair with QTL that is driven by the CTCF. In
this example, the distal (b) CTCF-RNA pair are tightly cor-
related and are under the influence of a QTL; individuals
are coloured based on their genotype (a). The QTL is both
a cis CTCF-QTL (e) and a trans eQTL (c). By regressing
out the CTCF the eQTL is removed (d). By regressing out
the RNA the CTCF-QTL is only slightly impacted (f).
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4.2.3.2 RNA driving CTCF
In contrast to the CTCF-RNA pairs that are driven by CTCF,
the pairs that are driven by RNA are mostly distal from each
other (86% of pairs, > 250kb). The reason for this could be that
all of the observed effects on this side of the distribution are
indirect, operating via a trans regulatory effect, and that the
real biochemical event is unmeasured. In addition, there is a
significant chance that many of the overlaps are coincidental and
thus not caused by the same locus. For this reason, the example
shown is for a distal CTCF-RNA pair (Figure 4.11A, p-value <
<2.8x10−5). The CTCF site (chr12:122467093-122467538) is cor-
related to RNA expression (chr12:6560856-6575683) 115,9Mb
away (Figure 4.11B). The QTL rs2041385 (chr12:6562293) is
significantly associated with the CTCF site (Figure 4.11E, p-
value <4.4x10−4) and the RNA expression (Figure 4.11C, p-value
<8.9x10−7). Similar to earlier examples, both the CTCF (Figure
4.11D, p-value <5.7x10−6, delta Rho = 0.11) as well as the RNA
expression (Figure 4.11F, p-value = 0.45, delta Rho = 0.39) are
regressed out to determine direct versus indirect causality. In
this example, when only considering these two molecular phen-
otypes, the RNA is a direct causal effect of the QTL. However,
given the large distance between both phenotypes, this is un-
der the condition that this QTL effect is caused by coincidental
overlap.
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Figure 4.11: CTCF-RNA pair with QTL that is driven by the RNA. In
this example, the distal (b) CTCF-RNA pair are tightly cor-
related and are under the influence of a QTL; individuals
are coloured based on their genotype (a). The QTL is both
a cis eQTL (e) and a trans CTCF-QTL (c). By regressing
out the CTCF the eQTL is only slightly impacted (d). By
regressing out the RNA the CTCF-QTL is removed (f).
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4.2.4 CTCF to CTCF
There were 8,060 significant CTCF-CTCF pairs discovered on
autosomes, and 186 CTCF-CTCF pairs determined to be under
the influence of a QTL.
4.2.4.1 The effect of CTCF-QTLs on CTCF-CTCF pairs
The existence of CTCF-QTLs shows that CTCF binding can be
altered by genotypic differences. However, the effect these QTLs
have on CTCF-CTCF pairs is largely unknown. Therefore, sim-
ilarly as for the other phenotype-to-phenotype pairs, I regress
out the genotypic effect to determine how CTCF-CTCF pairs are
affected by CTCF-QTLs.
When a QTL affects a CTCF site within a CTCF-CTCF pair,
this can result in three different potential effects. First, there
is no effect and the CTCF-CTCF pair is not affected. Second,
due to the alteration of a CTCF site, the association between the
CTCF sites disappears. Third, the direction of the association is
inverted (e.g. the Rho value is changed from positive to negative).
For each of these three effects, I selected an example to illustrate
how a positively correlated CTCF-CTCF pair can be under the
influence of a QTL (Figure 4.12).
In the first example, two CTCF sites are correlated and are
independently under the influence of a QTL (Figure 4.12A1).
Both axes represent a CTCF site, and each point is an individual.
The colour of the points indicates the alleles of the individu-
als: AA, AT or TT. The red line indicates the direction of the
correlation (Rho) between the two CTCF sites. In a second plot,
the QTL effect is removed (Figure 4.12A2). In this example, the
correlation between the CTCF sites remains intact after removal
of the QTL effect. This result suggests that the CTCF-CTCF pair
correlation is not driven, or altered, by the QTL, but rather by
other unmeasured factors.
The second example illustrates another correlated CTCF-
CTCF pair (Figure 4.12B1). In contrast to the first example, the
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removal of the QTL effect leads to the removal of the CTCF-
CTCF pair correlation (Figure 4.12B2). This result suggests that
this CTCF-CTCF pair is driven by the QTL.
In a final example, the CTCF-CTCF pair is again positively
correlated (Figure 4.12C1). However, after removing the QTL
effect, the actual direction of association (Spearman’s Rank Rho)
is reversed (Figure 4.12C2), though not significant (Spearman’s
Rank p-value > 0.05).
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Figure 4.12: CTCF-CTCF pairs that are positively correlated with each
other and have a shared QTL. By regressing out the QTL
effect on both CTCF sites, the causal effect of the QTL on
the discovered CTCF-CTCF pair is visualised. Individuals
are coloured based on their genotype. There are QTLs that
do not affect the CTCF-CTCF pair correlation (a), QTLs
that reduce the correlation (b), and inverse the correlation
(c).
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Figure 4.13: CTCF-CTCF pairs with shared QTL. Each CTCF-CTCF
pair in this figure has a single QTL that is affected by both
CTCF sites simultaneously. On the x-axis is the original
Spearman’s Rank Rho value between both CTCF sites.
On the y-axis is the Spearman’s Rank Rho value after
regressing out the QTL effect. The colour indicates which
CTCF site in the pair is causal. If the pair is driven by
CTCFa the deltaP is negative, if the pairs is driven by
CTCFb the deltaP is positive.
4.2.4.2 The causal CTCF site
In the previous sections, I attempted to establish the direct effect
of a QTLwithin a phenotype-to-phenotype correlation. However,
for CTCF-CTCF pairs it is clear that, at least within the pair,
CTCF must be the driver. Although the direction is often not
interesting, there is interest in determining whether there is an
imbalance in the effect a CTCF-QTL has on CTCF-CTCF pairs.
There are 186 significant CTCF-CTCF pairs under the influence
of a QTL, which are predominantly positively correlated (Figure
4.13, coloured points are significant pairs). The Y-axis shows
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the effect of removing the QTL effect on the CTCF-CTCF pair.
Noteworthy is that there are no cases where the QTL negatively
affects the CTCF-CTCF pair. There are 55 CTCF-CTCF pairs in
which there is a strong change in correlation (> 0.3 Spearman’s
Rank Rho change), indicating that the left (negative difference
p-value) or the right (positive difference p-value) is the causal
CTCF site for this QTL. For the remaining 131 CTCF-CTCF pairs,
it is not possible to determine whether a single CTCF site is
mostly affected by the given QTL. This could indicate that, in
these cases, the QTL affects both CTCF sites equally or that the
CTCF-CTCF pair is driven by another unmeasured factor.
To illustrate a CTCF-CTCF pair in which the CTCF-QTL is
driving one CTCF site, I selected an example of two prox-
imal CTCF sites that correlate (Figure 4.14). For this example,
I label one CTCF site CTCFa (chr14:106800840-106803801) and
the other CTCFb (chr14:106790714-106791186). CTCFa is correl-
ated to CTCFb (p-value < 5.3x10−14), 13kb away (Figure 4.14B).
The QTL rs11623092 (chr14:106822043) is significantly associ-
ated (CTCFa-QTL p-value < 2.5x10−10, CTCFb-QTL p-value <
3.5x10−10) with both CTCF sites (Figure 4.14C,E). To understand
whether CTCFa or CTCFb is the actual CTCF site for the CTCF-
QTL, the same correlations are calculated after regressing out
the different CTCF effects. Accordingly, for the CTCFa-QTL, the
CTCFb effect is regressed out (Figure 4.14F, p-value = 0.02, delta
Rho = 0.44), and for CTCFb-QTL, the CTCFa effect is regressed
out (Figure 4.14D, p-value 0.94, delta Rho = 0.76). The results
of these regressions indicate that, for this specific CTCF-CTCF
pair under the conditions of this QTL, the CTCF loop mostly
depends on CTCFb. This is shown in the following way: by
regressing out CTCFb, the association is removed, while this
is not the case when CTCFa is removed. Therefore, the QTL
is most likely causal for variations of CTCFb binding and not
CTCFa binding.
4.2 results 165
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
−2
0
2
A/A A/T
14
:1
06
79
07
14
−1
06
79
11
86
CTCFa-QTL
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
−2
−1
0
1
2
3
A/A A/T
14
:1
06
80
08
40
−1
06
80
38
01
CTCFb-QTL
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
−1.0
−0.5
0.0
0.5
1.0
1.5
A/A A/T
14
:1
06
79
07
14
−1
06
79
11
86
CTCFb-QTL removed CTCFa
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
−1.0
−0.5
0.0
0.5
1.0
1.5
A/A A/T
14
:1
06
80
08
40
−1
06
80
38
01
CTCFa-QTL removed CTCFb
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
−2
0
2
4
−2 −1 0 1 2 3
14:106800840−106803801
14
:1
06
79
07
14
−1
06
79
11
86
●
●
A/A
A/T
CTCF−CTCF  rs11623092
p13 p11.2 q11.2 q12 q21.1 q21.2 q21.3 q23.1 q24.3 q31.1 q31.3 q32.2
(a)
(b)
CTCF
(c) (d)
(e) (f)
CT
CF
QTL QTL
QTL
QTL
QTL
CT
CF
QTL
CT
CF
CT
CF
CT
CF
CTCFCTCF
13,087 bp 18,242 bp
Rho 0.83
Rho 0.75 Rho -0.01
Rho 0.75 Rho 0.31
Figure 4.14: CTCF-CTCF pair with QTL that is driven by one CTCF
directly. In this example, the proximal (b) CTCF-CTCF
pair are tightly correlated and are under the influence of
a QTL; individuals are coloured based on their genotype
(a). The QTL is for CTCF "a" a cis CTCFa-QTL (c) and
for CTCF "b" a cis CTCFb-QTL (e). By regressing out the
CTCFa effect, the CTCFb-QTL is only slightly impacted
(f). By regressing out the CTCFb effect, the CTCFa-QTL is
removed (d).
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4.3 conclusions
The results of this chapter, combined with those of the cor-
relations chapter, (Chapter 3) provide a great insight into the
complex interplay of genetics and epigenetics.
4.3.1 Common direction of causality
Building on the previously-established phenotype-phenotype
correlations, QTLs can provide great insight into the regula-
tion of these correlations. Incorporating the QTLs within the
phenotype-to-phenotype correlation enables the dissection of
causality. Doing this, it becomes clear that for many correlations
there is a favourable direction of causality. However, for some
correlations, no distinction of causality can be made. This lack
of a significantly direct causal effect most likely indicates that
both measured phenotypes are under the same genetic influence.
Alternatively, a potential explanation for this could be that both
measured phenotypes are actually under the regulation of an
unmeasured third component that is actually regulated by the
QTL. It would have been of great interest to model each of these
outcomes and to distinguish them. However, given the current
method based on differences in p-values, this is desirable but
not feasible. I have shown that the same analysis performed
with random genotypes yields a different result; however, these
provide no easy starting point for determining a fixed threshold
to permit distinguishing each of the pairs. For this reason, in
this thesis I only use the difference in p-values to rank each of
the pairs to highlight general trends and select some examples.
Subsequently, no claims about significance are made for each of
the causality claims.
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4.3.1.1 CTCF is the most common driver
Correlation between CTCF and the FAIRE signal is common.
For many CTCF-FAIRE pairs, incorporating the genetic effect of
a QTL can permit us to distinguish between direct and indirect
causality (i.e. driven by CTCF or FAIRE). The most observed
effect, under condition of a QTL, is that a CTCF site is driving the
FAIRE site or that both are equally affected by the QTL (Figure
4.6). In contrast, there are several CTCF-FAIRE pairs in which
the FAIRE site is the direct causal effect; nevertheless, nearly
all of these cases are related to distal CTCF and FAIRE sites,
making the result biologically difficult to interpret. However,
proximity is not essential for chromatin looping interactions,
and long-range interactions are commonly found (Sanyal et al.,
2012).
Similarly, CTCF is the driver in many of the CTCF-RNA pairs.
In the comparison between CTCF-QTLs and eQTLs, within these
pairs, the removal of the molecular effect is striking. For eQTLs,
the removal of CTCF or RNA can lead to any outcome, while
for CTCF-QTLs, the direction is strongly biased towards CTCF
being causal (Figure 4.9).
This result is a strong indication of how, irrespective of the
molecular assay of QTL discovery, CTCF is most likely chan-
ging the chromatin accessibility and thus gene expression. For
example, CTCF is changing chromatin into an accessible state so
that other transcription factors can bind and transcription can
occur. These results are complementary to the results found by
Kilpinen et al.: they established that genetic changes are driving
TF binding and histone modification, which in turn are the main
determinant for gene regulation (Kilpinen et al., 2013). There is
evidence that, in this context, histone modifications are merely
reflecting earlier regulatory events (Kilpinen et al., 2013), and
are often correlated with genetic changes in TF binding sites
(McVicker et al., 2013). However, many of these effects will be
locus-specific, and there is evidence that epigenetic changes are
168 the driver of epigenetic correlations
both causal and a result of gene expression. For example, in
yeast the interplay of TF binding and chromatin are responsible
for regulating gene expression, essential for the phosphate re-
sponse pathway (Lam et al., 2008). In contrast, another study
in yeast shows how even after fixing histone modifications that
are known to be essential for gene expression, the gene expres-
sion abundance is unaltered (Zhang et al., 2014). Although my
results suggest that CTCF is a driver of gene expression and
chromatin status, some additional experiments are desirable. It
would be of great interest to determine the effect of alternating
CTCF binding in the discovered phenotype-to-phenotype pairs
that are driven by CTCF.
4.3.2 CTCF loops
There is a notable difference between CTCF-CTCF pairs and
any of the other phenotype-to-phenotype pairs tested in this
chapter. Nearly all CTCF-CTCF pairs are positively correlated to
each other. Given the biological nature of CTCF-CTCF pairs, i.e.
being biochemically linked in so-called loops, this is to be expec-
ted, and adds new weight to the discovered CTCF-CTCF pairs.
CTCF-CTCF pairs under the influence of a QTL demonstrate
that there are three distinctive QTL effects. First, they do not
change, and it seems that the individual QTL has a minimal ef-
fect on the CTCF loop. Second, the CTCF-CTCF pair disappears,
making the QTL a master switch in enabling and disabling the
loop. Third, the loop effect is reversed, which entails a positive
correlation being converted into a negative one.
When considering CTCF-CTCF pairs under influence of a
QTL, there is a considerable number of pairs in which the QTL
drives, or alters, both CTCF sites simultaneously (Section 4.2.4).
Because of this, the removal of the effect of a QTL quite often
leaves the CTCF-CTCF pair correlation intact. Another large
group of CTCF-CTCF pairs demonstrates how a QTL affects
only a single CTCF site (Section 4.2.4.2). This result suggests
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that a single QTL can regulate the binding of a single CTCF
site that in turn affects the entire CTCF loop and its potential
biological regulatory function.
4.3.2.1 False discoveries
Similar to when discovering molecular QTLs, or performing
phenotype-to-phenotype correlations, larger sample sizes will
yield better results. With increased sample size, the less-strong
effects could become significant, which will help to create a
more comprehensive epigenomic view. Furthermore, inclusion
of additional molecular phenotypes will help to dissect epi-
genetic causality. For these reasons, it would be ideal to assay
as many molecular traits in the same individuals as possible.
In this way, the full cascade of causality can be discovered, as
well as the direct effect of molecular QTLs that regulate gene
expression.
4.4 data
4.4.1 Molecular QTLs
A combination of QTL datasets is created for this chapter. QTLs
mapped for gene expression, FAIRE and CTCF, are used. Com-
bined, there are 31,406 unique molecular QTLs. There are 26,554
CTCF-QTLs (Chapter 3), 164 FAIRE-QTLs (Chapter 2), and 4,781
RNA-QTLs (Montgomery et al., 2010).
4.4.2 Karyotypes
In the example plots, I use karyotypes to indicate the location of
the correlating molecular phenotypes. Karyotypes and chromo-
somal locations of the CTCF sites, FAIRE sites, genes and QTLs
were obtained from the Ensembl genome browser (Flicek et al.,
2012).
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4.5 methods
4.5.1 Testing for associations
I used Spearman’s Rank correlation to perform the pairwise
associations between each of the phenotypes and the genotypes.
For each association, the Spearman’s Rank Rho and p-value are
stored. Within R, the function spearman.test from the package
pspearman was used for this analysis.
4.5.1.1 Direction of causality
A simplistic model was created to determine the most likely
direct and indirect causal effect of a QTL, given a phenotype-to-
phenotype correlation. In this model, I assumed the variance for
each phenotype to be similar.
For a given phenotype-to-phenotype correlation, under the
influence of a QTL, I performed the following steps. I inde-
pendently regressed out the effect of each molecular phenotype
on the phenotype-to-phenotype correlation. This can be repres-
ented as 8, where A and B are the different phenotypes, 1 is
a vector of ones, i_A and i_B are the intercepts for A and B,
respectively, s_A and s_B are their slopes, and the error is an N
by 2 matrix (N = number of samples). Between the residuals of
the regression and the QTL, a Spearman’s Rank correlation is
performed to test the after-regression association. For these two
correlations, the p-value and Rho are stored, and the difference
in p-value is used to determine the causality.
[A,B] = 1 ∗ [iA, iB] +A ∗ [sA, sB] + error (8)
For example, in a CTCF-FAIRE pair, I regress the CTCF signal
out of the FAIRE signal. Then, the residuals of this regression
are correlated with the genotype using Spearman’s Rank correl-
ation, and the p-value is stored. Subsequently, the same process
is performed, but now the FAIRE signal is regressed out before
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applying Spearman’s Rank correlation. The difference in p-value
in -log10 scale of these regressions is calculated and is called the
delta p-value. The delta p-value is broadly able to classify three
different classes. A negative delta p-value indicates that the first
phenotype has the largest effect (in the example, this would be
CTCF). A positive delta p-value indicates that the second phen-
otype has the largest effect. Finally, all delta p-values around
zero indicate that both phenotypes affect the pair similarly. In R
code, this was done by the following steps:
1 #load R package for Spearman’s Rank test
2 library("pspearman")
3
4 #data object with both CTCF, FAIRE abundances, and the
genotypes (QTL)
5 data = cbind(CTCF, FAIRE, QTL)
6
7 #regression of both phenotypes
8 data.minusCTCF = residuals(lm(data~CTCF))
9 data.minusFAIRE = residuals(lm(data~FAIRE))
10
11 #correlation on the residuals
12 cor.FAIRE = spearman.test(data.minusCTCF$FAIRE,data$QTL,
approximation=" t−distribution ");
13 cor.CTCF = spearman.test(data.minusFAIRE$CTCF,data$QTL,
approximation=" t−distribution ");
14
15 #calculation of the delta p.value
16 delta = -log10(cor.FAIRE$p.value)- -log10(cor.CTCF$p.value) 
4.5.1.2 Causality of random associations
To assess whether the difference in variance of each molecular as-
say is attributed to a bias in causality direction, I performed the
same regression method using randomly-generated genotypes.
I generated a set of 500 random genotype assignments. Each
genotype assignment consists of a random combination of A/A,
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A/T and T/T. As these genotypes are randomly-assigned, any
significant association is purely due to chance. Because of this,
each genotype has a similar chance to be correlated with any of
the molecular phenotype pairs.
In a subsequent step, I sampled 3,000 significant CTCF-RNA,
CTCF-FAIRE and FAIRE-RNA pairs (empirical p-value <0.1;
1,000 pairs each) and used these within the regression model
4.5.1.1. The delta p-values (in -log10) of these random tests were
stored. The delta p-values can be used to determine any bias
derived from variance introduced by the different molecular
assays or signals.
4.5.2 Data visualisation
Within R (Team, R Development Core, 2005), the package Gg-
plot2 (Wickham, 2009) was used to visualise all data.
Part IV
X -CHROMOSOME BIOLOGY

5
CTCF INVOLVEMENT IN X-CHROMOSOME
INACTIVAT ION
This chapter describes the results obtained from studying CTCF
binding on the X chromosome to characterise the role of CTCF
in X-chromosome inactivation. When studying the biochemical
mechanistic link between CTCF sites by correlating CTCF sites
binding to each other, I observed striking difference for CTCF-
CTCF pairs on the X chromosome. Many CTCF sites on the X
chromosome are correlated with each other, which is driven by
the gender of the cell lines. This chapter is part of a paper on
which I am the joint first author and that is has been submitted
for journal publication.
5.1 introduction
In humans, the sex chromosomes consist of the X and Y chro-
mosomes. Females will have two copies of X (XX), and males
will have one X copy and one Y copy (XY). As females have
two copies of the X chromosome, this could lead to double the
amount of gene expression in a similar situation than in males
if both X chromosome are transcribed. This poses a problem:
effectively, because of this discrepancy, males and females can
be considered to be two different organisms. Hence, dosage
compensation between the genders is essential. Humans and
other mammals use a mechanism of dosage compensation in
which one of the female X chromosomes becomes inactivated;
in this way, females have one active (Xa) and one inactive (Xi)
X chromosome. This dosage compensation mechanism is an
extraordinary piece of epigenetic biology that has been studied
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extensively (see review (Payer and Lee, 2008; Schulz and Heard,
2013)).
While CTCF is known for being involved in X-chromosome
inactivation at the Xist locus, the scale of its involvement has
not been fully explored (Chao et al., 2002; Pugacheva et al., 2005;
Spencer et al., 2011). In this chapter, I show that there are three
classes of CTCF sites on the X chromosome. First, CTCF sites are
dosage-compensated, i.e. CTCF binding in males and females is
equal. Second, other CTCF sites are not dosage-compensated,
and there is binding to both X chromosomes. Third, a few other
CTCF sites are directly involved in regulating the transcription
of noncoding-RNAs (ncRNAs) in females that show evidence of
involvement in X-chromosome inactivation.
5.2 results
When studying the correlation of CTCF-CTCF pairs (Chapter
3.2.6), I noticed a striking difference in results for the X chromo-
some. The association between the 1,968 X chromosomal CTCF
sites was significant between almost all sites, a clear indication
of some hidden population structure or systematic bias. As
the CTCF dataset was normalised and the first Principal Com-
ponents Analysis (PCA) component was removed, there was
no indication that a large systematic variable remained in our
dataset that could explain this behaviour. Also, all other chromo-
somes showed far fewer significant associations, indicating that
this might be an X chromosome-specific behaviour. The striking
number of highly-associated CTCF sites were determined to be
driven by the gender of the individual samples.
5.2.1 CTCF binding on chromosome X has a gender-specific profile
To understand the reason for the large number of significant
associations of CTCF binding sites on the X chromosome, I
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performed a more detailed exploration of the CTCF affinity.
Examining the distribution of CTCF binding affinities, divided
per individual, there is a significant distinction between the male
(average binding 0.85) and female (average binding 1.34) LCLs
(Student’s t-test p-value < 2.1x10−10, Figure 5.1). This is a strong
indication that most of the observed significant correlations are
due to gender. Although the majority of CTCF sites on the X
chromosome tend to be highly correlated, there is still a large
group of CTCF sites that do not show any difference in CTCF
binding affinity between the sexes.
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Figure 5.1: Boxplot for CTCF binding affinity on the X chromosome
for each LCL. (a) Individuals are ordered and coloured by
gender. There is a significant difference in binding affinity
between sites in male and female lines (Student’s t-test
p-value < 2.1x10−10).
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5.2.2 Overall lack of dosage compensation for CTCF
To separate CTCF binding sites on the X chromosome that are
gender-specific from the ones that are not, I applied a site-by-site
Mann Whitney U (MWU) test. In this test, the distribution of
the male samples is compared with the female samples, and
a significant MWU means that the distributions have different
median values.
The gender-specific CTCF binding pattern that was observed
could be due to CTCF binding to both the Xa and the Xi chro-
mosomes, which results in females having twice the amount of
CTCF binding. To investigate this scenario, I obtained messen-
ger RNA (mRNA) and non-coding RNA (ncRNA) data for the
same cell lines from the gEUVADIS project (Lappalainen et al.,
2013) and studied their transcript behaviour. As CTCF does not
seem to be dosage-compensated for the majority of sites, another
key question is whether this behaviour is specific to CTCF, or
whether it is a more widespread effect that can also be found in
other molecular assays. At the time of my study, there had been
no other molecular assays performed on a similar scale that
overlapped my samples. The closest available dataset, from a
QTL study by Degner et al., comprises DNaseI-sequencing data
for 90 YRI HapMap LCLs (Degner et al., 2012). Although, this
DNaseI-QTL study was performed on a different population,
our focus is on an essential phenotype that this is unlikely to be
highly specific to a population.
The results of the site-by-site MWU test on mRNA, ncRNA,
DNase I and CTCF were reported by an autosomal group and an
X chromosome group (Figure 5.2). The test shows that there are
almost no gender-specific mRNA and ncRNA transcripts. Fur-
thermore, there is no significant difference in reported p-value
distributions between the autosomes and X chromosome for
mRNA (Student’s t-test p-value = 0.08) and ncRNA (Student’s
t-test p-value = 0.87). In contrast, for the DNase I sites, there is
a significant increase of gender-specific sites on the X chromo-
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some (Student’s t-test p-value < 2.1x10−12). Likewise, the test
indicates that the majority of CTCF sites on the X chromosome
have a gender-biased binding affinity (Student’s t-test p-value
< 2.8x10−70), strongly suggesting that a large number of CTCF
sites are influenced or driven by gender.
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Figure 5.2: MWU results for autosomes and X chromosome for mRNA,
ncRNA, DNase I and CTCF. The p-value indicates the de-
gree of gender bias in each of the datasets. The mRNA
and ncRNA transcripts show very few gender-specific tran-
scripts. For both DNase I and CTCF, there is an indication
that sites on the X chromosome are gender-biased.
To highlight the differences for the X chromosome, all mRNA,
ncRNA, DNase I, and CTCF sites outside the pseudoautosomal
region (PAR) regions are classified as being gender-specific or
not (Figure 5.3). In total, 87% of CTCF sites on the X chromosome
outside the PAR show a strong gender-specific effect (MWU
P-value < 0.01), while for the other assays, this number is much
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lower. A gender-specific effect occurs in only 3% of mRNAs, 9%
of ncRNAs, and 4% of DNase I sites.
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Figure 5.3: Number of mRNA, ncRNA transcripts, and DNase I, CTCF
sites that are significantly biased against gender (MWU
p-value < 0.01).
5.2.3 CTCF site classification
The CTCF binding affinity difference between males and females
can be classified in gender and non-gender driven sites using the
MWU test. Comparing the average binding of males and females
suggests that there is also a third class of CTCF sites, which
only binds in females (Figure 5.4, note that the female binding
is divided by two). Taking this into consideration, there are two
main classes of CTCF sites and one additional subclass. The first
main class comprises CTCF sites that have similar binding be-
haviour in males and females, and are therefore not significant
in the MWU test. I call these CTCF sites "dosage-compensated".
The second main class includes CTCF sites that show twice as
much binding in females than in males, and are thus significant
in the MWU test (p-value < 0.01). This class of CTCF sites can
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be further subdivided into CTCF sites that have only binding
in females, which I refer to as "female-specific" sites, and "both-
active" sites. This classification divides the X chromosome CTCF
sites into 1,692 CTCF sites that are both-active, 253 CTCF sites
that are dosage-compensated, and 23 CTCF sites that show a
female-specific binding affinity.
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Figure 5.4: CTCF sites on the X chromosome classified based on
their MWU p-value and the ratio between the average
female/average male. In an effort to aid the visual sep-
aration of classes, the female signal is shown as a single
X chromosome and not as a pair. In this way, both-active
CTCF sites in females have a similar binding affinity to
CTCF sites in males (on red diagonal). The red line repres-
ents when CTCF sites are both-active. This classification
results in 1,692 both-active, 253 dosage-compensated, and
23 female-specific CTCF sites.
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Figure 5.5: CTCF sites that are classified as dosage-compensated, both-active and female-specific are overlapped with ENCODE and
Ensembl data. The number of sites overlapping is represented in a proportion overlapping. For some datasets, there are
replicates from different labs resulting in multiple data points (CTCF for example). All 3 classes of CTCF sites show enrichment
for several HM and TF, though some class-specific overlaps can be observed.
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5.2.4 Biochemical enrichment of different CTCF classes
In order to study, and potentially understand, the functional
differences between the different classes of CTCF sites, I invest-
igated the overlap of these sites with transcription factor (TF)
binding and histone modification (HM) from the ENCODE con-
sortium (ENCODE Project Consortium, 2012). Additionally, I
analysed an overlap of CTCF sites with evolutionary constraint
regions identified by GERP (Cooper et al., 2005) and promoter
sites (Flicek et al., 2012), also in GM12878, to understand the gen-
omic context. To ensure that differences in TF binding and HMs
are not due to sites being located inside a promoter, only CTCF
sites that are not located in a promoter region were analysed.
The overlap was performed both a) on all sites and b) on
the sites with the highest signal (top 50%), in which I expected
better classification. I present here the top 50% figures; except
for noise due to lower numbers, the overlaps using "all sites" are
almost identical to the top 50% values.
CTCF sites that are both-active, dosage-compensated, or female-
specific are all highly conserved, indicating a strong functional
selection of all sites. All of the female-specfic sites overlap the
36 eutherian mammal GERP data (Flicek et al., 2012), while the
both-active and dosage-compensated sites respectively overlap
62% and 53%, well in excess of the genome-wide coverage of
GERP, which is 5.5% (Cooper et al., 2005).
The data show a strong tendency for sites to overlap with
some key elements of CTCF biology (Figure 5.5). To avoid any
promoter bias, all CTCF sites overlapping a promoter were
removed for this analysis. First, the members of the cohesion
complex, SMC3 and Rad21 (part of the ENCODE data), show
a large overlap for both the both-active (SMC3 > 25%, Rad21 >
25%) and the dosage-compensated (SMC3 > 60%, Rad21 > 65%)
CTCF sites. Although there are only 23 female-specific CTCF
sites, these sites seem to suggest that this class of CTCF sites are
in regions with high amounts of biochemical activity.
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For FAIRE and DNase I, sequencing was performed within
ENCODE on the female LCL GM12878. Therefore, it is reas-
onable to expect that any essential biochemical activity neces-
sary for female X chromosome biology is present in these over-
laps. Irrespective of the classification, approximately 50% of the
CTCF sites overlap a FAIRE region. Interestingly, DNase I shows
much more disparity, with 100% female-specific, 72% dosage-
compensated, and only 38% both-active CTCF sites. Further
analysis of DNase I in this chapter will demonstrate that DNase
I and CTCF show a high amount of overlap in classification
(Section 5.2.5.2).
A Chi-square test was performed to identify which data-
sets show significantly different overlapping between dosage-
compensated and both-active CTCF sites. To visualise these
results, the ratio between the overlap for both-active and dosage
compensation is plotted and coloured for the p-value results
of the Chi-square test (Figure 5.6). Dosage-compensated sites
tend to overlap more often with other HMs and TFs than both-
active sites (all data points below ratio 1). This could suggest
that dosage-compensated CTCF sites have a stronger regulatory
role and are consequently more likely to overlap with other
factors or marks. However, some sites show higher overlap with
both-active CTCF sites. Unfortunately, these overlaps are not
significant (Chi-square p-value > 0.05) and are biased because
of the low number of sites overlapping with HMs or TFs (red
points at the top of the plot).
The dosage-compensated sites overlap significantly more with
DNase I sites (Chi-square p-value < 2.4x10−6). This suggests that
chromatin is more accessible for dosage-compensated CTCF
sites, which is something that is known to be essential for reg-
ulatory regions. Although CTCF sites that are inside known
promoter regions are filtered out, there is still a significant over-
lap with POLR2A for dosage-compensated sites (Chi-square
p-value < 0.011). POLR2A is the largest subunit of RNA poly-
merase II that transcribes DNA into RNA. All of these results
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are consistent with the hypothesis that dosage-compensated
sites are in fact CTCF sites that have a regulatory function.
For CTCF to form insulating loops, it needs to interact with
protein members of the cohesin complex. This complex ma-
chinery consists of several proteins bound together in a single
complex (Section 1.3.1). In ENCODE, only SMC3 and RAD21 are
quantified using ChiP-seq. If a site is active for SMC3, RAD21,
and CTCF, this provides a convincing indication of the presence
of the cohesin complex. Both SMC3 and RAD21 are signific-
antly (Chi-square p-value < 5.0x10−5) enriched in the dosage-
compensated sites compared with the both-active CTCF sites.
This suggests that dosage-compensated sites are more often
involved in the cohesin complex and are subsequently more
likely to form insulating loops.
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Figure 5.6: CTCF sites that are classified as dosage-compensated or both-active-were overlapped with ENCODE and Ensembl data. On
the Y-axis is the ratio of overlap, meaning that at ratio 1, both dosage-compensated and both-active CTCF sites have a similar
overlapping profile. The points are coloured by the Chi-square test p-value (in - log10), indicating a significant difference in
overlap between both groups. For most datasets, there is no difference in overlap between both groups (red points). In general,
CTCF sites that are dosage-compensated, overlap significantly more often with other marks and factors than both-active sites
(Chi-square p-value < 0.03).
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5.2.5 Binding signal and spacing of TF and HM
As shown previously (Section 5.2.4), there is a significant dis-
parity regarding which TFs and HMs overlap with CTCF sites
that are classified as both-active and dosage-compensated. To
study the exact difference in binding affinity, aggregate plots
were created based on the CTCF locations for both classes. Ag-
gregation plots were created for the following HMs: H3K4me3,
H3K4me1, H3K27ac and H3K27me3 (figure 5.7A). Interestingly,
H3K27me3 did not show any increased binding for the dosage-
compensated or the both-active CTCF sites. This was surprising,
as H3K27me3 is known to be involved in X-chromosome inactiv-
ation (Brinkman et al., 2006; Marks et al., 2009). However, active
CTCF sites were investigated, and thus potential CTCF sites that
are repressed by H3K27me3 were not part of this comparison.
The HMs for the dosage-compensated CTCF sites show strong
evidence for accessible chromatin.
Another set of aggregation plots was created for the nuc-
leosome spacing around CTCF sites (Figure 5.7B). The nucle-
osome spacing of both classes of CTCF sites is useful to de-
termine whether both CTCF sites are actually used. The spa-
cing is similar for both classes, and the both-active CTCF sites
even seem to have a more distinctive profile than the dosage-
compensated CTCF sites. This evidence is compatible with the
dosage-compensated sites being actively bound and being func-
tional. The depletion of nucleosome spacing at the CTCF site
suggests that both classes of sites are bound by CTCF at the
centre and organise the nucleosomes around them.
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Figure 5.7: CTCF sites that are classified as dosage-compensated
or both-active are aggregated with ENCODE data for
GM12878. The top 50% abundant CTCF sites that are not
classified as promoters are considered. A) Aggregate sig-
nal for several histone modifications. Dosage-compensated
CTCF sites show higher level of HMs activity, excepting
H3K27me3. This suggests accessible chromatin for the
dosage-compensated sites. B) Aggregate signal for nuc-
leosome spacing. Irrespective of the CTCF classification,
the CTCF is bound and the nucleosomes are organised
accordingly.
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5.2.5.1 X chromosome signal for mRNA, ncRNA, DNase I and
CTCF
In a next step to understand whether other molecular data-
sets are dosage-compensated, a comparison plot was created
comparing mRNA, ncRNA, DNase I and CTCF (Figure 5.8). To
create comparable datasets, each of the values was transformed
to values ranging between 0 and 1. The actual signal intensities
are not important for this plot, as the main interest is the trends.
The datasets are shown in a comparison between the haploid
female signal (Y-axis, average female signal divided by 2) and
the gender difference (X-axis, average female signal divided
by 2, minus the average male signal). This transformation of
the data emphasises the difference between dosage compensa-
tion and both-active sites. Accordingly, there are 3 groups to be
distinguished: first, the sites that are dosage-compensated are
approximately on the red diagonal line. Next, the both-active
sites are approximately on the green vertical line. Finally, there
are female-specific sites on the right of the green vertical line.
The mRNA panel shows that the majority of mRNAs are, as
expected, dosage-compensated. The ncRNA are mostly dosage-
compensated, while the different Xist transcripts have only tran-
scription for the females. For the chromatin structure inform-
ation provided by DNase I, the sites are spread out between
dosage-compensated and both-active. In the CTCF panel, there
is a spread of sites between being dosage-compensated and
active on both chromosomes. Also, there is a rather large group
of sites that appear to be female-specific. In comparison with
CTCF, for DNase I there are far fewer sites that are active on
both chromosomes, and the majority of sites are closest to be-
ing dosage-compensated. This is a good indication that CTCF
is more important for the both-active regions than DNase I is.
Note that there are some regions in DNase I that might indicate
male-specific behaviour, but these are not further analysed in
this thesis.
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Figure 5.8: Trends in signal for mRNA, ncRNA, DNase I and CTCF on
chromosome X. The signal difference between the expected
level of signal when both X chromosomes are active and
when one is inactivated is plotted. The Y-axis shows the
average female signal divided by 2, which would be the
normal dosage-compensated signal. On the X-axis, I have
the same average female signal divided by 2, but then I
subtract the average male signal; this gives an indication
of the signal being biased towards males or females. In
the ncRNA panel, I assigned the Xist transcripts a differ-
ent symbol. The red line indicates the trend for dosage-
compensated sites. The green line indicates the trend for
both-active sites.
192 ctcf involvement in x-chromosome inactivation
5.2.5.2 Overlap of CTCF classes with DNase I
I observed that DNase I has more dosage-compensated regions
than CTCF. However, there are DNase I sites that act similarly
to CTCF in being active on both X chromosomes in females.
The most confident of 5% DNase I sites on the X chromosome
were compared for the haploid female DNase I intensity against
the haploid female to male DNase I intensity difference (Figure
5.9A, same as in Figure 5.8). I then coloured by the classification
of the CTCF when there is an overlap. The CTCF classification
is a good prediction for the DNase I intensity, because the sites
that overlap show similar behaviour.
The DNase I sites with a CTCF classification are compared by
the average DNase I intensity for males and females for both-
active and dosage-compensated classification (Figure 5.9B). The
dosage-compensated DNase I sites have similar average intensit-
ies for both male and female (Student’s t-test p-value > 0.05). For
the DNase I sites that overlap the both-active CTCF-classified
sites, females have double the amount of DNase I intensity than
males and are significantly different (Student’s t-test p-value <
2.3x10−8). This indicates that these DNase I sites have a similar
behaviour as the overlapping CTCF sites.
These results show that the CTCF classification predicts the
behaviour of DNase I sites. This is despite the fact that these
are different cell lines, from a different population, grown in a
different laboratory, and analysed using a very different assay.
Interestingly, the female-specific CTCF sites have no overlapping
DNase I sites. This could indicate that the female-specific sites
identified are, most likely, more closely related to CTCF biology
than chromosome structure. There are, however, some other
DNase I sites that show a slight tendency to be female-specific,
but this trend is not as strong as the trend observed in mRNA,
ncRNA or CTCF.
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Figure 5.9: The CTCF classification is imposed on the most confident
5% DNase I sites on the X chromosome. a) Haploid female
DNase I intensity is compared against the haploid female-
to-male DNase I intensity difference. For DNase I sites
overlapping CTCF sites, the CTCF classification is used
for colouring. The CTCF classification is able to predict
most of the DNase I effect for being dosage-compensated
(red line) or both-active (green line). b) The DNase I sites
overlapping the CTCF sites are compared on the CTCF
classification. For the dosage-compensated sites, the aver-
age male intensity is similar to the average female intensity
(Student’s t-test p-value > 0.05). In contrast, for the both-
active sites, the average female intensity is significantly
twice as high as the average male intensity (Student’s t-test
p-value < 2.3x10−8).
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5.2.6 X-chromosome inactivation centre
The X-chromosome inactivation centre (XIC) plays a central role
in the X-chromosome inactivation pathway. In this region is the
Xist gene that is transcribed into the Xist ncRNA, as well as
the antisense Tsix ncRNA. Xist is the major executor in X chro-
mosome inactivation; it coats and silences the X chromosome.
The average Xist transcript intensities, for each cell line, are
compared between male and female LCLs (Figure 5.10). There is
a clear, and expected, difference between females and males for
Xist, where obviously the female lines show much higher Xist
transcript levels (Student’s t-test p-value < 1.3x10−8). Although
this result is not novel, it is a positive control of our transcript
dataset, which ensures that, in the processing and normalisation
pipeline, gender-specific signals like Xist are retained and not
removed as being classified as an artefact.
A more detailed investigation of the XIC region was conduc-
ted to study the signal trends of both CTCF and DNase I sites.
The RNA transcript abundance data shows a gender-specific
signal. In close proximity to the XIC region, I found three CTCF
sites and two DNase I sites. Previous studies have suggested
that CTCF, together with the TF YY1, are essential for activation
or silencing of the Xist transcript (Donohoe et al., 2007; Jeon
and Lee, 2011; Moseley et al., 2012; Thorvaldsen et al., 2011).
Both the CTCF and the YY1 GM12878 ENCODE signal tracks
were selected (GM12878 is a female cell line) (ENCODE Project
Consortium, 2012). To minimise lab-specific bias, different tracks
from different labs were selected (Figure 5.11). Interestingly, the
YY1 track peak does not overlap any CTCF site, but overlaps
two DNase I sites (green box). The DNase I sites overlapping
the YY1 binding are female-specific. The three CTCF sites in
the XIC show no evidence of being gender-specific (Figure 5.12,
Student’s t-test p-value > 0.05), suggesting that the CTCF sites
that are used in this study are not involved with maintaining X
chromosome inactivation. In contrast, both DNase I sites overlap
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Figure 5.10: Xist average transcript abundance for male and female
cell lines. The female cell lines have significantly higher
transcript abundance for Xist (Student’s t-test p-value <
1.3x10−8).
with YY1 and are gender-specific (MWU p-value < 0.05). This
observation suggests that the XIC region, and in particular this
region in proximity to the Xist transcript, is being regulated on
a chromatin accessibility basis, or by another factor such as YY1,
but most likely not by CTCF.
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Figure 5.11: Screenshot Ensembl (Flicek et al., 2012) of the XIC re-
gion. Classification of our CTCF sites is shown (only
"both-active" in current view), classification of mRNA
and ncRNA (both gender-specific, MWU p-value < 0.05)
and classification of DNase I sites (female-specific, MWU
p-value < 0.05 and no male signal). From the ENCODE
consortium, the CTCF and YY1 signal track is shown. The
green box is drawn to illustrate the overlap between YY1
and DNase I sites.
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Figure 5.12: CTCF sites in the XIC region nearby the Xist transcript
binding affinity are shown. For each site, the male-versus-
female binding is portrayed in box plots. None of the
CTCF indicates a gender-specific bias (Student’s t-test
p-value > 0.05).
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5.2.7 Female specific CTCF sites
There are 23 CTCF sites with a distinctive female-only binding
affinity on the X chromosome. Interestingly, these sites do not
overlap XIST nor the XIC region, while such overlap might have
been expected. These 23 sites cover two different X chromosome
regions. Each of these two regions exactly overlaps a different
ncRNA (X56 and X130) that is without extensive annotation.
Both ncRNAs have been shown in previous studies to be altered
in X-chromosome inactivation (Horakova et al., 2012). It has been
shown that CTCF sites that overlap with YY1 are involved in
X-chromosome inactivation (Donohoe et al., 2007; Jeon and Lee,
2011; Moseley et al., 2012; Thorvaldsen et al., 2011). However,
when inspecting the ENCODE Consortium YY1 peaks called
for GM12878, all of the female-specific sites are enriched for
YY1 (Section 5.2.4 , Figure 5.5). In addition, strong enrichment
for histone marks, H2AFZ, H3K27ac, H3K4me2 and H3K4me3
are present in all sites and H3K9ac in 80% of the sites. Another
TF that is present in all sites is POU2F2, although there is no
obvious hypothesis to explain why this is the case. Adding that
all of these sites are conserved regions in the genome according
to the GERP data from Ensembl, the most likely conclusion on
functionality for these CTCF sites is that they are, most likely,
vital for the regulation of these two ncRNAs.
In previous studies, in female cells, both of these ncRNAs were
expressed on the Xa. To study the transcript behaviour of these
2 ncRNAs more comprehensively, I asked our collaborators at
the Wellcome Trust Sanger Institute to perform fluorescence in
situ hybridisation (FISH) for these ncRNAs in male and female
cells. Furthermore, FISH was conducted on the XIST transcript
as a positive control. Results from the RNA-FISH experiment
show that for each of these 2 ncRNAs, the signal is mainly
female-specific and originates from the Xa (Figure 5.13). Inter-
estingly, the male cells also show a signal for both X56 and X130,
although with a lower intensity than the female nuclei.
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Figure 5.13: RNA-FISH results for female-specific ncRNAs X56, X130
and XIST. A) Representative RNA-FISH image of X56
(white signal) and X130 (red signal) expression relative to
XIST RNA (green signal) in female nuclei (counterstained
with DAPI) and sequential DNA-FISH representative im-
age with X chromosome paint probe (red signal). The
staining shows that X56 and X130 are transcribed from
the active X chromosome nuclear territory. B) Represent-
ative images of X56 (white signal) and X130 (red signal)
expression by RNA-FISH in male nuclei (counterstained
with DAPI).
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5.3 conclusion
The transcription factor CTCF is known for its multifunctionality.
In Chapter 3 I described that CTCF sites correlate with each
other, suggesting biochemical binding between these sites. In
this chapter, I show that CTCF has a strong involvement in
X-specific behaviour. Notably, the CTCF behaviour found in this
chapter is not related to Xist or the XIC region.
CTCF sites on the X chromosome tend to have three different
behaviours. First, there are the dosage-compensated CTCF sites
that behave similarly to mRNA. Second, there are both-active
CTCF sites that have double the amount of binding as dosage-
compensated sites. Third, there are CTCF sites that are only
bound in female lines. By using this distinction, I classified the
X chromosome CTCF sites into 1,692 sites that are both-active,
253 sites that are dosage-compensated, and 23 sites that are
female-specific.
A reasonable hypothesis is that these distinctively different
behaviours of CTCF are due to differences in function. For the
dosage-compensated CTCF sites, I expect that these are normal
regulatory CTCF sites. The both-active sites I expect to be in-
volved in enabling the 3D structure of the X chromosomes. The
chromosome structure is important for both Xi and Xa, hence
these sites are bound on both the Xi and the Xa. The female-
only CTCF sites are most likely involved in X-chromosome
inactivation processes. This study presents a simple and robust
method to identify the difference between regulatory (dosage-
compensated), structural (both-active) sites and X-chromosome
inactivation related (female-specific) sites.
The LCL GM12878 has been studied in depth within EN-
CODE and was used to determine co-binding of the CTCF sites.
Each class of CTCF sites shows a unique pattern in the factors
that are co-binding and the histone modifications that overlap.
However, GM12878 is female, and for this reason it is impossible
to indicate for each of the found overlaps if these are gender-
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biased. Ideally, at least one male LCL would have been available
to study in similar depth as GM12878. In this way, for each of
the overlaps, a rough ratio between binding in male and female
could be determined. This ratio could provide an indication of
how these overlapping factors are gender-biased and, poten-
tially, similar to CTCF involved in X chromosome inactivation.
Aggregation plots of the histone marks H3k4me3, H3k4me1 and
H3k27ac show clear distinctive differences between both-active
and dosage-compensated sites. H3k27me3, which is known to
be involved in X-chromosome inactivation, appears to be indif-
ferent between both classes, and the signal intensity seems to be
only that of a background level.
It will be interesting to determine in the near future, when
additional similar projects are published, how other molecular
assays behave on the X chromosome. There are, most likely,
several other transcription factors and histone modifications
that are involved with the X-chromosome inactivation process.
The identification of male- or female-specific sites is of great
interest to enhance our understanding of X chromosome biology
and the different functional roles that sites can have. Combining
the knowledge of other assays performed in a population could
help to create better distinctive classifications of CTCF sites.
This would help to identify the actual functional difference
between each of the classes. In particular, population data for
the TFs and HMs, which were shown to be significantly different
in overlap in the GM12878 cell line, are of great interest for
further X chromosome studies. It is my expectation that there
are clear, distinctively different roles for CTCF sites, where some
are involved in the chromosome structure and some are more
regulatory.
While our study has been performed on human cell lines,
there is no reason to believe that the same methods cannot be
applied on other mammals with similar X-chromosome inactiva-
tion. The human CTCF sites are highly conserved, and it would
be interesting to see how CTCF binding in mice would behave,
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as well as whether homologous sites have similar CTCF binding
differences between males and females.
The two identified female-specific ncRNAs have homologues
in mice. To understand the exact role of these two transcripts,
different knockout mice could be created. Using these knockout
mice, the functional role of these two ncRNAs could be studied.
Although Xist is known to be the most important ncRNA in the
X-chromosome inactivation process, these two transcripts could
be involved with other essential biochemical mechanisms.
5.4 data
5.4.1 CTCF
Refer to Chapter 3.4.1. Differently than in previously chapters,
the CTCF data in this chapter is utilised without removing the
first PC from the PCA analysis. Consequently, no significant
gender bias is removed by this normalisation step.
5.4.2 DNase I
I obtained DNase I sequencing data for 70 individuals from the
YRI HapMap population (Degner et al., 2012). To ensure that
none of our results are biased due to normalisation, the author
of the study kindly provided us with GC-corrected DNase I
sensitivities for all of the sites they call. By using data that has
not been normalised, any significant gender bias that may be
present remains intact.
5.4.3 RNA-seq
I obtained RNA-sequencing data for 51 individuals from the
CEU HapMap population from the Geuvadis consortium (Lap-
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palainen et al., 2013). The dataset consists of FPKM values for
all mRNAs and ncRNAs.
5.5 methods
5.5.1 Classification of CTCF sites
To ensure that our normalisation would not introduce any bias,
I used the raw CTCF binding intensities. Our dataset consists of
27 females and 24males. After blacklisted regions were removed,
there were 1,968 CTCF binding regions on the X chromosome.
For each CTCF site, I assessed gender specificity for the bind-
ing region by a Mann-Whitney U (MWU) test between the male
and female samples. The MWU test evaluates for significant
difference between the medians of both groups (male versus
female). A significant result in the MWU test (p-value < 0.01)
results in a CTCF site being classified as gender-biased, i.e. there
is significant disparity in binding between males and females.
The sites that are not gender-biased (non-significant in the MWU
test) are termed "dosage-compensated".
In a next step, for each gender-biased CTCF site, the ratio
between the average CTCF binding in males and females is
calculated. If this ratio indicates a five-fold or greater difference
in binding in favour of the female cell lines, they are classified
as "female-specific". The remaining gender-biased sites are clas-
sified as "both-active". There were no sites that were binding in
favour of male; otherwise, those would have been classified as
"male-specific".
For the mRNA, ncRNA, and DNase I data, the same MWU
analysis was performed. These classifications were used to in-
dicate the gender bias within the Ensembl browser.
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5.5.2 Biochemical co-activity with CTCF sites
For the dosage-compensated and both-active sites, I analysed the
overlap of each category of sites with the ENCODE TFs and his-
tone modifications datasets for the female CEU LCL GM12878.
Consequently, for each CTCF site, I was able to determine which
other biochemical binding takes place. As a definition of an
overlap, I consider a partial overlap an overlap (1bp minimal).
The Chi-square test was used to identify TFs or histone modi-
fications that are significantly more or less overlapping with
each of the CTCF classifications. Arbitrary p-value thresholds
were set to identify the "level" of significance of disparity of
these overlaps.
5.5.3 Aggregation plots
For the dosage-compensated and both-active sites, I analysed
the overlap of each category of sites with the ENCODE TF and
histone modification datasets for the female CEU LCL GM12878.
To avoid bias introduced by unequal distribution of promoter
sequences between the classes, I removed all sites that overlap
with promoters identified in GM12878.
Signal aggregation of each of the classes of sites for histone
modification and TF ChIP-seq data, and micrococcal nuclease
cleavage, was calculated using the ACT toolkit (http://act.ger-
steinlab.org/, (Jee et al. 2011)) with the parameters nbins=50
mbins=0. Only CTCF sites that are in the 50% of bound sites
were used in this aggregation. ENCODE bedGraph files for both
TF and histone modifications were obtained from ftp.ebi.ac.uk:pub-
/databases/ensembl/encode/integration_data_jan2011/byData-
Type/signal/jan2011/bedgraph/ and converted into signal files
that are used as input for ACT.py.
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5.5.4 Data visualisation
Within R (Team, R Development Core, 2005), the package Gg-
plot2 (Wickham, 2009) was used to visualise all data.
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F INAL REMARKS AND FUTURE DIRECT IONS
For this thesis, three research projects were designed and con-
ducted. The first project entailed discovering molecular Quant-
itative Trait Loci (QTLs): in this case, chromatin status QTLs
using Formaldehyde-Assisted Isolation of Regulatory Elements
(FAIRE)-chip data. The second project involved integrating mo-
lecular assays and discovering complex interactions using a
systems genetics approach. The third project studied the unique
behaviour of CTCF on the X chromosome and its involvement
in the inactivation of the X chromosome.
6.1 chromatin as a heritable trait
For the first project, a novel dataset was generated to measure
chromatin accessibility with FAIRE in 60 humans. The FAIRE
signal was quantified using an in-house designed tiling array tar-
geting 10,507 known regulatory genome regions. I have demon-
strated that it is feasible to use FAIRE to identify QTLs. Consider-
ing that I used a relatively small population, used only HapMap
tagging SNPs, and used tiling arrays, this project proved to be
quite successful with the mapping of 167 FAIRE-QTLs when
using probesets. In addition, when using each independent
FAIRE-probe, a total of 16,972 FAIRE-QTLs where discovered.
The FAIRE-QTLs tended to be proximal to the measured FAIRE
signal and were not restricted to the promoters of genes. Several
of our FAIRE-QTLs were also previously identified as eQTLs;
this indicates that, in some cases, the chromatin is directly cor-
related with gene expression. Also, using our current samples,
the FAIRE-QTLs show a higher association with autoimmune-
related diseases than other genome-wide association studies
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(GWAS) phenotypes such as height. These overlaps may aug-
ment our understanding of the molecular effect of GWAS SNPs
for complex diseases.
The main limitation to discovery of FAIRE-QTLs at this stage
is the small sample size. If a larger group of individuals was
measured using the FAIRE-chip, or even more preferably, us-
ing FAIRE-seq, a more comprehensive collection of FAIRE-
QTLs could be discovered. Also, the introduction of a differ-
ent background population could help to distinguish between
population-specific FAIRE-QTLs and the more universal FAIRE-
QTLs. Also, overlap with GWAS catalogues indicates that hav-
ing genome-wide FAIRE data, or any other chromatin assay, for
some immune-related diseases might be of great interest.
I am able to identify a reasonable number of FAIRE-QTLs
using microarrays. However, using next-generation sequencing
(NGS) instead of microarrays would most certainly help to
discover a larger set of FAIRE-QTLs, due to its genome-wide
coverage and lower readout noise. As FAIRE assays how ac-
cessible chromatin is, it will quite often discover QTLs that are
only circumstantial for FAIRE. The real biochemical reason for
the discovery of these QTLs is due to the transcription factor
(TF) binding or histone modifications (HM) that are actually
controlling the accessibility of chromatin.
6.2 system genetics
When partially reconstructing the epigenomes of a small pop-
ulation using only FAIRE, CTCF, and gene expression, a high
degree of correlation between the different assays was observed.
This in itself indicates how complex and intertwined our epigen-
ome is. There are thousands of significant correlations between
each of the molecular phenotypes, and when all of these correl-
ations are integrated, the results suggest that there is a particu-
lar preferred way to regulate gene transcription. As the actual
direction of causality cannot be determined by correlations, con-
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clusions drawn from correlations are susceptible to different
interpretation. The CTCF-to-FAIRE correlations suggest that
CTCF binding increases the FAIRE signal, which indicates that
the chromatin is in a more accessible state. Both the FAIRE-to-
gene expression and the CTCF-to-gene expression correlations
suggest that an increase in either FAIRE or CTCF is increasing
gene expression.
By correlating CTCF sites to each other, I discovered many
potential CTCF interactions. These CTCF interactions can be
involved in insulating essential regulating features through loop-
ing interactions. In addition, there appears to be a significant
difference in biochemical activity depending on the length of
the loops, which indicates a divergence in functionality. How-
ever, a clear functional reason for this disparity in biochemical
activity is not clear. One potential reason might be that these
longer CTCF interactions are different CTCF sites that are pulled
together into transcription factories.
As each of the molecular phenotypes can have a biochemical
effect on other phenotypes, determining the direct and indirect
causal effects can be difficult (e.g. is CTCF changing FAIRE, or is
FAIRE changing CTCF?). However, by incorporating genetic in-
formation, i.e. QTLs, a starting point for causality is introduced.
Knowing what is the direct or the indirect effect of a QTL will
help to unravel molecular regulatory mechanisms. QTLs can
drive epigenetic changes that, as a result, can change gene ex-
pression; however, obviously, this causality cannot occur the
other way around (genotypes are fixed and cannot be changed).
With the incorporation of QTLs, it is possible to dissect these
strong epigenetic correlations and determine what is the direct
causal effect. I discovered that QTLs are the main drivers of
CTCF binding. For example, CTCF affects FAIRE or RNA, and
not the other way around. The CTCF binding is the strongest
indication of transcription and the accessibility of chromatin.
In conclusion, I have established the distinction between in-
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direct and direct causality for many phenotype-to-phenotype
correlations using QTLs.
For CTCF-CTCF pairs that are under the influence of a CTCF-
QTL, it was discovered that the genetic control often adjusts only
one of the CTCF sites, rather than affecting both equally. Further-
more, when the QTL effect is removed for CTCF-CTCF pairs,
the correlation can be removed or sometimes even reversed.
Another main conclusion from this chapter is that eQTLs are
quite often proxy-QTLs. This means that, although a QTL can
initially be identified as an eQTL, this change in expression
is due to more upstream biochemical processes. In essence, a
molecular QTL most likely indirectly affects the gene expression
through a regulatory feature, and thus is more likely to be a
CTCF-QTL, FAIRE-QTL, or any other molecular-QTL. These res-
ults correspond to findings in Yoruba in Ibadan, Nigeria (YRI)
LCLs, where it is shown how DNase I and gene expression
QTLs commonly overlap and are sometimes located within a
transcription factor binding region (McVicker et al., 2013). Com-
plementary to my findings, there are studies showing how TF
binding and histone modifications are the main determinants
for gene expression (Kilpinen et al., 2013). This result is a strong
indication of how, irrespective of the molecular assay of QTL
discovery, CTCF most likely changes the chromatin accessibility
and thus gene expression. For example, CTCF may change chro-
matin into an accessible state so that other transcription factors
can bind and transcription can occur. However, it is too early to
reach a final conclusion about this topic. There are examples in
which the epigenetic state is causal for expression (Lam et al.,
2008) as well as for the result of changes in gene expression
(Zhang et al., 2014). Thus, although my results suggest that
CTCF is a driver of gene expression and chromatin status, some
additional experiments are desirable. It would be of great in-
terest to determine the effect of alternating CTCF binding in
the discovered phenotype-to-phenotype pairs that are driven by
CTCF.
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I show that the independent mapping of molecular QTLs
for each molecular phenotype is not comprehensive enough to
fully grasp the genetic effects. There is a high level of overlap,
and thus understanding the real direct causal effect of a QTL
is not easy. This is especially true when considering that some
TFs might have both proximal and distal effects (Sanyal et al.,
2012). Because of this, it is of great importance to understand
what a molecular QTL actually affects on a molecular level. This
would be particularly useful if the results are used to improve
the annotation of disease GWAS results (He et al., 2013). Al-
though software tools such as Sherlock can successfully map a
molecular QTL to a disease GWAS, if the true molecular effect
of the QTL is unknown, these results might not improve the
understanding of the disease and its pathways. Understanding
the molecular mechanisms regulated by QTLs will provide as-
sistance to identify new hypotheses for potential drug targets.
This will add value to and use personal genomes in everyday
medicine.
6.3 ctcf binding on the x chromosome
CTCF is known to be a multifunctional protein that is involved
in a wide variety of tasks for both regulatory and chromosomal
structural functions. On the X chromosome, CTCF is more than
just a regulator that is involved with the X-chromosome inac-
tivation center (XIC). The population data suggest that CTCF
binding can be classified into three distinct classes. Most CTCF
sites are bound (or active) on both the inactive X (Xi) as well
the active X (Xa) chromosome. Another large subset of CTCF
sites is dosage-compensated (bound on Xi or, most likely, Xa). A
minority of CTCF sites are only bound in females. I show that
each of these classifications could be associated with different
functional roles.
In the present analysis, the data suggest that the CTCF sites
that are active on both chromosomes are most likely involved
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in a chromosomal structural role. On the other hand, CTCF
sites that are only bound on one chromosome show evidence
of a more regulatory role. Most certainly, the regulatory CTCF
sites are only bound on the Xa chromosome. The female-specific
CTCF sites regulate the expression of two different ncRNAs
(X56 and X130) and are most likely are involved in, or controlled
by, X-chromosome inactivation processes. RNA-fluorescence in
situ hybridization (FISH) experiments on these two ncRNAs
show, similar to Xist, expression from mainly the inactivated
X chromosome. All of these results suggest yet another major
biological role for CTCF.
Using the CTCF site classification, I was able to predict the
corresponding DNase I signal for overlapping genomic regions.
In the current limited view, it appears that CTCF is a stronger
indicator for both active sites than DNase I is. However, by
increasing the number of molecular assays performed on my
population of cell lines, a more comprehensive epigenomic view
of the X chromosome could be attained. There are, without
doubt, other molecular phenotypes that are, similarly to CTCF,
essential for the X chromosome. In particular, now that the
different behaviours of CTCF on the X chromosome have been
revealed, it would be interesting to determine whether this
result can be used to train a model to predict whether CTCF
sites on other chromosomes are regulatory or structural. Using
overlap with transcription factors and histone modifications
from ENCODE, a model could be trained for this purpose.
However, the ENCODE cell line GM12878 is a female line, and
hence it is difficult to predict how the overlap would look for a
male cell line.
6.4 integration of epigenetic data
In this thesis, I was successful in discovering a large number of
correlations between different epigenetic traits. I also showed
that when genetic information is added, a better understanding
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of the causality cascade in epigenetic trait correlations can be
achieved. However, this study would have benefited consider-
ably from a larger population size, as the discovery of causal
loci is mainly limited by sample size (Spencer et al., 2009). With
an increased population size, QTLs that are further away could
also be included for QTL mapping. For the projects described
in this thesis, I focussed only on coding genes; however, this
excludes important ncRNAs that are known to have regulatory
function (Ambros, 2001). Including those genes would improve
the overall quality of the created epigenome, as it is almost
certain that ncRNAs will influence the molecular phenotypes
that were included in the epigenome. Also, obviously, the ex-
pansion to more epigenetic phenotypes would help to construct
a better epigenome that, in turn, could be used to improve the
annotation of disease GWAS results.
If the number of correlations observed in this thesis is a good
representation of the kinds of biochemical interactions that occur
in healthy individuals, it would be of great interest to create the
same correlations for disease samples and to compare the res-
ults. Differential interactions analysis could help to distinguish
between housekeeping and disease-specific biochemical inter-
actions. A great example of how an epigenetic phenotype can
help to explain a disease GWAS result can be found for Type 2
diabetes (T2D). For this disease, a region of islet-selective access-
ible chromatin overlaps a SNP that is strongly associated with
T2D; this links genetics, epigenetics and environment together
(Drong et al., 2012; Gaulton et al., 2010; McCarthy, 2010)).
6.4.1 Single molecular level
To date, nearly all studies, including those in my thesis, have
been performed using a mixture of cells, because for the assays
to work, a large quantity of DNA is required. Furthermore, it is
nearly impossible to ensure that cells have equivalent epigenetic
state and genetic background. There has been some success
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with single-nucleus sequencing for breast cancer, indicating how
diverse the genetics within a tumour can be (Navin et al., 2011).
Obviously, single-cell sequencing is also applicable for the tran-
scriptome (Yan et al., 2013) and other epigenetic marks. These
singe-cell studies have shown that the transcriptome profile is
unique for cell state and cell type (Jaitin et al., 2014; Ramsköld
et al., 2012; Shalek et al., 2013). The success of singe-cell sequen-
cing for the genome and transcriptome indicates that there is
need to expand these methods towards regulatory features. As I
have shown, using a population of cells (even from a cell line)
necessitated the removal of highly-variable FAIRE probes from
my experiments. Most likely, this variance is an indication of an
epigenetic differentiation at the specific regulatory feature that
could be studied using single-cell approaches.
New methods such as Assay for Transposase-Accessible Chro-
matin using sequencing (ATAC-seq) reduce the amount of input
required, from approximately two million cells to less than
50,000 cells (Buenrostro et al., 2013). These reductions will yield
more robust results, as there will be less internal variance due
to the great number of different cells. Furthermore, this lower
number of required cells means that ATAC-seq could be used to
identify regulatory regions in disease samples or can be used in
a diagnostic setting. Moreover, if the quantity of input material
could be lowered even further, the assessing the accessibility
of chromatin could be used on a single-cell level, which would
greatly improve our understanding of the regulation of the
epigenome. Early studies have been able to explain how DNA
methylation drives embryonic differences (Lorthongpanich et al.,
2013). And the first single-cell DNA methylation methods are
capable of measuring 10M CpGs in mice, which is nearly half
of the CpGs sites known (Smallwood et al., 2014).
Studying the direct interaction between TF binding and chro-
matin is useful for understanding their relationship. Methods
like DNase I-released fragment-length analysis of hypersensit-
ivity (DNase-FLASH) show promising results for directly map-
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ping the interaction between TF binding and the accessibility of
the chromatin (Vierstra et al., 2014). By comparing the length
of the DNase I-released fragments, an indication can be given
about DNA fragments being located in accessible chromatin
(~200kb fragments length) or being flanked by the nucleosome
(~500kb fragments length).
Understanding the chromatin landscape is essential for un-
ravelling the human epigenome. However, all of the current
methods have their limitations, and even when assaying na-
ked DNA, differences in chromatin will be measured, due to
unknown digesting preferences from DNase I rather than real
epigenetic changes (He et al., 2014). These disparities obviously
mean that some of the identified regulatory features will need
to be reevaluated.
The additional information of the epigenome on a single-
cell level would help to address the variance of biochemical
interactions. Even more, these data would be powerful when
integrated into a more complex structural equation modeling
(SEM) system,. Attaining a clear overview of the normal, healthy
epigenome is a starting point for exploring environmental effects
or diseases.
6.5 the epigenome era
In recent years, several large-scale epigenome projects have been
initiated. For example, the NIH Roadmap Epigenomics Map-
ping Consortium was launched with the goal of producing a
public resource of human epigenomic data to catalyse basic
biology and disease-oriented research (Bernstein et al., 2010;
Chadwick, 2012). Other projects have more specific goals: for
example, the BLUEPRINT consortium is interested in establish-
ing a full epigenome view of haematopoietic cells (Martens and
Stunnenberg, 2013), and the International Cancer Epigenome
Project is, broadly speaking, interested in mapping cancer epi-
genomes (Beck et al., 2012). These consortia have in common
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that they use a mixture of healthy cell lines and disease cell
lines. Potentially more importantly, LCLs are slowly being re-
placed in research projects by induced pluripotent stem (IPS)
cells (Takahashi and Yamanaka, 2006). IPS has the great benefit,
in comparison with the lymphoblastoid cell lines, that any cell
type can be used to create an IPS cell line. This means that,
for studying whole-body phenotypes in the current research
environment, a more fitting cell type (or several) can be used
instead.
Evidently, these kinds of improvements in cell line technique
and large-scale consortia will increase our understanding of the
human epigenome. However, many consortia focus mainly on
disease samples or a wide range of different cell types, and thus
their findings will not be as generally applicable as the results
presented in this thesis. In order to improve our epigenome
view, it will be essential to have studies that are not focussed on
comparing different cell lines with some replicates, but rather to
emphasize studies of populations of a specific cell type. Because
of this issue, integrating the data is difficult, as cell types and
unknown population structure will drive many correlations and
will make it nearly impossible to determine what is causing the
correlation. These consortia, using a mixture of cell types, will
be more applicable to extending our knowledge; for example, I
used ENCODE in this thesis to confirm my hypothesis and to
provide an indication of what might be occurring in particular
regions of the genome.
One important piece of future work will be the extensive ex-
ploration of inter-individual and intra-individual (e.g. between
cell types or sick and healthy) differences in epigenomes. These
studies would elucidate the, so-far, poorly characterised genetic
regulation of the whole epigenome. Furthermore, increased un-
derstanding of the epigenome will be applicable within the field
of personal medicine.
Part VI
APPENDIX

A
INDIV IDUALS USED IN THIS THES I S
a.0.1 Overlap assays
The CEU population used in this thesis has been assayed for
a variety of molecular assays. However, there is some slight
disparity for what molecular assay has been performed for each
individual (Table A.1).
Table A.1: Overview individuals and the molecular assays performed
on them
Individual RNA FAIRE CTCF
NA06986 yes yes yes
NA07037 yes yes yes
NA07051 yes yes yes
NA07346 yes yes yes
NA07357 yes yes yes
NA11829 yes yes yes
NA11830 yes yes yes
NA11831 yes yes yes
NA11832 yes yes yes
NA11840 yes yes yes
NA11881 yes yes yes
NA11894 yes yes yes
NA11918 yes yes yes
NA11920 yes yes yes
NA11931 yes yes yes
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Table A.1: Molecular assays performed on individuals
Individual RNA FAIRE CTCF
NA11992 yes yes yes
NA11993 yes yes yes
NA11994 yes yes yes
NA11995 yes yes yes
NA12003 yes yes no
NA12004 yes no yes
NA12005 yes yes yes
NA12006 yes yes yes
NA12043 yes yes yes
NA12045 yes yes yes
NA12144 yes yes yes
NA12154 yes yes yes
NA12155 yes yes yes
NA12156 yes yes yes
NA12234 yes yes yes
NA12249 yes yes yes
NA12287 yes yes yes
NA12489 yes yes yes
NA12749 yes yes yes
NA12750 yes yes yes
NA12751 yes yes yes
NA12760 yes yes yes
NA12761 yes yes yes
NA12762 yes yes yes
NA12763 yes yes yes
NA12776 yes yes yes
NA12812 yes yes yes
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Table A.1: Molecular assays performed on individuals
Individual RNA FAIRE CTCF
NA12813 yes yes yes
NA12814 yes yes yes
NA12815 yes yes yes
NA12828 yes yes no
NA12872 yes yes yes
NA12873 yes yes yes
NA12874 yes yes yes
NA12891 no yes no
NA12892 no yes no
NA11919 yes no no
NA12044 yes no yes
NA12414 yes no no
NA10847 yes no yes
NA06985 yes no yes
NA06994 yes yes yes
NA12717 yes no yes
NA07000 yes no yes
NA12716 yes no yes
NA07347 yes no yes
NA10851 yes no yes

B
OVERVIEW ALL FAIRE -QTLS
Table B.1: Overview FAIRE-QTLs. The FAIRE target, FAIRE target genomic location, associated SNP, Spearman’s Rank p-value (-log10)
and Rho, and empirical p-value are given. The Spearman’s Rank result for when using HapMap genotypes and 1,000 Genomes
(1kg) genotypes are given.
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_6940 1:172631563-172632321 rs12060864 173064777 432456 -0.54 4.82 0.29 2.60
target_6940 1:172631563-172632321 rs12075195 173065003 432682 0.54 4.82 0.29 2.60
target_10251 2:127829389-127830505 rs12475915 127902187 71682 -0.58 5.49 0.00 4.34
target_10251 2:127829389-127830505 rs2118508 127909259 78754 0.58 5.43 0.00 4.34
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_10251 2:127829389-127830505 rs3943703 127897320 66815 0.56 5.21 0.00 4.11
target_10251 2:127829389-127830505 rs2118506 127897503 66998 -0.56 5.21 0.00 4.11
target_11148 2:120048442-120048900 rs1530562 120048729 0 0.54 4.83 0.33 4.76
target_11148 2:120048442-120048900 rs4848546 120051015 2115 0.54 4.83 0.33 4.76
target_11912 2:153045957-153046723 rs1806557 153056846 10123 0.54 4.74 0.50 3.89
target_3655 3:192616451-192617016 rs12485900 192623779 6763 0.58 5.48 0.17 4.06
target_3655 3:192616451-192617016 rs9869202 192625190 8174 0.58 5.48 0.17 4.06
target_3655 3:192616451-192617016 rs1948721 192629447 12431 -0.58 5.48 0.17 4.06
target_3655 3:192616451-192617016 rs4687368 192631810 14794 -0.55 4.91 0.38 2.95
target_3655 3:192616451-192617016 rs4687367 192631798 14782 0.54 4.81 0.50 2.99
target_8329 3:132377918-132379799 rs9854387 132862516 482717 0.56 5.12 0.00 4.85
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_8329 3:132377918-132379799 rs13079918 132866503 486704 -0.56 5.12 0.00 4.85
target_8841 3:108125294-108125916 rs936266 108125614 0 0.65 7.18 0.00 6.22
target_8841 3:108125294-108125916 rs4855651 108111663 -13631 0.56 5.17 0.45 4.21
target_8841 3:108125294-108125916 rs4855559 108115036 -10258 0.56 5.17 0.45 4.21
target_8841 3:108125294-108125916 rs4855650 108109031 -16263 -0.56 4.97 0.38 4.21
target_1980 4:118055550-118055749 rs1948223 118545387 489638 -0.58 5.54 0.50 5.30
target_10519 5:133223715-133224381 rs244693 133455153 230772 0.56 5.03 0.50 2.54
target_11459 5:18466219-18466561 rs7728989 18460758 -5461 -0.64 6.91 0.00 6.63
target_11459 5:18466219-18466561 rs10942236 18511790 45229 -0.64 6.91 0.00 6.63
target_11459 5:18466219-18466561 rs1527374 18459977 -6242 -0.63 6.29 0.00 6.63
target_11459 5:18466219-18466561 rs10042810 18482995 16434 -0.57 5.27 0.00 4.35
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_11459 5:18466219-18466561 rs2962949 18424199 -42020 0.53 4.56 0.47 4.34
target_8236 5:35920892-35921444 rs12657378 35608310 -312582 0.59 5.71 0.00 4.49
target_8236 5:35920892-35921444 rs7720593 35608763 -312129 0.59 5.71 0.00 4.49
target_8236 5:35920892-35921444 rs12514518 35614503 -306389 0.59 5.71 0.00 4.49
target_8236 5:35920892-35921444 rs12657936 35616027 -304865 -0.59 5.71 0.00 4.49
target_8236 5:35920892-35921444 rs11951251 35616805 -304087 0.59 5.71 0.00 4.49
target_8236 5:35920892-35921444 rs10512624 35585671 -335221 -0.59 5.70 0.00 4.47
target_8236 5:35920892-35921444 rs10050597 35585954 -334938 -0.59 5.70 0.00 4.47
target_8236 5:35920892-35921444 rs10057637 35586010 -334882 0.58 5.65 0.00 4.47
target_8236 5:35920892-35921444 rs1508650 35618486 -302406 0.54 4.83 0.17 3.72
target_8236 5:35920892-35921444 rs1508652 35618540 -302352 0.54 4.83 0.17 3.72
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_8236 5:35920892-35921444 rs1508653 35618552 -302340 0.54 4.83 0.17 3.72
target_8236 5:35920892-35921444 rs12652967 35596972 -323920 0.54 4.68 0.29 3.48
target_8236 5:35920892-35921444 rs4703415 35589089 -331803 0.53 4.58 0.32 3.36
target_8689 5:108017046-108017283 rs7737443 108016782 -264 -0.55 5.02 0.00 3.23
target_8689 5:108017046-108017283 rs7703883 108017262 0 0.55 5.02 0.00 3.23
target_8689 5:108017046-108017283 rs10477928 108018082 799 0.55 5.02 0.00 3.23
target_8689 5:108017046-108017283 rs11952230 108018395 1112 0.55 5.02 0.00 3.23
target_11554 6:3187079-3187396 rs6912511 3187454 58 0.62 6.40 0.00 6.28
target_11554 6:3187079-3187396 rs9392465 3162378 -24701 0.57 5.45 0.00 4.89
target_12051 6:30461304-30462395 rs2523989 30078275 -383029 0.53 4.60 0.13 3.74
target_12051 6:30461304-30462395 rs2239529 30078330 -382974 0.53 4.60 0.13 3.74
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_12051 6:30461304-30462395 rs2249099 30079307 -381997 -0.53 4.60 0.13 3.74
target_12051 6:30461304-30462395 rs2517598 30080274 -381030 -0.53 4.60 0.13 3.74
target_12051 6:30461304-30462395 rs2844793 30080496 -380808 -0.53 4.60 0.13 3.74
target_12051 6:30461304-30462395 rs2523985 30081334 -379970 -0.53 4.60 0.13 3.74
target_12051 6:30461304-30462395 rs2523984 30082003 -379301 0.53 4.60 0.13 3.74
target_12051 6:30461304-30462395 rs2523735 30122657 -338647 0.53 4.59 0.13 3.65
target_12051 6:30461304-30462395 rs3094034 30363351 -97953 0.53 4.50 0.14 3.00
target_12051 6:30461304-30462395 rs3130782 30914843 452448 0.52 4.48 0.15 3.42
target_12051 6:30461304-30462395 rs3131934 30931844 469449 -0.52 4.48 0.15 3.42
target_12051 6:30461304-30462395 rs3131783 30932068 469673 -0.52 4.48 0.15 3.42
target_12051 6:30461304-30462395 rs3132649 30321057 -140247 -0.52 4.41 0.15 3.46
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_12051 6:30461304-30462395 rs3094061 30321189 -140115 0.52 4.41 0.15 3.46
target_12051 6:30461304-30462395 rs3130374 30321336 -139968 0.52 4.41 0.15 3.46
target_12051 6:30461304-30462395 rs3094627 30321482 -139822 -0.52 4.41 0.15 3.46
target_12051 6:30461304-30462395 rs3130375 30321732 -139572 -0.52 4.41 0.15 3.46
target_7145 6:163601983-163602667 rs7742763 164084488 481821 -0.55 5.02 0.00 4.62
target_7145 6:163601983-163602667 rs9458878 164073368 470701 0.55 4.95 0.00 3.53
target_7145 6:163601983-163602667 rs9364696 164065525 462858 0.54 4.84 0.38 3.27
target_6533 7:127670510-127672406 rs11971935 127422539 -247971 -0.52 4.33 0.47 2.58
target_6970 7:100197836-100198529 rs35111986 100000274 -197562 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs1000215 100004543 -193293 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs3900792 100004577 -193259 0.50 4.12 0.17 2.81
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_6970 7:100197836-100198529 rs7783159 100017454 -180382 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs28490152 100020982 -176854 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs6975729 100028187 -169649 -0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs1073 100031612 -166224 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs11761725 100039815 -158021 -0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs11761784 100039970 -157866 -0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs28578163 100044754 -153082 -0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs2406255 100053690 -144146 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs7794485 100068936 -128900 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs4472444 100070758 -127078 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs7809801 100072031 -125805 0.50 4.12 0.17 2.81
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_6970 7:100197836-100198529 rs11766752 100073292 -124544 -0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs11559117 100076614 -121222 -0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs2406253 100077273 -120563 -0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs11760536 100078754 -119082 -0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs11763511 100081944 -115892 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs11769700 100090049 -107787 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs7783550 99987805 -210031 -0.50 4.12 0.17 2.06
target_6970 7:100197836-100198529 rs11769886 99998607 -199229 0.50 4.12 0.17 2.81
target_6970 7:100197836-100198529 rs34989573 100097895 -99941 -0.50 4.01 0.22 2.81
target_6970 7:100197836-100198529 rs7787620 100089234 -108602 -0.49 3.93 0.32 2.81
target_7342 8:120428095-120429658 rs3134058 119954108 -473987 0.60 6.01 0.00 4.00
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_7342 8:120428095-120429658 rs3134057 119953468 -474627 -0.55 5.01 0.00 4.10
target_7342 8:120428095-120429658 rs1564861 119965909 -462186 -0.53 4.56 0.33 4.10
target_10690 9:37966185-37966913 rs1887455 37488725 -477460 0.55 5.01 0.50 4.42
target_10690 9:37966185-37966913 rs6476635 37498334 -467851 -0.55 5.01 0.50 4.42
target_10690 9:37966185-37966913 rs10973394 37522672 -443513 -0.55 5.01 0.50 4.42
target_3019 9:37465999-37466571 rs10758440 37573330 106759 0.63 6.65 0.00 4.41
target_3019 9:37465999-37466571 rs7027222 37651804 185233 0.54 4.83 0.27 2.92
target_3019 9:37465999-37466571 rs10814581 37584687 118116 -0.53 4.62 0.48 2.81
target_3019 9:37465999-37466571 rs4599892 37603046 136475 -0.53 4.62 0.48 2.81
target_3019 9:37465999-37466571 rs12380266 37606701 140130 0.53 4.62 0.48 2.81
target_3019 9:37465999-37466571 rs10814586 37610198 143627 0.53 4.62 0.48 2.81
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_3019 9:37465999-37466571 rs10973438 37615548 148977 0.53 4.62 0.48 2.81
target_3019 9:37465999-37466571 rs2209561 37620873 154302 -0.53 4.62 0.48 2.81
target_3019 9:37465999-37466571 rs10814588 37621667 155096 0.53 4.62 0.48 2.81
target_6090 9:138444546-138446041 rs2590504 138365495 -79051 0.65 7.20 0.00 6.37
target_6090 9:138444546-138446041 rs12238018 138365624 -78922 -0.65 7.20 0.00 6.12
target_6090 9:138444546-138446041 rs2777323 138364389 -80157 -0.63 6.65 0.00 5.31
target_12170 10:108030713-108031514rs1556379 107998037 -32676 0.55 4.68 0.00 2.43
target_12461 11:62264440-62265021 rs953894 62762422 497401 -0.57 5.44 0.00 3.01
target_12461 11:62264440-62265021 rs2187384 62761161 496140 -0.57 5.33 0.00 3.01
target_2934 11:46721763-46722968 rs7107778 46860855 137887 0.50 4.11 0.38 3.81
target_2934 11:46721763-46722968 rs7929294 46776176 53208 -0.51 4.09 0.38 3.81
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_2934 11:46721763-46722968 rs10734548 46787573 64605 -0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs7940578 46812227 89259 -0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs10769208 46822240 99272 -0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs10734549 46822686 99718 -0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs7101374 46824241 101273 -0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs1007738 46849360 126392 -0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs7480140 46856335 133367 0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs1551744 46865000 142032 -0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs10769211 46872873 149905 -0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs7943866 46881954 158986 0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs2306026 46889713 166745 -0.49 3.96 0.47 3.81
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_2934 11:46721763-46722968 rs3816614 46890165 167197 0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs2290884 46890388 167420 0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs11039014 46895378 172410 -0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs964551 46897995 175027 0.49 3.96 0.47 3.81
target_2934 11:46721763-46722968 rs2306027 46907827 184859 0.49 3.96 0.47 3.81
target_3094 12:775816-776770 rs2535426 686076 -89740 0.61 6.28 0.00 5.28
target_3094 12:775816-776770 rs2535436 698634 -77182 0.57 5.30 0.20 4.68
target_3094 12:775816-776770 rs2607924 700675 -75141 -0.56 5.12 0.29 4.61
target_3094 12:775816-776770 rs3809263 773456 -2360 0.53 4.50 0.48 3.59
target_4346 12:12716524-12717414 rs16907810 12327655 -388869 0.57 5.28 0.33 3.23
target_4346 12:12716524-12717414 rs11054701 12289156 -427368 0.56 5.08 0.50 3.03
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_4346 12:12716524-12717414 rs16907786 12314602 -401922 0.56 5.08 0.50 3.03
target_4346 12:12716524-12717414 rs2300231 12315880 -400644 0.56 5.08 0.50 3.03
target_7442 13:22423199-22423877 rs9550818 22754120 330243 -0.60 5.80 0.50 4.96
target_1190 14:53172966-53174397 rs17725312 53065714 -107252 -0.52 4.48 0.45 3.49
target_2278 14:90135472-90135995 rs4904547 89794530 -340942 0.57 5.37 0.50 3.46
target_12381 17:47856476-47857395 rs1867087 47440420 -416056 0.54 4.80 0.40 3.83
target_12381 17:47856476-47857395 rs365038 47967675 110280 -0.54 4.78 0.40 3.08
target_2715 17:37906275-37907227 rs4795405 38088417 181190 0.52 4.34 0.13 3.77
target_2715 17:37906275-37907227 rs4378650 38080865 173638 -0.51 4.15 0.27 3.39
target_3368 17:18854435-18854773 rs1859083 18843306 -11129 0.49 3.84 0.50 3.17
target_506 17:47491425-47492976 rs596783 47329705 -161720 -0.58 5.58 0.00 3.98
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_506 17:47491425-47492976 rs757554 47345847 -145578 0.55 5.03 0.50 3.82
target_506 17:47491425-47492976 rs16947546 47324353 -167072 -0.53 4.62 0.36 3.16
target_7683 17:40266513-40267923 rs2033675 40110764 -155749 -0.53 4.60 0.22 3.23
target_7683 17:40266513-40267923 rs12602950 40123829 -142684 0.53 4.60 0.22 3.23
target_7683 17:40266513-40267923 rs4796744 40096473 -170040 0.49 3.89 0.47 3.23
target_7683 17:40266513-40267923 rs4594300 40098187 -168326 0.49 3.89 0.47 3.23
target_7683 17:40266513-40267923 rs4796750 40114544 -151969 -0.49 3.89 0.47 3.23
target_11408 19:50957982-50959368 rs3745504 50771609 -186373 -0.58 5.56 0.00 4.77
target_6274 19:52598247-52599273 rs10410908 52680938 81665 0.56 5.15 0.36 3.95
target_6274 19:52598247-52599273 rs10411335 52681110 81837 -0.56 5.15 0.36 3.95
target_9523 19:13999997-14001221 rs12610739 14461417 460196 0.55 4.84 0.50 3.82
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Table B.1: Overview FAIRE-QTLs
FAIRE-peak FAIRE-peak posi-
tion
SNP SNP posi-
tion
distance Rho p-value empirical
p-value
p-value
1kg
target_373 20:49942253-49943223 rs1474843 49950741 7518 0.60 6.05 0.00 3.86
target_373 20:49942253-49943223 rs6021118 49950753 7530 0.60 6.05 0.00 3.86
target_373 20:49942253-49943223 rs4811159 49955717 12494 0.59 5.70 0.00 4.41
target_10733 X:115028350-115029418rs6608481 115046966 17548 0.75 10.42 0.00 7.83
target_10733 X:115028350-115029418rs11091032 115021945 -6405 0.67 7.69 0.00 5.70
target_10733 X:115028350-115029418rs11091036 115023111 -5239 -0.56 5.08 0.25 4.62
target_1817 X:115085080-115085589rs6608481 115046966 -38114 0.52 4.47 0.29 3.60
target_1817 X:115085080-115085589rs11091032 115021945 -63135 0.50 4.12 0.44 3.35
target_6542 X:12842980-12843491 rs4316308 12719036 -123944 0.58 5.61 0.00 2.62
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